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ABSTRACT
The Effects of Cryotherapy on Eccentric Peak Torque 
Recovery after an Intense Eccentric Exercise
by
Michelle Nicole Peluaga
Dr. Mack D. Rubley, Examination Committee Chair 
Associate Professor of Kinesiology and Nutrition Sciences 
University of Nevada, Las Vegas
This study investigated the effects o f a 45-minute cryotherapy application post­
exercise repeated daily for 3-days on the recovery o f the quadriceps after inducing 
DOMS. Results showed eccentric mean PT was greater at baseline than 24-hours after 
eccentric exercise. Knee AROM, joint line, 5cm, and 10cm girth measurements resulted 
in no differences. However, 15cm and 20cm sites revealed baseline values being lower 
than 4 8-hours.
Tenderness at VMO post-treatment resulted in a difference with the initial 
application being lower than 24-hours. The 15cm site pre-exercise and post-treatment 
resulted in differences where baseline was lower than 24 and 48-hours. Post-exercise 
revealed the treated limb was lower than the untreated at 48-hours. The 20cm site at all 
time points resulted in baseline value being less than 24 and 48-hours. In conclusion, 
there were no differences between treated and untreated limbs with once daily 45-minute 
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Cryotherapy, a cold modality that results in heat withdrawal when applied to the 
body is the most common modality used in the treatment of acute musculoskeletal 
injury.’ As cryotherapy causes a decrease in tissue temperature, local metabolism in those 
tissues will also decrease.’ This is significant because the application of cryotherapy may 
diminish secondary injury (hypoxic or enzymatic).’’^  Secondary injury is defined as the 
process of living cells on the periphery of the primary injury dying or bursting during the 
cleanup and repair processes or being deprived of o x y g e n . M e r r i c k  has shown in an 
animal model that the immediate application of cryotherapy will diminish the magnitude 
of secondary injury.® Dolan et al. have shown the immediate application of cryotherapy 
diminished the volume of edema that forms.^ Therefore, the most important goal in acute 
injury care is to decrease secondary injury. This goal can be achieved with cryotherapy, 
thus facilitating faster recovery following acute traumatic injury.’’®’*
Knight’ defined acute injury as any event that impairs tissue structure or function. 
Acute injury may occur with forceful eccentric muscle actions during exercise, resulting 
in the following signs and symptoms: pain, swelling, decrease range o f motion, and 
strength loss. It has been argued that eccentric exercise-induced muscle damage may lead 
to ultra-structural changes within skeletal muscle(s) caused by mechanical stress.® This
exercise-induced damage has been suggested to stimulate an acute injury model.*"'® This 
acute injury caused by excessive eccentric loading during exercise in m uscle tissue 
causes a development o f  delayed on-set muscle soreness (DOM S).*’""'  ^ It is believed that 
the signs and symptoms o f  DOMS will peak 24-72 hours post exercise'®’'"''^ '' and subside 
within 5-7 days.*'^^'^ Symptoms o f  DOMS include point tenderness (pain), swelling, 
decreased range o f  motion (ROM), and a decrease in strength. ' ^ 4 34 8.19.25.26 these
symptoms are similar to an acute injury.
Many authors quantify DOM S with the assessment o f  pain in the affected muscle, 
14-25 ,27-32  girth measurements to assess swelling, 10,16,19,23.24,28,29,32,33 ROM,'®’'®"
19,24,28,29,32 strength measurements o f  the affected muscle. ' 0 4  6 - 19,2 1 ,2 3 ,2 4 ,27 -30 ,32,33
Previous investigations for treatments to reduce the symptoms o f  DOM S have included 
electrical stimulation^'' and cryotherapy The investigation o f  the impact o f
cryotherapy, has focused on the application prior to strength testing,®’®''’®®"^® between 
sets,^® and post intense eccentric exercise 2 0 ,24 ,28 -30 ,32,33  induce DOM S.
Strength measurements with cryotherapy application either pre- or post-exercise 
are inconclusive with some studies showing no difference, 24.30,33,36,37 increase,
while others a decrease®'**'*® in strength being reported follow ing treatment. The 
effects o f  cryotherapy on increasing active ROM following DOM S were 
inconclusive.*®’*'''*® Cryotherapy’s impact on DOMS associated with pain are also 
inconclusive from no differences with treatment*®’*®’*® and decrease*'' in pain being 
reported. Girth measurements may increase due to swelling with the acute injury' 
however with DOM S it was inconclusive whether or not the application o f  cryotherapy
diminishes swelling following DOMS inducing eccentric exercise as measured by limb 
girth.*®'**
To date, many o f these studies may have been flawed because; 1) strength testing 
was done immediately after cryotherapy application, 2) application was delayed 24 to 48 
hours thus allowing secondary injury to occur, 3) the duration of the cryotherapy 
treatment was inappropriate to treat deep muscle tissue, and/or 4) pain assessments were 
taken with subjects applying pressure to themselves or by the investigator’s thumb which 
was lacking in control. Most of these studies that may have been flawed were multiple 
day studies®'*®'*'*'**'*®'**'**'**'*®'**'*® with 2 studies being a single day study.*'*’** Therefore, 
the purpose of this study was to investigate the effects of an immediate 45 minute 
cryotherapy application repeated once daily for 3 days post DOMS inducing eccentric 
exercise on the recovery of the function of the quadriceps muscles. Quadriceps muscle 
recovery was quantified by measuring mean eccentric peak torque (PT), active range of 
motion (AROM), limb girth and pain (applied using a standard force).
Hypothesis
The hypotheses are that the application of cryotherapy post exercise will decrease 
the magnitude of DOMS symptoms 24, 48, and 72 hours after intense exercise: 1) 
facilitate the recovery of quadriceps PT, 2) decrease pain experience during palpation of 
the thigh, 3) diminish increased quadriceps girth measurements as a result of swelling, 
and 4) restore knee AROM to pre-test values, sooner than without cryotherapy.
Limitations
Some limitations o f this study included the following: 1) participants may not put 
forth 100% effort in maximum eccentric strength testing or training, 2) the magnitude of
tissue cooling in the quadriceps was not measured, and 3) individual reactions to 
eccentric loading may vary.
CHAPTER 2
LITERATURE REVIEW 
Major Concepts in Cryotherapy on Muscle Soreness Research:
Secondary Injury
With an acute injury there is primary injury, i.e. trauma caused by direct 
compression or a stretching or shearing force, which results in ultra-structural changes in 
muscle and comiective tissue, or/both nerves and blood vessels.' In 1976, Knight 
introduced the theory of secondary injury for acute injuries.'' Secondary injury is the 
process of living cells on the periphery of the primary injury dying or bursting during the 
cleanup and repair processes.'’''’* Knight’s'' original paper only discussed secondary 
injury as being hypoxic. Cells require energy to function, but with injury surviving cells 
around the area of injury may be deprived o f oxygen causing the body’s metabolism to 
switch from aerobic to anaerobic, which cannot be sustained for a long duration, causing 
living cells to die without replenishment of energy and oxygen.'
Secondary injury is not only hypoxic but also enzymatic, resulting from enzymes 
designed to digest debris that are released from lysosomes of dead and dying cells.'’® This 
may damage the membrane of healthy cells and their cellular proteins leading to cell 
death of initially uninjured cells.' ® In this paper, secondary injury refers to both hypoxic 
and enzymatic injury resulting from primary injury.
The main reason for the application of cryotherapy during acute injury is to 
decrease secondary injury,' thereby decreasing pain, swelling, and muscle spasms.' '''® ''® 
By applying cryotherapy a decrease in metabolism occurs to the area decreasing oxygen 
demand, allowing living cells on the periphery to remain unharmed.' '''®
Cryotherapy
Cryotherapy is any substance that decreases the temperature o f the tissue(s) being 
treated.'"'''''®''''' In 1976, Knight'' discovered the benefits of applying this modality to an 
acute musculoskeletal injury. The most common applications of cryotherapy are in the 
form of a crushed ice bag, an ice massage or a cold water immersion.
When ice is used to treat acute injury the main goal is to prevent further injury by 
decreasing secondary injury to injured area.'"'''''®''''' Cryotherapy may cause a decrease in 
temperature thus decreasing blood flow and reducing muscle spasms.* ''*"*' The decrease 
in blood flow in healthy subjects is caused by the vasoconstriction of the vessels.'’*’''’'''' 
Without this decrease in blood flow, metabolism to the injured area is not decreased, thus 
allowing dying cells to consume the oxygen needed for living cells on the periphery of 
the injured area.'’*’''’''* Following injury, damaged cells in the injured area - and those 
cells that lyse and burst - release chemicals (this is also seen in intense eccentric exercise 
causing DOMS)** informing the body that the cell(s) have been damaged.'’'' ''* This 
causes a cascade of chemically induced events that allow for an increase in cell 
permeability, hence increasing edema and swelling in the injured area'’*’''’''* therefore, 
causing pain. To review: an injury occurs, releasing chemicals in the body, causing an 
increase in cell permeability, increasing protein/damage, increasing edema formation and
decreasing oxygen supplied to healthy cells. This causes a shift from aerobic to anaerobic 
metabolism, which in turn shifts the cells’ osmotic balance causing it to burst.
In the current literature on cryotherapy there is evidence that cryotherapy decrease 
the effects of secondary injury when applied acutely.*’*’''’''* In animal studies cryotherapy 
application decreased the accumulation of limb volume*’''® and decreased mitochondrial 
injury that occurs during secondary injury.* The decreased swelling with cryotherapy can 
reduce pain and muscle spasms, the reduction o f muscle spasms comes from a decrease 
in nerve conduction velocity and pain.*’''
Application of cryotherapy has shown to increase muscle strength, in non-DOMS 
related studies these studies usually performed one set at sub-maximal strength over 3-8 
repetition.®’**"*®’**’*'' In a study conducted by Denegar et al.*'' cryotherapy was applied 48 
hours post-exercise while Paddon-Jones et al.*® applied cryotherapy immediately 
following DOMS-inducing exercise. Both studies showed that post-exercise cryotherapy 
application had no effect on strength outcomes.*'*’*® Kimura et al.*® however, showed that 
there was no effect on PT with a 30-minute application of cryotherapy prior to exercise, 
but it did increase total eccentric work. Verducci’s**study showed that 3-minute interval 
cryotherapy between sets caused an increase in muscle endurance. Denegar et al.*'* had a 
decrease in muscle soreness following a 20-minute application o f cryotherapy to healthy 
uninjured subjects 48 hours after the DOMS-inducing exercise bout. Studies that did not 
produce DOMS have shown a decrease in muscle strength with testing immediately 
following cryotherapy treatment.®’**"*®’**’*'' This decrease in strength may be due to 
strength testing subjects immediately following cryotherapy, which has been shown to
decrease metabolism,*’'*’'" ’''*’*®’*’ blood flow,'*®'** and nerve conduction velocity*’*® to the 
area, and therefore, possibly effecting muscular strength.
Cryotherapy application causes a rapid decline on skin surface and a more gradual 
decline with deep tissues.**’*® Jutte et al.*® noticed decline in tissue temperature of 27°C at 
skin surface and 8°C at 2 cm subadipose tissue.*® Adipose tissue can affect the efficacy of 
the cryotherapy treatment, with thick adipose causing less of a decrease in tissue 
temperature.**’** With persons having greater adipose tissue thickness longer treatment 
time are required.
If adipose thickness has an impact on tissue temperature, then inadequate 
application times may allow tissue to re-warm faster with exercise post cryotherapy 
application. Myrer et al.*® showed that with exercise post cryotherapy application there 
was a greater increase in tissue temperature.*® Long et al.®® showed that cryotherapy 
application post exercise caused a greater decrease in tissue temperature at skin surface 
than I cm and 2cm subadipose.®® The question as to when should we apply cryotherapy 
pre or post exercise to individuals for the greatest benefit should be assessed.
There are many discrepancies in the literature regarding mode, when to apply, 
and the appropriate duration of cryotherapy application. Starting with the mode; stated 
earlier there are three common ways of administering cryotherapy: I) ice bag,*’®’**’'**''*®’**' 
®® 2) ice massage,*’^ ®'**’**’*'*’*®'*®’**’*''’®*’®*’®*'** and 3) cold water immersion.^®’^ *’** Myrer et 
al.**’®* in their investigations revealed that ice bag with compression has a greater 
decrease in tissue temperature than ice alone®* and cold water immersion.®* Plus ice bags 
last longer and can draw four times as much heat from the body than other forms.** The 
possible reasons for ice bags and compression causing a greater decrease in tissue
temperatures may be due to a greater conduction between the ice bag and the skin; 
compression may secondarily decrease blood flow.**’**’** Ice bags have also been shown 
to cause a greater decrease in tissue temperature over chemical frozen pack.®® In areas of 
odd shapes such as the ankle, elbow, and hand, cold immersion may be a more 
appropriate modality choice, since this may have better conduction. As to the when of 
cryotherapy application, it is suggested that the application occur within 5-10 minutes 
post-injury.*’*’**’*®
Historically, cryotherapy has been applied for as little as 3-minutes** to as much 
as 45-minutes.** The appropriate duration for cryotherapy treatment should depend on 
adipose thickness, location of injury, the form of treatment, and patient sensitivity.*’*’**’** 
Application of cryotherapy for acute injury care should be between 20-45*’**’** minutes 
with thicker tissues such as the quadriceps receiving longer durations every 1-2 hours in 
order to maintain decreased metabolism.*’** With cryotherapy application subjects are 
going to have pain, burning, tingling, and then numbness occurring usually within 5 
minutes of the application.**’** With repeated bouts of cryotherapy the sensation of pain 
will decrease.*®’** Also, with a colder modality the decrease in pain sensation occurs more 
rapidly in repeat bouts.*® Some discomfort is expected with cryotherapy especially with 
the initial bouts, just be cautious o f persons with hypersensitivity. Hypersensitivity 
although rare may occur with these conditions: 1) cold uticaria, which causes hives with 
cold application, 2) cold hemoglobinuria, free hemoglobin in the urine, 3) Raynaud’s 
phenomenon, excessive vasoconstriction causing cyanosis, or 4) vasospastic disorders, 
the vessels in the body do not dilate properly.**
The effects of cryotherapy on acute injury decreases temperature, blood flow, 
pain, muscle spasms, secondary injury and increase tissue stiffness and viscosity. 
Cryotherapy being widely used for the acute musculoskeletal injuries, may have other 
benefits as a recovery modality after training and competitions.**
Eccentric Muscle Action 
Eccentric muscle action is the lengthening of the muscle by a resistance greater 
than the torque produced by the muscle.**'*®'**'*®’*® When studying the effects of exercise- 
induced muscle damage that produce DOMS, investigators use eccentric exercise 
performed on an isokinetic dynamometer,**’*®’**’*®’*®’**’**’**’** isotonic eccentric exercise 
sustained for several seconds,*®'*^’**’*®’**’** step test with one leg constantly performing 
concentric muscle action and the other performing eccentric muscle action,**’** or 
downhill running.** Eccentric muscle actions have a greater peak torque production 
(strength) than concentric muscle actions.**’*®’** This increase in the production of force 
could be one of the reasons why eccentric exercises are commonly employed for 
exercise-inducing muscle damage.
With eccentric exercises, there has been a noticeable decrease in muscle strength 
immediately following the exercise bout.*®’**’**'*®’**’**’*®’**’**’** Other symptoms that occur 
after intense eccentric exercise are muscle tenderness,*®’**'*®’*®’**’**’**’**’**’** decrease in 
ROM,*®’*®'*®’**’*®’** and an increase in girth measurements of the muscle that performed 
the eccentric exercise.*®’*®’*®’*®’*®’** Unique to the quadriceps subjects that perform intense 
eccentric exercise they have experienced a feeling of weakness and instability after 
exercise.**’** These symptoms are only observed after exercises involving eccentric 
muscle action. These symptoms may be diminished with the application of cryotherapy.
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Possible reasons/theories for some of these symptoms following eccentric muscle 
action are injury to the muscle fiber from forceful lengthening of the m uscle."’*®’*® This 
injury to the muscle immediately following eccentric muscle action can be caused by the 
disruption or damage of the sarcomeres being over-stretched and/or microtears within the 
cells membrane.*®’*® The disruption and/or damage following intense eccentric muscle 
actions trigger the muscles into a remodeling phase allowing the muscle to hypertrophy.*® 
The symptoms that occur due to damage of the muscle after intense novel eccentric 
exercise is often referred to as DOMS.
Delayed On-set Muscle Soreness 
In 1902, Hough** discovered this phenomenon of delayed on-set muscle soreness, 
better known as DOMS. In his observation, he noticed that subjects developed pain and 
tenderness in his muscle hours and days after the initial exercise bout, peaking 24-48 
hours post-exercise.** The interesting fact is that still over 100 years after this initial 
study, the cause and how to best prevent DOMS and it’s symptoms, remains unknown.
DOMS can be defined as pain due to an acute injury to skeletal muscle causing 
decreased ROM, a decrease in strength, increase in pain localized to the 
musculotendinous junction of the muscle belly, and an increase in circumference caused 
from swelling or edema formation following unaccustomed eccentric 
exercise.®’" ’**’**’*®’*®'** These symptoms of DOMS peak 24-48 hours after the 
unaccustomed exercise and subside within 7-10 days. *40*2,22,26,76-78
The literature that is present today agree that heavy unaccustomed eccentric 
exercise leads to an increase in muscle pain,***44-24,27.29,31,32,75  increased circumference of 
the muscle being stressed,*®’*®’*®’*®’*®’**’** a decrease in active range of motion
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(AROM),'®'*"-** *®-**'*®'*® ** and a loss of strength*®'*®'**'**'**-**'** following exercise, all o f
which peaks 24-48 hours post-exercise. But whether there is a greater increase in pain at 
the musculotendinous junction or belly o f the muscle following intense eccentric exercise 
is still debated. Paddon-Jones et al.*® and Cleak and Eston** revealed that pain increase 
was equal between the musculotendinous junction and the belly o f the muscle acutely, 
whereas Baker et al.** had a greater increase in pain at the belly o f the muscle which 
developed DOMS. Whether pain occurs at the musculotendinous junction or muscle 
belly, we do know that there is an increase in pain in the muscle when DOMS occurs.
There are several theories as to why and how DOMS occurs.®’**’*® The elevation 
of exercise intensity or unaccustomed exercise can be accompanied by increase in tension 
in contractile elastic elements causing structural and physical damage, increased 
metabolism in waste accumulation, increase temperature causing structural damage or 
altered neural control producing spasms eliciting pain.®’**’*®
Cheung et al.*® breaks these DOMS-causing concepts down even further into 
possible mechanisms as to why this soreness may occur: 1 ) The lactic acid theory states 
that accumulation o f lactic acid causes noxious stimulus and perceived pain being 
delayed; 2) The muscle spasm theory states that increased muscle activity during rest 
after eccentric exercise, leads to compressed local blood vessels, causing ischemia; 3)
The connective tissue damage theory states that stretched-induced and strain damage to 
the connective tissue and collagen degradation; 4) The muscle damage theory states that 
disruption o f contractile component may cause microscopic lesions disrupting the 
sarcomere, which leads to a decrease in motor unit recruitment during eccentric actions, 
stimulating nociceptors; 5) The inflammation theory is the edema formation caused by
12
secondary injury; and 6) The enzyme efflux theory states that calcium accumulates in 
injured muscles following sarcolemma damage.*® These possible theories for the cause of 
DOMS are similar to an acute musculoskeletal injury; therefore using cryotherapy may 
decrease the symptoms o f DOMS.*’*"’*®
A phenomenon associated with DOMS is the “repeat bout effect” or RBE, which 
is the second bout of DOMS inducing exercise causing fewer symptoms than the initial 
bout of eccentric exercise.**’**’*®’**
Repeat Bout Effect
The “repeat bout effect” (RBE) is a phenomenon only seen in eccentric exercise
l O  O T  C O  o c
resulting in muscle damage. ’ ’ ’ Symptoms resulting from a bout of muscle damaging 
eccentric exercise include, pain, strength loss, and muscle tenderness; a repeat bout of the 
same eccentric exercise causing minimal sensation of these symptoms is an RBE.** Only 
muscles that are eccentrically lengthened result in the RBE phenomenon with the second 
bout o f exercise as compared to a muscle that is concentrically shortened.** Several 
studies have investigated this phenomenon. Smith et al.** concluded after the second bout 
of eccentric exercise 4 days post initial bout caused some soreness, but a second bout 13 
days post initial bout produced no soreness.**’** Nosaka and Clarkson*® noted that with a 
second bout o f exercise 3 and 6 days post the initial bout, muscle soreness was no 
different than baseline. So when performing intense eccentric exercise 9 days after the 
initial bout the RBE that occurred allowed the subject to have high exercise intensity with 
minimal to no soreness.
McHugh et al.** discussed three theories that may explain the RBE phenomenon: 
neural theory, connective tissue theory, and cellular theory. 1) Neural theory; exercise-
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induced damage involves eccentric exercise, which initiates high threshold motor units 
recruitment of fast-twitch muscle fibers that are more susceptible to damage with 
excessive stress;** 2) Connective tissue theory: A mechanical failure o f myofilaments or 
structural failure occurs caused by repetitive tensile stress.** The passive lengthening of 
the muscle while increasing force production (as seen in eccentric exercise) causes 
muscle stiffness.** Mechanism for this stiffness include edema formation, contractile 
resistance to passive ROM or changes in mechanical properties o f the connective tissue 
caused by the injury;** 3) Cellular theory: forcible detachment o f crossbridges or 
“popping” of sarcomeres, causing a greater strength deficit at short muscle lengths and 
the RBE may cause a adaptation in the sarcomeres, so only the strongest or more adaptive 
sarcomeres survive.** The figure below describes these theories in adaptation and how 
they may aid in this RBE phenomenon (Figure. 1). The inclusion of the RBE is important 
to this study in that the RBE only occurs with eccentric exercise and to account for this 
effect some studies state that RBE can occur in as little as 2 days post the initial exercise 
bout.**’** This effect in untrained individuals was considered in the design o f the study by 
allowing a 48 hour period between the first and second familiarization days. Also the 
methods allowed for a total of 5 days between the second familiarization day and day 1 of 
testing (pre-test). According to Mair et al.** the RBE can last up to 13 days following the 
initial bout of exercise. With untrained individuals some soreness may be reported even 
with the familiarization procedures.
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Repeated bout of eccentric exercise
Cellular Theory







Figure 1. Potential mechanisms which may explain the repeat bout effect (RBE). 
Reproduced with permission from Sports Medicine. March 1999; 27(3):157-170.
Summary
The use of cryotherapy with acute musculoskeletal injury causes a decrease in 
pain, swelling, secondary injury, and muscle spasms. Secondary injury causes healthy 
cells on the periphery of the initial injury to die by lyses or bursting. DOMS is similar to 
an acute injury in that it causes similar signs and symptoms of secondary injury. 
Increases in swelling, pain, and secondary injury occur, with decreases in strength and
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ROM also occurs. Therefore, in a controlled setting we used DOMS inducing exercise to 





This study was a 2(treatment) x 4 (test) repeated measures design with the 
following independent variables; treatment (Ice/No lee) and test time (4 days). The 
dependent variables were quadriceps mean peak eccentric torque (PT), muscle pain with 
palpation, knee flexion active range of motion (AROM), and thigh circumference (girth) 
measurements.
Description of Subjects
Subjects whom participated in this study were 16 healthy adults (8 male and 8 
female, age 26.81 ± 1.22 years, height 168.32 ± 2.22 cm, and weight 72.71 ± 3.89 kg) 
that had not undergone lower body weight training or had injury to the knee joint or 
surrounding musculature in the past six months and were not hypersensitive or allergic to 
ice. The subjects came from the general student population.
Instrumentation
An isokinetic dynamometer was used (Biodex System 3, Biodex Medical 
Systems, Shirley, New York) to measure peak torque of the quadriceps. A modified Borg 
scale of perceived pain was used to determine the discomfort/tenderness of the 
quadriceps during palpation. To ensure all subjects had the same amount of force applied 
during palpation, 5ON of force was applied using a Force Dial algometer (FDN 200;
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Wagner Instruments, Greenwich, Connecticut) with a 1.5 cm compression plate. A 
goniometer (Sammons Preston Rolyan, Bolingbrook, Illinois) was used to assess AROM 
about the knee joint and a Medco tape measure (Medco, Tonawanda, New York) was 
used to measure circumference (girth) o f the quadriceps. A 12”x 24” ice bag (Cramer 
Products Inc., Gardner, Kansas) filled with enough crushed ice to cover 2/3 o f the 
subject’s quadriceps of the treatment leg after testing or exercise was concluded. This 
was held in place by an 18’ x 6” elastic wrap (Hartmann-Conco Inc., Rock Hill, South 
Carolina) applied over the quadriceps.
Protocol
The week prior to testing, subjects were instructed to reported to the Athletic 
Training Research labratory on 2 occasions seperated by 48 hours and 72 hours prior to 
testing for familiarization. This ensured all subjects where familiar with all testing and 
data collection procedures. Subjects practiced isokinetic concentric/eccentric knee 
extension exercises on the Biodex for 4 sets at 60 deg*sec'’; 1) consisting of 2 maximal 
effort repetitions for initial quadriceps mean PT, 2) 10 repetitions at 25% of their initial 
maximum quadriceps mean PT, 3) 5 repetitions at 75% of their initial maximum 
quadriceps mean PT and 4) 3 maximal repetitions for both limbs. After familiarization, 
subjects reported back to the lab the following week for testing and treatment on 5 
consecutive days (Table 1). Subjects were verbally instructed by the investigators to 
refrain from taking any oral analgesics (e.g., Ibuprofen or Aspirin), stretching, 
messaging, or placing hot or cold packs on the quadriceps to aid in the relief o f the 
discomfort from the exercise.
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Table 1. Daily Protocol Schedule.
W ednesday F riday M onday T uesday W ednesaday T hursday F riday
U Ü M S  In d u c in g 24  h o u rs  F o s t- 4 8  h o u rs  P o s t- 72  h o u rs  P o st-
F a m ilia r iz a tio n F a m ilia r iz a tio n B ase lin e D ay DOM S DO M S DOM S
• 4 se ls • 4 se ts • l.)ay 1 * Day 2 • Days 3 • D ays 4 • Day 5
2 m ax im u m 2 m a x im u m M easurem ents M easurem ents M easu rem en ts M easu rem en ts M easu rem en ts
rep e titio n s re p e titio n s (A R O M , girth. (A R ()M . girth. (A R O M , girth. (A R O M , girth. (.AROM , girth .
10 re p e titio n s  a t 10 re p e titio n s  at pain prc- pain p rc- pain  pre- pain p rc-
2 5 %  o f  in itia l 25 "o  o f  in itia l exercise) cxcrcisc) cxcrcise) ex ercise) cxercise)
m ax m ax 3 m axim al S sets o f  10 3 m axim al 3 m axim al 3 m axim al
5 re p e titio n s  a t 5 re p e titio n s  a t eccen tric m axim al eecen trie eecen trie eccen tric
7 5 %  o f  in itial 75"'i) o f  in itia l con trac tions eccen tric con trac tions co iilrae tions eon lractio iis
Pain con trac tions  with Pain Pain Painm ax m a  X
60 seconds restlucasu rcm en ts m easu rem en ts m ca.surcm ents m easurem ents
3 m ax im u m 3 m a x im u m
hetw ecn each set
re p e titio n s
post-exercise p ost-exercise p ost-exercise post-exercisc
re p e titio n s
Pain
m easurem ents 
post-cxcrcise  
4 5 -n iin u te  ice
45 -m in u te  ice 
bag app lication  
d irec tly  on the 
sk in  cov erin g  2/3
4 5 -m in u te  ice 
bag app lication  
d irec tly  on the 
skill co v erin g  2/3
hag application o f  the  quad riceps  o f  th e  quad riceps
directly  on the Pain Pain
skill covering  2/3 m easu rem en ts m easu rem en ts
o f  the quadriceps p o st-trea tm en t post-trea tm en t
Pain
m easurem ents
post-trea tm en t
Prior to the beginning of testing on each of the 5 consecutive test days, subjects 
warmed-up to achieve 65% of their target HR (220-age*0.65) for 5 minutes on a 
treadmill (Precor model C966, Precor Inc., Woodinville, Washington). Subject’s knee 
AROM was then assessed with a goniometer (Figure. 2). The fulcrum of the goniometer 
was placed over the lateral epicondyle, the proximal arm was aligned with the greater 
trochanter, and the distal arm was aligned with the lateral malleolus and fibular head.^^ 
Girth measurements were taken at the knee joint line and then 5 cm, 10 cm, 15 cm, and 
20 cm above the joint line (Figure. 3).*° Measurements were taken three times at each of 
the above designated sites then averaged to ensure accuracy (days 1-5). Subjects were
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asked to give their level of pain (discomfort/tenderness) with palpation (perpedicular 
force o f SON)’"^ o f the quadriceps, investigator used the Force Dial algometer and a 
modified Borg’s scale for perceived pain. Subjects gave the investigator the number that 
corresponded to their pain level. Palpation pain sites included the belly of the VMO, and 
sites 5 cm, 10 cm, 15 cm, and 20 cm above the joint line (which were the same sites used 
for girth) (Figure. 4). Pain was assessed pre-exercise, post-exercise (days 1-5) and post 
treatment (days 2-4). The same investigator administered all measurements and palpation.
4
Figure 2. Knee AROM Measurement Figure 3. Girth Measurement Sites.
Subjects performed all testing and training seated in the Biodex dynamometer 
chair. The upper body and lower body were secured with a lap belt and two crossing 
shoulder straps. The chair was positioned so that the hip was in an 80° position, while the 
knee joint was aligned with the axis of rotation of the dynamometer shaft. The knee 
attachment o f the dynamometer was adjusted so that it was proximal to the medial 
malleoli. Subject positioning in the Biodex was set according to the manufacturer
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guidelines (Figure. 5). The dynamometer was set to the isokinetic setting with eccentric 
contraction mode at 60 deg*sec’  ^ (all testing and exercise were performed at this speed).
Figure 4. Sites for Pain with Palpation. Figure 5. Biodex Setup.
During day 1 (pre-test), subjects performed 3 maximum eccentric contractions. 
During day 2 (exercise day) of testing, subjects performed 8 sets o f 10 maximal eccentric 
contractions which was used to induce DOMS.^^ Between each set, a 60 seconds rest 
interval was given, similar to previous studies that induced After
completion of these sets, an ice bag held in place with an elastic wrap applied to the pre­
selected quadriceps for 45-minutes. ^ 4.43,44,53,64 legs were tested, but only the pre­
selected leg received the cryotherapy treatment. The testing protocol was the same as 
testing day 1 (3 maximal eccentric contractions) on days 3 through 5. Following exercise 
on day 2 and testing on days 3 and 4, the pre-selected quadriceps received the 45-minute 
ice bag application. Table 2 below demonstrated the counter balancing of the limb and 
treatment order for testing.
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Table 2. Subject Testing Order.
Limb Treatm ent Subjects Day 1 Day 2 D ay 3 Day 4 D a y s
R v s L Ice/No Ice 1,5,9,13 Pre-Test Exercise Test Test Test
L v sR Ice/No Ice 2,6,10,14 Pre-Test Exercise Test Test Test
R vs L No Ice/Ice 3,7,11,15 Pre-Test Exercise Test Test Test
L vs R No Ice/Ice 4,8,12,16 Pre-Test Exercise Test Test Test
Data Analysis
Eccentric mean peak torque was normalized to body weight by dividing peak 
torque by body weight. Then peak torque, range of motion (ROM), thigh girth, and point 
tenderness data were collected during the 5 days o f this experiment.
Statistical Analysis
A factorial repeated measures ANOVA (a = .05 and Bonferroni adjustment for 
multiple comparisons) was used for all data reduction were analyzed across treatment (ice 
vs. no ice), time (day 1, day 3, day 4, and day 5), and treatment by time interaction. Main 




Analysis of eccentric peak torque resulted in statistically significant differences 
for time ( F 1 . 9 7 , 2 9 .4 8  = 4.480, and p = .020), where quadriceps mean peak torque at day 1 
(3.14 ±0.16 Nm/BW) was greater than day 3 (2.62 ±0.16 Nm/BW) whieh is 24 hours 
post-intense eccentric exercise (p = .029). Day 4 (2.43 ±0.18 Nm/BW), and day 4 (2.79 ±
0.19 Nm/BW) were not statistically different from day 1, day 3, and eaeh other. There 
were no statistieal differences for treatment (Fi.oo, 15.00  = .001, p = .979) or treatment by 
time interaction (Fs o o . 4 5 .0 0  = 1.742, p = .172) as seen in table 3.
Table 3. Quadrieeps Eceentric Mean Peak Torque with Standard Deviation
Treated Untreated
Day 1 3.09 ± 0 .8 7  Nm/BW 3.19 ± 0 .9 5  Nm/BW
Day 3 2.6 ± 0.85 Nm/BW 2.64 ± 1.01 Nm/BW
Day 4 2.52 ± 0 .9 8  Nm/BW 2.35 ± 1.05 Nm/BW
Day 5 2.78 ± 1.06 Nm/BW 2.79 ± 1.07 Nm/BW
Knee range of motion (ROM) analysis resulted in no statistical significance for 
any data at treatment (Fi.oo, 15.00  = .405, p = .534), time (Fi.i62, 17 .4 4  = 2.408, p = .136), or 
treatment by time interaetion ( F 3  0 0 .4 5 .0 0  = .561, p = .993). See table 4 for recorded values.
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Table 4. Mean Knee Flexion Active Range of Motion with Standard Deviation
Treated Untreated
Day 1 138.35 ± 9 .1 9 ° 138.01 ± 9 .7 5 °
Day 3 133.69 ± 9 .9 4 ° 133.29 ± 11.53°
Day 4 122.40 ± 37.39° 121.75 ± 36.29°
Day 5 133.86 ± 15.06° 133.63 ± 13.88°
The analysis of thigh girth measurements taken at knee joint line, 5, and 10 cm 
resulted in no significant differences, while those at 15 and 20 cm above joint line did, as 
seen in table 5. Data analyzed at knee joint line were not significant for treatment (F i.o o ,
15.00 = .070, p == .795), time ( F 3  0 0 , 4 5 .0 0  = 1.037, p = .385), nor treatment by time 
interaction ( F 3 . 0 0 , 4 5 .0 0  = .56, p -  .644). Girth measurements at 5 cm above joint line 
measurements were not significant for treatment (F i.o o , 15 .00  =  .286 , p = .601), time ( F 3 .0 0 0 ,
45.000 = 2.409, p  = .079), nor was there a treatment by time interaction ( F 3 . 0 0 , 4 5 .0 0  = .314, p 
= .815). At 10 cm girth site, none of the measurements had statistical significance for 
treatment (F i.o o , 15.00 = 1.349, p = .264), time (F2.17, 32.59 = 718, p = .506), or the treatment 
by time interaction ( F 3 . 0 0 , 4 5 .0 0  = .858, p = .471).
There were statistical significances found at 15 cm above joint line for time ( F 3 .0 0 ,
4 5 .0 0  = 7.415, p < .001) and treatment by time interaction ( F 3 . 0 0 , 4 5 .0 0  =  2.827, p == .049), but 
there was no statistical significance for treatment (F i.o o , 15 .0 0  = 4.330, p = .055). Time 
analysis revealed statistical differences from day 1 (50.61 ± 1.52 cm) to day 4 (51.184 ±
1.54 cm, p = .001). Day 1 values were lower than day 4 values. Since the data were 
statistically significant for treatment by time interaction a paired T-test was used for 15 
cm above joint line limb girth.
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Day 1 37.42 ±3.47 cm 37.26 ±3.00 cm
Day 3 37.38 ± 3 .28 cm 37.31 ±3.16 cm
Day 4 37.38 ±3.21 cm 37.42 ±2 .95 cm
Day 5 37.48 ±3.42 cm 37.47 ±3.21 cm
Day I 39.87 ± 4 .2 9 cm 39.99 ±4.40 cm
Day 3 39.90 ±4 .26 cm 40.04 ±4.52 cm
Day 4 40.13 ± 4 .2 9 cm 40.15 ±4.36 cm
Day 5 40.13 ±4.44 cm 40.18 ± 4 .4 7 cm
Day 1 45.30 ±5 .83 cm 45.03 ±5.58 cm
Day 3 45.40 ±5.47 cm 45.23 ±5 .53 cm
Day 4 45.53 ± 5 .2 2 cm 45.20 ±5.43 cm
Day 5 45.35 ±5.68 cm 45.40 ±5 .33 cm
Day 1 51.01 ± 6.48 cm 50.21 ±5.70 cm
Day 3 51.03 ± 6.26 cm 50.70 ± 6 .1 9 cm
Day 4 51.43 ±6.25 cm 50.94 ± 6.06 cm
Day 5 51.23 ±  6.29 cm 51.02 ± 5.86 cm
Day 1 55.23 ±6.20 cm 54.95 ±6.54 cm
Day 3 55.69 ±6.31 cm 55.43 ± 6 .5 5 cm
Day 4 55.97 ± 6.88 cm 55.76 ± 6 .7 7 cm
Day 5 55.46 ±6.31 cm 55.50 ±6.61 cm
Day 1 values in the treated (51.01 ± 1.62 cm) limb were greater than the untreated 
(50.21 ± 1.43 cm) limb (tis.oo = 2.471, p = .026) and day 4 values in the treated (51.43 ±
1.56 cm) limb were again greater than the untreated (50.94 ±1.51 cm) limb (tis oo -  
2.291, p = .037). However, the 15 cm superior to joint line girth measurement for day 3 
(ti5 .o o  = 1.686, p = .112) and day 5 (ti5 ,o o  = .756, p = .461) were not statistically 
significant.
No statistical significance were seen at girth site 20 cm superior to joint line for 
treatment (Fi.oo, 15.00 = .806, p = .383) or treatment by time interaction (F3 .00, 4 5 .0 0  = 726, p
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= .542), however time resulted in a statistically significant difference (F3 00, 45.00 = 4.848, 
p = .005). Where day 1 (55.09 ± 1.59 cm) and day 4 (55.87 ± 1.70 cm) were statistically 
different (p = .027). Day 1 girth was less than girth measurements on day 4.
Pain measurements were taken pre-exercise, post-exercise, and post-treatment for 
all pain sites (VMO, 5cm, 10cm, 15cm, and 20cm above joint line) as seen in table 6.
The measurements for point tenderness at the VMO site during the pre-exercise 
time point, the treatment (F i.o o , 15.00 = .011, p = .916), time (F3.00,45.00 = 1.274, p = .295), 
and treatment by time interaction (F3 .00,45.00 = .706, p = .554) analyses all resulted in no 
significant differences. The point tenderness assessment at the VMO site immediately 
post-exercise again resulted in no significant differences for treatment (F i.o o , 15.00 -  .685, p 
= .421), time (F2 .15, 32.24 = 1.326, p = .281), or the treatment by time interaction (F3 00,45.00 
= .847, p = .475) analysis. In addition treatment data resulted in no significant differences 
at the VMO site post-treatment (F i.o o , 15.00 = .000, p = 1.000).
Point tenderness data at the VMO site during the post-treatment assessment 
resulted in statistically significant differences for time (F2 .00, 30.00 -  4.650, p = .017) and 
treatment by time interaction (F1.405,21.072 ~ 6.072, p = .015). Point tenderness at the VMO 
site was different after the initial treatment with cryotherapy on the day 2 (1.45 ± .30) and 
day 3 (2.42 ± .44) post-eccentric exercise (p = .012). To further analyze the treatment by 
time interaction a paired T-test was used for the simple main effects analysis.
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Table 6, Recorded Pain Measurement Values for All Site with Standard Deviation
B o rg  P rec ieve d  P a w  P re-E xe rc ise  V alue B o rg  P rec ieve d  P a in  P o s t-E x erc ise  V alue B o rg  P re c ie v e d  P a in  P o st- J 'reatm ent Value
P re-E xercise T reated U n treated P o st-E x e rcise T reated U n treated P o st-T r ea tm en t T reated U n treated
V M O  P re-E x V M O  P ost-E x V M O  P o s t-T x
D ay  1 2 .1 6 ±  1.93 2 .0 5  ± 2 ,0 2 D ay  1 1.91 ± 0 .1 .5 5 1.97 ±  1.44 D ay  1 * *
D ay 2 • * D ay 2 • * D ay 2 1 .1 9 ±  1,47 1 .7 2 ±  1.26
D ay 3 2 .69  ±  1.98 2 .88  ±  1.86 D ay 3 2.63 ± 2 .1 5 2 .4 7  ±  1.53 D ay 3 2 .5 0  ± 2 .0 6 2 .34  ±  1.54
D ay 4 2 .7 2  ±  1.87 2 .5 6  ± 0 .1 .8 2 D ay 4 2 ,1 9 ± ] .8 2 1,91 ±  1.93 D ay 4 2 .38  ± 2 ,2 7 2 .0 0  ±  1.82
D ay 5 2 .13  ± 0 .1 .9 5 2.13  ± 0 .1 .8 8 D ay 5 2 ,0 0  ± 2 .2 1 2 .0 0  ± 2 , 18 D ay 5 * •
5 cm  P re-E x 5 cm  P ost-E x 5 cm  P o st-T x
D ay 1 0 .9 4  ± 0 .8 9 0 .88  ± 1 .0 1 D ay 1 ] ,1 3 ± 1 .2 8 1.06 ± 0 ,9 8 D ay 1 * *
D ay 2 • * D ay 2 * * D ay 2 0 .78  ± 0 .9 7 0 .7 2  ± 0 ,7 3
D ay 3 0.91 ± 0 .9 7 1.00 ± 0 .9 3 D ay 3 0,91 ± 0 .9 0 0.91 ± 0 .9 2 D ay 3 1 ,0 0 ±  1.13 0 .9 4  ± 0 ,8 9
D ay  4 1.03 ± 0 .9 9 1.0 0  ±  1,00 D ay 4 0,81 ± 0 ,9 3 0 .94  ± 0 ,9 6 D ay 4 0.81 ±  1.01 0.81 ± 0 .9 5
Day 5 0 .8 4  ± 0 ,9 3 0 .78  ±  1.00 D ay 5 0 ,78  ± 0 .9 3 0 .75  ±  1.01 D ay 5 * *
10 cm  P re-E x 10 cm  P ost-E x 10 cm  P ost-T x
D ay I 1 .0 9 ±  1.19 0 .8 8  ± 0 .9 7 D ay 1 1,06 ±  1,09 ! .0 6 ±  1,15 D ay 1 * *
D ay 2 * * D ay 2 * * D ay 2 0 .9 4  ±  1.22 0.91 ±  1.04
D ay 3 1.50  ±  1.25 1 .6 9 ±  1.39 D ay 3 1,13 ± 0 .7 9 1.41 ±  1.27 D ay 3 1,41 ±  1.17 1 .3 8 ±  1.40
D ay 4 I .5 6 ±  1.20 1.72 ±  1.85 D ay 4 ] ,3 8 ±  1.53 1.38 ±  1.30 D ay 4 1 ,1 9 ±  1.21 ] .3 8 ±  1.52
D ay 5 1 .1 6 ±  1.11 1.31 ±  1.33 D ay 5 0 .97  ± 0 .8 7 1 .2 2 ±  1.17 D ay 5 * *
15 cm  P re-E x 15 cm  P ost-E x 15 cm  P o st-T x
D ay 1 ! .6 6 ±  1.75 1 .2 2 ±  1.38 D ay 1 1 .3 8 ±  1.62 1 .3 4 ±  1.41 D ay 1 * *
D ay 2 * * D ay 2 * * D ay 2 1.47 ± 2 .0 7 1 .1 6 ±  1.09
D ay 3 2 .63 ±  1.45 2 .7 8  ±  1.47 D ay 3 1.91 ±  1.04 2,41 ±  1.40 D ay 3 2 ,5 0  ±  1,62 2 .2 8 ±  1.39
D ay 4 3.31 ±  1.49 3 .5 6  ±  1.97 D ay 4 2 .4 4 ±  1.31 2 ,94  ±  1,39 D ay 4 2 .88  ±  1.75 2 .97  ± 2 .0 7
D ay 5 2 .75  ±  1.60 2 .63  ±  1.67 D ay 5 1 .8 8 ± 1 .1 3 2 ,44  ±  1.55 D ay 5 * •
2 0  cm  P re-E x 20  cm  P ost-E x 2 0  cm  P o st-T x
D ay  1 1 .7 5 ±  1.65 i . 8 4 ±  1.76 D ay 1 1,63 ± 2 .0 2 I .8 4 ± 2 ,1 7 D ay 1 * *
D ay 2 * * D ay 2 * * D ay 2 1.31 ±  1.34 1 .7 8 ±  1.69
D ay 3 3 .2 5  ±  1.34 3 .6 9  ±  1.66 D ay 3 2 ,88  ± 1 .3 6 3 ,1 3 ±  1.67 D ay 3 3 .0 9  ±  1.99 3 .0 6  ±  1,65
D ay 4 4 .1 9 ±  1.68 4.41 ± 2 .5 5 D ay 4 3.63 ± 1 .7 8 3 .94  ±  1,73 D ay 4 3 ,69  ± 2 ,4 1 3 .88 ± 2 ,5 3
Day 5 3 .5 9 ± 2 .3 8 4 .0 9  ± 2 .6 0 D ay 5 3 .3 4 ±  1.90 3 .75  ± 2 ,3 2 D ay  5 * *
* N o  d a ta  co llec ted  on  th ese  days.
No statistical significances were found between the treated and untreated limb. Day lo f 
the VMO point tenderness resulted in no differences post-treatment between the treated 
(1.19 ± .37) and untreated (1.72 ± .32) limb (tis oo = -1.622, p = .126), and Day 3 (tis.oo = 
.639, p = .533) between the treated (2.50 ± .51) and the untreated (2.34 ± .38) limb. The 
treated (2.38 ± .58) and untreated ( 2.00 ± .45) limb had no differences in point 
tenderness on day 4 as a result of the cryotherapy (tis.oo -  1.464, p = .164).
Analysis of the pre-exercise point tenderness at 5 cm superior to the joint line site 
resulted in no significant differences for treatment (Fi.oo, is.oo = .031, p = .863), time ( F 2 .1 7 ,
3 2 ,5 4  = .591, p -  .573) or treatment by time interaction ( F 1 . 4 1 , 2 1 . 2 2 =  .247, p = .706). 
Analysis of the post-exercise pain at 5 cm superior to joint line resulted in no differences
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for treatment (F i.o o , 15.00 = 0.50, p = .827), time (Fi.62,24.32 = 1.332, p = .278), or for the 
treatment by time interaction (Fi.34  ^20.07 = .672, p = .464). Also, no statistical significance 
occurred in any of the data for point tenderness immediately following cryotherapy 
application at 5 cm superior to the joint line for treatment (Fi.oo, 15.00 = .149, p = .705), 
time (F2.00, 30.00 = .961, p = .394), and treatment by time interaction (F 2 .0 0 ,30.0 0 = .063, p = 
.939).
Analysis of the pre-exercise point tenderness at the measurement site 10 cm 
superior to joint line resulted in no significant differences for treatment (F i .o ,  15,0  = .487, p 
= .496), time ( F 1 . 7  2 5 .9  = 2.384, p = .118) or treatment by time interaction ( p 3 . o , 4 5 . o =  .771, 
p = .516). The analysis of post-exercise point tenderness at the measurement site 10 cm 
superior joint line analysis resulted in no differences for treatment (F i .o ,  15 .0  = 2.442, p = 
.139), time (F 3 .0 ,45.0 = .973, p = .414), or for treatment by time interaction (F 3 .0 ,45.0 = .791, 
p = .505). Also, no statistical significance occurred in any o f the variables for post­
treatment point tenderness at the measurement site 10cm superior joint line treatment 
(F i .o , 15 .0  =  .039, p =  .847), time (F 2 .0 ,30.0 =  2.180, p =  .131), and treatment by time 
interaction (F 2 .0 ,30.0 = .346, p = .711).
The point tenderness site at 15 cm superior to joint line at the pre-exercise time 
point resulted in no differences for treatment (F i.o o , 15.00 = .034, p = .855) or treatment by 
time interaction ( F 3 . 00, 45.00 = 1.301, p = .286). However, there were statistical differences 
for time (Fi.99  ^2 9 .7 9  = 7.595, p -  .002). Day 1 (1.44 ± .37) point tenderness was lower than 
day 3 (2.70 ± .34) post-intense eccentric exercise (p -  .016) and day 1 point tenderness 
was lower than day 4 (3.43 ± .40) post-intense eccentric exercise (p = .011). Also, the 
point tenderness at the 15 cm superior to joint line site measured pre-exercise was highest
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on day 4 (3.43 ± .40) than day 5 (2.69 ± .36) it appears point tenderness peaked around 
the 48 hour time point.
Analysis of the post-exercise point tenderness at the 15 cm site for treatment 
(F i.o o , 15 .00  = 10.281, p = .006) and time (F3 .0 0 ,4 5 .0 0  = 4.749, p = .006) were statistically 
different, but treatment by time interaction did not occur (F3,0 0 ,4 5 .0 0  = 2.644, p = .061). 
Treatment analysis resulted in the treated limb (1.90 ± .23) being lower than the untreated 
limb (2.28 ± .28) suggesting that cryotherapy application aided in maintaining baseline 
point tenderness values (p = .006). Analysis of the day 1 (1.36 ± .37) values were 
significantly lower than 48 hours (2.69 ± .32) post-intense eccentric exercise value (p = 
.022).
Analysis of the post-treatment pain site 15 cm superior to joint line resulted in no 
differences for treatment (Fi 0 0 ,1 5 .0 0  = .305, p -  .589) or treatment by time interaction 
(F2 .00,30.00 = .559, p = .578). However, there were statistical differences for time (F2 .00,
30.00 = 8.498, p = .001). Point tenderness at the 15 cm site measured post-treatment on day 
1 (1.31 ± .36) was lower than day 3 (2.40 ± .35) following intense eccentric exercise (p = 
.024). Day 1 values were also lower than day 4 (2.92 ± .45, p = .013), during the post­
treatment point tenderness assessment.
The point tenderness site 20 cm superior to joint line at pre-exercise time point 
resulted in no differences for treatment (F i.o o , 15.00  = 1.291, p = .274), and there were no 
occurrence of treatment by time interaction ( F 2 . 2 0 , 33 .0 3  = .416, p = .682). However the 
time data were statistically different (Fi 75 2 6 .2 7  = 8.498, p = .002), pre-exercise resulted in 
day 1 (1.80 ± .40) values being less than either day 3(3.47 ± .36) or day 4 (4.30 ± .48) 
post-intense eccentric exercise (p -  .008, p = .005).
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Analysis of the point tenderness site 20 cm superior to joint line post-exercise 
data resulted in no significant difference for treatment (Fi.oo, 15 .0 0  = 2.945, p = .107) or 
treatment by time interaction ( F 2 . 2 5 , 3 8 .6 7  = .099, p = .924), but time data resulted in a 
statistical differences ( F 2 . 1 0 , 3 1 .5 2  = 7.987, p = .001). Day 1 (1.73 ± .50) values were lower 
compared to day 3 (3.00 ± .37, p = .044) and day 4 (3.78 ± .41) values following intense- 
eccentric exercise (p = .014).
Point tenderness analysis at site 20 cm superior to joint line at the post-treatment 
time point resulted in no differences occurring for treatment (Fi.oo, 1 5 .0 0  = .526, p = .479) 
or treatment by time interaction ( F 2 . 0 0 , 30.00 = .754, p = .479). However, time again was 
statistically different ( F 2 . 0 0 , 3 0 .0 0  = 10.081, p < .001). Day 1 (1.55 ± .36) values were 
statistically lower compared to both day 3 (3.08 ± .43) and day 4 (3.78 ± .57) values (p = 
.026, p = .004).
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CHAPTER 5
DISCUSSION AND CONCLUSION 
The present study investigated whether the application o f cryotherapy would 
decrease the effects o f delayed onset muscle soreness. To investigate this question 
eccentric mean peak torque, knee joint ROM, thigh girth measurements, and point 
tenderness were assessed. The results revealed that there were no significant difference 
between the treated and the untreated limb (except at 15 cm above joint line post-exercise 
pain), suggesting that a once daily application of cryotherapy may not affect the 
symptoms of DOMS.
Eccentric Mean Peak Torque 
The qucidriceps eccentric mean peak torque decrease was observed from dayl to 
day 3 post-intense eccentric exercise and remained low at day 4 and day 5. The fall in 
torque production peaked during day 4 post-intense exercise, which is similar to 
previously published 1 iterature. '  ^ ' ,2 3 ,2 4 ,2 7 -2 9 ,3 2 ,5 2 ,7 4  fjgwever, there were no differences
between the treated and untreated limb. In studies by Ruiz et al.^ and Maattacola et al.^  ^
strength diminished after application of cryotherapy. These two studies strength tested 
their subjects immediately following the cryotherapy application. This differs from the 
present study since no differences were seen between treated and untreated limbs and our 
subjects were strength tested prior to the cryotherapy application. Kimura et a\?^ found 
that there was no impact on force production. There is still uncertainty whether the
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application o f  cryotherapy may decrease strength and force production. R.B. Armstrong^® 
suggested that injury to the muscle may be a reason for the decrease in force production. 
The muscle injury may be a disruption o f  the myofilament structures, loss o f  
intramuscular proteins into the plasma, or sarcolemma damage that temporarily reduce 
force production.^^ Knight et al.  ^ suggested that with trauma that disrupts the muscle cells 
cryotherapy should be applied immediately following the traumatic event, and repeated 
frequently to maintain a decreased metabolism in the area and thus decreasing the effects 
o f  secondary injury.
Cryotherapy cannot impact the muscle healing directly; however, it can have an 
impact on muscle cell metabolism, and secondary injury^. Based upon the results o f  this 
study it appears that the once daily application, does not reduce edema formation without 
repeated application. Thus, it is conjectured that a single cryotherapy application will 
decrease the m uscle cells metabolism for a short period o f  time, however the treatment 
effects are negated by an increase in cell metabolism with further m uscle activity. To 
maintain the effects o f  the cryotherapy treatment, repeated bouts are apparently 
necessary. Dolan et al.’ found that with a 3 0  minute on and 3 0  minute o ff  cycle  
cryotherapy application reduced edema formation in the treated limb, but edema did still 
form. The once daily treatment o f  cryotherapy may not have had lasting enough benefits 
and may explain why there was no difference in the treated and untreated leg.
Range o f  Motion
Unlike previous studies '  ^7,19,20,23.24.28.29.32^  the present study resulted in no 
differences o f  ROM about the knee joint after intense-eccentric exercise were observed. 
Previous s t u d i e s ^ ,24.28,29,32 a decrease in ROM after a DOM S inducing
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exercise which peaked 48 hours post-exercise. A possible reason for this discrepancy in a 
decrease in ROM may be due to the faet that we investigated the ROM of the knee rather 
than the elbov/ as in many of the previous s t u d i e s ^ 1 9 .2 0 ,2 3 .2 4 ,2 8 ,2 9 .3 2  the disruption 
of the musele tissues, pain and edema formation may oecur, thus eausing the swelling and 
pain of the stretehing musele to limit ROM. With the applieation of eryotherapy to reduee 
edema formation and pain, ROM may be maintained. Also, the present researeh may 
suggest that active ROM was less affeeted by DOMS than passive ROM or that subjects 
are more apprehensive about having investigators move their arm or allowing gravity to 
extend their arm, thus affeeting ROM of the upper extremity more than the lower 
extremity. However sinee there was so mueh variability on day 4 in the AROM 
measurements, it is likely that the subjects were apprehensive to full flex the knee. 
Regardless, this variability appears to be equal in both the treatment and control 
conditions.
Girth Measurements 
The girth of a musele has been known to increase with DOMS.'^’’ ’^^ ’’^  ^However 
these studies have all foeused on the upper extremity (bieeps or forearm musculature) and 
all girth measurements were taken at the largest section or mid-belly of the musele. The 
present study looked at the joint line, museulotendinous (MT) junetion (sites 5 cm and 10 
cm above joint line), and mid-belly (15 em and 20 cm above joint line) sites. The joint 
line and MT sites were investigated were due to the faet that Bryne et al.^  ^ suggested that 
damage to the series elastie components may eause an inflammatory reaction, causing 
edema formation. The edema aecumulation would be easily measured at the joint line. 
Girth measurement did not increase at joint line, 5em or 10 cm above joint line, but like
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the previous s t u d i e s t h e r e  was an increase in the mid-belly sites. This increase 
peaked 48 hours (day 4) post-intense eccentric exercise which was in accordance to 
previous s t u d i e s . T h e  increase in swelling may have occurred from injury to the 
muscle caused by microtears or ultra-structural changes within the muscle belly. Even 
with the application of cryotherapy on the treated limb to decrease metabolism of the 
muscle tissues (decreasing the formation of edema, thus decreasing secondary injury'’^ ) 
there were no differences observed between the treated and untreated limbs. Dolan et al.’ 
however in their study observed that once the cryotherapy application was taken away 
from the treated limb that edema started to accumulate again and when the application 
was on there was a reduction in edema. Therefore, an increase that was seen in the 
present study could have been due to the fact that girth was not measured immediately 
following the cryotherapy application. This may suggest that the application of 
cryotherapy may need to be applied more frequently than once every 24 hours.
Point Tenderness
All subjects in this study experienced point tenderness following the intense- 
eccentric exercise. Point tenderness or soreness was measured at 3 different time points 
(pre-exercise, post-exercise, and post-treatment) on each testing day (day 1 and days 3-5 
post-intense eccentric exercise), except post-treatment it was not taken at day 1 or day 5 
post-intense exercise. Soreness for pre- and post-exercise time points resulted in no 
tenderness at the VMO, 5 cm or 10 cm above joint line. Point tenderness sites at 5 and 10 
cm above the knee joint line correlated to the musculotendinous (MT) junction of the 
quadriceps muscle, while 15 and 20 cm corresponded to the muscle belly of the 
quadriceps. However like Cleak et al.^^, Newham et al.^’ and Baker et al.^  ^the present
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study reported greater soreness in the belly of the muscle than at the MT junction. This 
differs from Paddon-Jones et al.’s^ *^  study which reported no difference in soreness 
between the MT and muscle belly. The increase in the soreness at the muscle belly may 
be attributed by the disruption of the myofilament structures,’  ^damage to the 
sarcolemma, thus causing edema which may increase the intramuscular pressure, thus 
applying pressure to sensitive pain receptors." At the 15 and 20 cm point tenderness sites 
values were greatest at day 3 and day 4 post-intense eccentric compared to day 1, but 
tenderness peaked at 48 hours (day 4) just as previous studies.
At time point post-treatment, which immediately followed the application of 
cryotherapy all muscle belly sites (VMO, 15, and 20 cm above joint line), soreness was 
greater at 24 and 48 hours after initial cryotherapy application, peaking at 48 hours. This 
differs from Carman et al.’*^ which showed a decrease in pain sensation after the initial 
day of cryotherapy with the repeated applications. Our finding may differ do to the added 
pressure o f the algometer to the muscle, where their study applied only cold with no 
additional pressure or exercise prior.
Conclusion
The conclusion of this study suggests that the once daily application of 
cryotherapy for 45-minute after and intense-eccentric exercise bout does not reduce the 
effects of DOMS. The lack of significant differences in pain reduction, ROM restoration, 
and edema formation suggest that the once daily application of cryotherapy every 24 
hours after the exercise allowed DOMS to remain as prevalent in the treated as the 
untreated limb.
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Limitation and Delimitations 
In this study there may have been some limitation that affected the results turn out 
the way they did. This study was very reliant on the effort that the subject put into their 
strength tests and ROM. Also, during the intense-eccentric day they were asked to give 
100% with each of the 8 sets of 10 repetitions, but highly dependent o f their effort and 
motivation. On the days following the intense-eccentric exercise bout since all subject 
were sore they may have been afraid to contract maximally during strength test do to 
their sore and stiff quadriceps. With the application of cryotherapy since all subjects had 
never received a cryotherapy application for that long or at all, most subjects were very 
hesitant and worried about the ice application. The ice application may have been on for 
too long for these subjects. Also with the ice not being applied every hour but every 24 
hours post-intense eccentric exercise, this may have hindered the effect of cryotherapy. 
The limitation that using the algometer was that in some subjects a contusion appeared 
that may have hindered accurate pain perception of the treatment, eccentric exercise and 
strength.
Implications for a Clinician 
The application of cryotherapy should be applied repeatedly as in Dolan et al.’ 
and Verducci’s^  ^ studies to limit the formation of edema and thus decreasing secondary 
injury that may occur with the disruption of muscle cells. That with modification to the 
application parameters, the application of cryotherapy should be more frequently than 
once daily may need to be employed to decrease the signs and symptoms of DOMS. In 
general a clinician can inform athletes that either have not worked out or are starting a
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more intense and new training regimen to start with lighter weights or easier aetivities 
and gradually increase their intensity to reduce the on-set of DOMS.
Future Research
Future researeh should involve the repeated applieation of cryotherapy for 45 
minutes on with an hour off time cycle to eombat this soreness developed. Also it may be 
reasonable to investigate the differenee in subjeets who are familiar with eryotherapy 
applieation from those who are not so that the psyehologieal aspeets of the cryotherapy 
applieation are not a variable. More research on DOMS and the quadrieeps should be 
done sinee there are several studies on the bieeps and forearm resulting in a deerease in 
ROM, and inerease girth but this was not seen in this study involving the quadrieeps.
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S l/R l 97.40 86 04 9840 114.90
SI/R2 92.70 88.90 99.70 118.70
S1/R3 82.90 8190 99.90 120.10




2" above JT Line 
4" above JT Line 
6" above JT Line 




















ROM: 134.00 135.00 135.00
Average 134.67
Circumfrence:
Joint Line 34.00 33.90 33.80
2" above .TT Line 3&M 36.00 36.20
4" above JT  Line 41.20 4040 41.50
6" above JT  Line 46.60 47.20 46.30
8" above JT  Line 5120 51.00 51.70
Pain: Pre Ex Post Ex P o s tT x
VM O 3.00 3.00 1.00
2" above JT Line 2.00 2 4 0 1.00
4" above JT  Line 3.00 2.00 1.00
6" above JT Line 3.00 1 0 0 1.00

















Pre Ex Post Ex P o s tT x
1 0 0 2.00 2.00
2.00 2.00 1.00
1.00 1.00 2.00
1.00 2 4 0 1.00











































S l/R l 77.40 69.70 79.20 72.90
S1/R2 64.40 69.80 82.10 82.90
S1/R3 67.80 67.90 84.30 77.90
81.87 77.90
DAY 4:
R O M :
A verage  
C ircu m fren ce :
Joint L ine 
2" above JT Line 
4" above JT Line 
6" above JT Line 
8" above JT Line
P ain :
VM O
2" above JT Line 
4" above JT Line 
6" above JT Line 
8" above JT Line
Treated
P eak  T o rq u e :
S l/R l








51.30 5 1 3 0 52.50






C o n cen tric

































A verage 66.63 91.70 104.63 137.20
DAY 5: 




139.00 1 141.00 139.00
A verage
C ircu m fren ce ;
Joint Line
139.33
34.40 34.20 34.20 34.27
139.67
33.80 33.80 33.70
2" above JT Line 36.00 36.00 36.20 36.07 36.10 36.10 36.00
4" above JT  Line 40.90 40.50 40.80 40.73 40.90 40.50 40.70
6" above JT Line 47.00 46.40 46.20 46.53 46.10 46.30 46.60














2" above JT Line 1.00 1.00 1.00 2.00 1.00
4" above JT Line 1.00 1.00 1.00 1.00 1.00
6" above JT  Line 2 00 1.00 1.50 3.00 2.00






























S l/R l 90.20 8 8 6 0 132.10 139.70
S1/R2 85.20 82.10 111.40 151.50




















I 142.00 1 143.00
142.33
Left Leg
142.00 I 138.00 I 140.00
140.00
Joint Line 33.40 33.20 33.20 33.27 33.30 33.20 33.10
2’ above JT Line 36.40 36.40 36.40 36.40 36.40 36.60 36.50
4' above JT Line 40.20 40.20 40.50 40.30 40.60 40.60 41.00
6' above JT Line 45.20 46.00 45.40 45.53 46.00 46.00 45.40










2" above JT  Line 
4" above JT Line 
6" above JT Line 
8" above JT  Line
Pre Ex Post Ex Post Tx Pre Ex Post Ex Post Tx
0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00










S l/R l 91.70 108.20 158.40 166.90
S1/R2 106.80 110.00 162.10 159.70










2" above JT  Line 0.00 0.00 0 0 0
4" above JT  Line 0.00 0.00 0.00
6" above JT  Line 0.50 0.50 0.50
8" above JT  Line 0.50 1.00 0.50
DAY 3:
Right Leg
ROM : 139.00 | 139.00 | 139.00
A verage 139.00 
Circumfrence:
Joint Line 33.40 33.30 33.40
2" above JT Line 36.60 36.90 36.70
4" above JT Line 40.40 40.10 40.60
6" above JT  Line 45.20 45.50 45.50
8" above JT  Line 50.20 50.20 50.20






2" above JT  Line 0.00 0.00 0.00
4" above JT  Line 0.00 0.00 0.00
6" above JT  Line 2.00 2.00 2.00






































































S l/R l 89.50 91.50 147.70 155.40
S1/R2 105.90 115.60 143.30 164.80
S1/R3 101.90 109.80 147.90 165.70
161.97
DAY 4:








2 "  above JT Line 36.20 36.50 36.50
4" above JT Line 40.20 40.50 40.90
6" above JT Line 45.40 45.70 45.70
8" above JT Line 49.50 49.30 50.20
Pain: Pre Ex Post Ex Post Tx
VMO 2.00 1.00 1.00
2" above JT Line 0.00 0.00 0.00
4" above JT Line 1.00 0.00 0.00
6" above JT Line 4.00 2.00 3.00
8" above JT Line 7.00 4.00 6 0 0
































S l/R l 106.00 99.80 152.90 169.30
S1/R2 106.20 112.30 154.20 160.70










A verage 105.87 106.13 150.80 164.23
D A Y S:
R O M :
A verage
C ireum frence :
Right Leg
145.00 I 147.00 I 147.00
146.33
Left Leg
145.00 I 145.00 I 146.00
145.33
Joint Line 33.00 33.20 33.00 33.07 33.20 33.20 33.10
2" above JT  Line 36.20 35.80 36.30 36.10 36.50 36.20 36.40
4" above JT  Line 40.30 40.10 40.40 40.27 41.00 40.30 40.20
6" above JT Line 45.20 45.30 44.80 45.10 45.80 46.10 46.20








2" above JT  Line 
4" above JT  Line 
6" above JT  Line 
8" above JT Line
Pre Ex Post Ex Post Tx Pre Ex Post Ex P ostT x
2.00 1.00 1.50 2.00 1.00 1.50
0.00 0.00 0.00 0.00 0.00 0.00
0.00 1.00 0.50 0.00 0.00 0.00
4.00 3.00 3.50 5.00 2TW 3.50
8.00 5.00 6.50 7.00 5.00 6.00







S l/R l 96.70 107.40 165.40 178.80
S1/R2 106.60 115.70 159.90 192.40
















ROM : 120.00 120.00 120.00
A verage 120.00
C ircum frence:
Jo in t Line 41.80 41.80 41.80
2 "  above JT  Line 44.70 45.40 45.00
4" above JT  Line 50.80 50.40 51.00
6" above JT  Line 57.00 57.80 57.10
8" above JT  Line 62.00 62.80 62.50
Pain: Pre Ex Post Ex Post Tx
VM O 1.00 1.00
2" above JT  Line 0.50 0.50
4" above JT  Line 0.50 0.50
6" above JT  Line 1.00 0.50
8" above JT  Line 0.50 0.50
Peak Torque: C oncentric
41.80
'4 5 .0 3
'5 0 .7 3
'5 7 .3 0































'4 4 .7 3
'5 1 .4 7
58.57
'6 3 .4 0
S l /R l 199.46 164.90 212.19 249.32
S1/R2 219.78 184.28 198.10 184.28

























2" above JT  L ine 0.50 0.50 0.50 0.50 0.50 0.50 0.00
4" above JT  Line 0.50 0.50 0.50 0.50 0.50 0.50 0.00
6" above JT  L ine 0.50 0.50 0.50 0.50 1.00 0.50 0.00
8" above JT  L ine 1.00 0.50 0.50 0.67 0.50 1.00 0.50








Join t L ine
118.67
42.00 42.00 42.00 42.00
124.67
41.20 41.60 41.30
2" above JT  Line 45.00 45.60 45.60 45.40 44.50 44.50 44.20
4" above JT  Line 51.60 51.90 51.30 51.60 50.30 50.90 50.80
6" above JT  Line 59.20 59.00 58.80 59.00 57.70 57.70 57.70
8" above JT  Line 62.00 62.80 62.90 62.57 63.00 63.50 63.00
Pain: Pre Ex Post Ex Post Tx Pre Ex Post Ex Post Tx
VM O 3.00 2.00 2.00 2 J 3 2.00 2.00 0.50
2" above JT  Line 0.50 0.50 0.50 0.50 0.50 0.50 0.00
4" above JT  Line 1.00 0.50 1.00 0.83 1.00 1.00 0.00
6" above JT  Line 3.00 2.00 2.00 2 3 3 3.00 2.00 0.50








'5 0 .6 7
'5 7 .7 0







Peak T orque: C oncentric
Untreater Treated





S l /R l 132.52 140.51 176.42 218.83
S1/R2 171.27 168.83 116.39 152.17
S1/R3 129.13 145.39 96.21 145.12
172.04
D A Y  4:
R O M : 104.00
Untreated
106.00 106.00
A v e ra g e
C irc u m fre n c e :
Jo in t L ine
105.33
41.80 41.40 41.00
2" above JT  Line 45.50 45.50 45.50
4" above JT  L ine 50.00 50.60 51.00
6" above JT  Line 58.00 58.00 58.00
8" above JT  Line 63.00 63.00 63.00
P a in : Pre Ex Post Ex Post Tx
V M O 1.00 1.00 1.00
2" above JT  Line 0.50 0.50 0.50
4" above JT  Line 0.50 0.50 0.50
6" above JT  Line 2.00 2.00 1.00
8" above JT  Line 2.00 2.00 2.00
P e a k  T o rq u e : C o n c e n tric
S l /R l
S1/R2
S1/R3
U ntreater T reated
41.40
45.50













120.00 I 118.00 I 120.00
119.33
41.80 41.60 41 .80  41.73
45.40 4 4 .40 44 .60  44.80
51.60 51.20 50.80 51.20
59.00 58.80 58 .80  58.87
63.20 63.80 63 .80  63.60






E c c e n tr ic










D A Y S :
U ntreated
R O M : 120.00 120.00 122.00
A v e ra g e 120.67
C irc u m fre n c e :
Jo in t Line 42.10 42.30 42.20
2" above JT  Line 45.30 45.50 45.50
4" above JT  Line 51.50 51.20 51.30
6" above JT  Line 57.50 58.20 58.20
8" above JT  Line 63.20 63.20 63.20
P a in : P re Ex P ost Ex Post Tx
VM O 1.00 0.50
2" above JT  Line 0.50 0.50
4" above JT  Line 0.50 0.50
6" above JT  Line 1.00 1.00
8" above JT  Line 1.00 1.00
P e a k  T o rq u e : C o n c e n tr ic
U ntreater T reated
42.20 
'4 5 .4 3
51.33





















E c c e n tr ic
U ntreated T reated
41.63
'4 4 .5 0
'5 0 .5 0







S l /R l 162.74 198.61 270.86 326.28
S1/R2 254.06 196.07 265.58 306.00
S1/R3 278.18 179.40 261.24 3 05 .96











R O M :
A verage
C ircu m fren ce :
Joint Line 
2" above JT Line 
4" above JT  Line 
6" above JT  Line 
8" above JT  Line
P ain :
VM O
2" above JT  Line 
4" above JT Line 
6" above JT Line 










Pre Ex Post Ex Post Tx
1.00 1.00
0.50 0.50














W eigh t: 























P e a k  T o rq u e :
A verage






T reated U ntreated
S l/R l 194.86 162.04 232.28 226.45
S1/R2 229.57 198.93 284.62 290.18

















P o s tT x
1.00
2" above JT  Line 0.50 0.50 0.50 0.50 1.00 0.50 0.50
4" above JT  Line 0.50 O jO 0.50 0.50 0.50 0.50 0.50
6" above JJ’ Line 0.50 0.50 1.00 0.67 1.00 0.50 0.50
8" above JT  Line O jO 0.50 1.00 0.67 1.00 1.00 0.50
D AY 3: 






C ircu m fren ce :
Joint Line
125.33
3 9 3 0 39.50 39.10 39.30
123.00
38.80 38.90 38.80
2" above JT Line 40.20 40.10 40.10 40.13 40.20 40.20 40.30
4" above JT  Line 44.90 44.80 45.00 44.90 45.10 45.30 45.10
6" above JT  Line 50.10 50.00 50.00 50.03 50.00 49.80 49.90
8" above JT Line 55.50 55.40 55.40 55.43 55.10 55.20 55.10
P ain : Pre Ex Post Ex Post Tx Pre Ex Post Ex Post Tx
VM O 2.00 1.00 1.00 1.33 2.00 2.00 1.00
2" above JT  Line 1.00 1.00 0.50 0.83 1.00 1.00 0.50
4" above JT  Line 2.00 1.00 1.00 1.33 3.00 2.00 1.00
6" above JT  Line 3.00 2.00 2.00 2 3 3 3.00 3.00 2.00


























S l/R l 197.30 148.08 242.45 168.96
S1/R2 245.84 169.91 252.76 205.03
S1/R3 197.30 183.33 216.96 177.77
183.92
DAY 4:








2" above JT Line 40.10 40.10 40.00
4" above JT Line 45.40 45.40 45.50
6" above JT Line 51.20 51.10 51.10
8" above JT Line 55.50 55.50 55.40
Pain: Pre Ex Post Ex Post Tx
VM O 2.00 2 0 0 1.00
2" above JT  Line 1.00 1.00 1.00
4" above JT  Line 1.00 1.00 1.00
6" above JT Line 3.00 3.00 3.00





























































Joint Line 38.90 39.00 39.00
2" above JT  Line 40.30 40.20 40.30
4" above JT Line 45.30 45.50 45.30
6" above JT Line 50.80 50.70 50.80
8" above JT Line 54.40 54.40 54.40
Pain: Pre Ex Post Ex Post Tx
VM O 2.00 1.00
2" above JT  Line 1.00 0.50
4" above JT  Line 1.00 0.50
6" above JT Line 3.00 2.00















































S l/R l 175.47 168.01 169.23 183.33
S1/R2 202.04 186.86 202.32 198.79













R O M : 140.00 140.00 140.00
A v erag e 140.00
C ircu m fren ce :
Jo in t Line 34.10 34.10 34.00
2" above JT  Line 37.00 37.00 36.80
4" above JT  Line 42.00 42.00 42.00
6" above JT  Line 47.00 47.00 47.20
8" above JT  Line 41.80 51.80 51.90
P ain : Pre Ex Post Ex Post Tx
V M O 1.00 2.00
2" above JT  Line 1.00 2.00
4" above JT  Line 1.00 2.00
6" above JT  Line 0.50 2.00
8" above JT  Line 0.50 2.00














































S l/R l 57.36 54.38 206.11 182.92
S1/R2 79.60 54.38 220.49 205.03
S1/R3 74.85 6 1 3 8 233.50 196.08
128.05
















P ost Tx 
2.00 1.17
2" above JT  Line 0.50 1.00 1.00 0.83 0.50 1.00 3.00 1.50
4" above JT  Line 0.50 1.00 1.00 0.83 1.00 1.00 2.00 1.33
6" above JT  Line 0.50 1.00 1.00 0.83 0.00 1.00 3.00 1.33
8" above JT  Line 1.00 1.00 1.00 1.00 1.00 2.00 1.00 1.33
D A Y  3: 









33.10 33.20 33.10 33.13
131.67
32.80 33.00 32.90 32.90
2" above JT  Line 36.10 36.00 36.10 36.07 35.40 35.50 35.50 35.47
4" above JT  Line 42.50 42.20 42.20 42.30 40.50 40.80 40.50 40.60
6" above JT  Line 47.00 47.10 47.00 47.03 46.40 46.30 46.40 46.37















2" above JT  Line 2.00 1.00 1.00 1.33 0.50 1.00 1.00 0.83
4" above JT  Line 2.00 2.00 1.00 1.67 1.00 1.00 1.00 1.00
6" above JT  Line 2.00 2.00 2.00 2.00 1.00 1.00 1.00 1.00
8" above JT  Line 2.00 2.00 2.00 2.00 1.00 2.00 1.00 1.33
52
Peak T orque: Concentric
Untreater Treated
A v erag e  55.32 55.91
Eccentric
Untreated Treated
S l/R l 61.29 58.04 167.74 145.50
S1/R2 53.97 62.10 183.06 163.13
S1/R3 50.71 47.60 185.91 158.11
178.90 155.58
DA Y  4:
R O M :
A v erag e
C ircu m fren ce :
Jo in t Line 
2" above JT  Line 
4" above JT  Line 
6" above JT  Line 
8" above IT Line











Pre Ex Post Ex P o s tT x
V M O 1.00 1.00 0.50
2" above JT  Line 2.00 1.00 1.00
4" above JT  Line 1.00 2.00 0.50
6" above JT  Line 3.00 3.00 1.00
8" above JT  Line 4.00 4.00 3.00
P e a k  T o rq u e : C o n c en tric

























E c c e n tric











S l/R l 42.17 44.88 171.40 150.52
S1/R2 4 1 2 6 43.53 177.50 154.31
S1/R3 42.85 47.73 179.53 170.58
A v erag e 42.76 45.38 176.14 158.47
D A Y S :
R O M :
A v erag e
C ircu m fren ce :
Jo in t Line 
2" above JT  Line 
4" above JT  Line 
6" above JT  Line 
8" above JT  Line
P ain :
V M O
2" above JT  Line 
4" above JT  Line 
6" above JT  Line 






















































P e a k  T o rq u e : C o n c en tric
U ntreater T reated
A verage 47.19 45.16
E c cen tric
U ntreated  T reated
S l /R l 42.85 44.07 184.01 172.89
S1/R2 43.93 48.14 195.54 187.26
S1/R3 54.78 43.26 195.67 188.62
191.74 182.92
53
Subject: DOMSsubOô Height: 169.55
Treatm ent: LI/Rno Age:
M ale









2" above JT  Line 38.00 38.00 38.00
4" above JT  Line 42.60 42.80 42.60
6" above JT  Line 47.70 47.70 47.60








2" above JT  Line 1.00 1.00
4" above JT  Line 0.50 OjO
6" above JT  Line 1.00 1.00

































S l/R l 201.50 209.50 310.80 327.34
S1/R2 184.94 189.30 320.66 315.00





2" above JT  Line 
4" above JT  Line 
6" above JT  Line 
8" above JT  Line







0.50 0.50 0 ^ 0













2" above JT  Line 
4" above JT  Line 
6" above JT  Line 





























































Pre Ex Post Ex P o s tT x
VM O 1.00 0.50 1.00 0.83 0.50 0.50 0.50
2" above JT  Line 0.50 0.50 1.00 0.67 0.50 0.50 0.50
4" above JT  Line 0.50 0 5 0 0.50 0.50 0.50 0.50 0.50
6" above JT  Line 1.00 1.00 1.00 1.00 1.00 1.00 1.00




















S l/R l 178.45 170.77 251.54 257.37
S1/R2 168.69 163.67 247.74 243.00
S1/R3 158.38 157.30 247.06 241.50
247.29
DAY 4:





Joint Line 36.30 36.30 36.50
2 "  above JT  Line 38.20 38.20 38.30
4" above JT  Line 42.50 42.60 42.50
6" above JT  Line 48.10 48.00 48.10
8" above JT  Line 51.80 51.80 58.90
Pain: Pre Ex Post Ex Post Tx
VM O 2.00 0.50
2" above JT  Line 0.50 0.50
4" above JT  Line 0.50 0.50
6" above JT Line 3.00 1.00










































S l/R l 69.43 154.04 116.75 224.69
S1/R2 84.61 157.30 149.16 208.69
S1/R3 109.97 146.04 177.36 224.69
A verage 88.00 152.46 147.76 219.36










36.70 36.60 36.70 36.67
137.00
36.80 36.70 36.80 36.77
2" above JT  Line 38.50 38.40 38.50 38.47 37.60 37.70 37.60 37.63
4" above JT  Line 43.80 43.90 43.80 43.83 43.60 43.60 43.50 43.57
6" above JT  Line 49.20 49.20 49.30 49.23 48.80 48.80 48.90 48.83
8" above JT  Line 5Z 80 52.90 52.90 52.87 51.60 51.70 51.60 51.63
Pain:
VM O 
above JT  Line 
" above JT  Line 
i" above JT  Line 







































S l/R l 88.14 142.24 178.79 212.35
S1/R2 141.43 150.79 204.08 242.18
S1/R3 135.74 153.23 211.81 240.01
55
Subject: DOM SsubO? Height: 168.91











2" above JT  Line 37.10 37.10 37.20
4" above JT  Line 40.70 40.70 40.80
6" above JT  Line 45.30 45.20 45.30








2" above JT  Line 1.00 1.00
4" above JT  Line 0.50 0.50
6" above JT  Line 0 50 0.50
8" above JT  Line 2.00 2.00
































S l/R l 2.85 85.83 4.61 193.77
S1/R2 79.05 94.41 175.87 202.18
















2" above JT  Line 
4" above JT  Line 
6" above JT  Line 
8" above JT  Line
Pre Ex
Treated 

































I 144.00 I 142.00
142.67
Joint Line 35.00 35.20 35.00 35.07 35.00 35.00 35.20
2" above JT  Line 37.40 37.40 37.50 37.43 37.40 37.30 37.40
4" above J l ’ Line 41.40 41.50 41.40 41.43 41.10 41.10 41.20
6" above J l ’ Line 46.00 46.00 46.20 46.07 46.20 46.30 46.20
8" above JT  Line 51.00 50.90 51.00 50.97 51.00 51.10 51.00
Pain: Pre Ex Post Ex P o stT x Pre Ex Post Ex Post Tx
VM O 1.00 1.00 0.00 0.67 1.00 1.00 1.00
2' above JT  Line 0.50 0.50 0.00 0.33 0.50 0.50 0.50
4' above JT  Line 0.50 0.50 0.00 0.33 0.50 0.50 0.50
6' above JT Line 2.00 1.00 0.50 1.17 0.50 0.50 0.50





















S l/R l 92.21 116.21 139.13 216.42
S1/R2 9 9 6 7 132.21 142.38 223.33
S1/R3 153.63 114.45 136.41 220.35
139.31 220.03













Joint Line 35.50 35.50 35.60 35.53 36.40 36.50 36.40
2" above JT Line 38.30 38.50 38.40 38.40 38.40 38.40 38.30
4" above JT Line 42.60 42.70 42.70 42.67 42.40 42.50 42.40
6" above JT Line 47.30 47.20 47.30 47.27 48.10 48.30 48.20











2" above JT Line
4" above JT L in e ________
6" above JT Line 4.00
8" above JT Line 6.00
























1.00 1.00 0 5 0




S l /R l 55 32 99.67 169.23 162.45
S1/R2 174.52 135.19 178.31 159.33







D A Y S:
Treated U ntreated
ROM : 145.00 146.00 145.00
A verage 145.33
Circum frence:
Join t Line 35.30 35.20 35.20
2" above JT Line 37.50 37.70 37.70
4" above JT  Line 41.80 41.80 41.90
6" above JT Line 46.80 46.80 46.80
8" above JT Line 51.20 51.20 51.30
Pain: Pre Ex Post Ex Post Tx
VM O 0.50 0.50
2" above JT Line 0.50 0.50
4" above JT Line 0.50 0.50
6" above JT Line 3.00 1.00
















































S l/R l 58.71 85.29 223.60 281.91
S1/R2 232.96 249.23 223.60 271.06













2" above JT Line 
4" above JT  Line 
6" above JT  Line 
8" above JT Line
Fain:
VMO
2" above JT  Line 
4" above JT  Line 
6" above JT  Line 


































































S l/R l 87.87 71.80 178.86 159.43
S1/R2 114.45 114.52 150.79 152.33
S1/R3 120.14 91.18 171.26 163.39
158.38

















2 "  above JT  Line 1.00 2.00 0.00 1.00 1.00 1.00 1.00 LOO
4" above JT Line 1.00 2.00 0.00 1.00 2.00 0.50 2.00 1.50
6" above JT  Line 2 00 3TW 0 00 1.67 2.00 1.00 2.00 1.67
8" above JT  Line 4.00 5.00 0.00 3.00 3.00 2.00 3.00 2.67










45.10 45.20 45.20 45.17
105.00
43.60 43.50 43.60 43.57
2" above JT Line 50.60 50.50 50.40 50.50 51.50 51.50 51.40 51.47
4" above JT  Line 59,10 59.10 59.20 59.13 59.10 59.20 59.10 59.13
6" above JT  Line 67.50 67.50 67.60 67.53 66.10 66.00 66.10 66.07















2" above JT  Line 2.00 2TW 2 0 0 2.00 2.00 2.00 2.00 2.00
4" above JT  Line 3.00 2.00 2.00 2.33 4.00 4.00 4.00 4.00
6" above JT  Line 5.00 3TW 4.00 4.00 5.00 5.00 5.00 5.00
8" above JT  Line 5.00 5.00 5.00 5.00 6.00 6.00 6.00 6.00
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Peak T orque: Concentric
Treated Untreated
A v erag e  78.42 80.01
Eccentric
Treated Untreated
S l/R l 43.12 45.56 111.60 109.29
S1/R2 91.67 97.23 123.12 112.55
S1/R3 100.48 97.23 130.99 123.12
121.90 114.99
D A Y  4:
T reated U ntreated
RO M : 98.00 102.00 102.00 107.00 112.00 112.00
A v erag e
C ircu m fren ce :
Join t L ine
100.67
44.80 44.70 44.70 44.73
110.33
42.50 42.60 42.70 42.60
2" above JT  Line 50.70 50.50 50.70 50.63 50.70 50.80 50.70 50.73
4" above JT  Line 59.50 59.50 59.60 59.53 58.80 58.70 58.70 58.73
6" above JT  Line 67.70 67.80 67.70 67.73 66.10 66.20 66.10 66.13













Post T x 
2.00 1.33
2" above JT  Line 2.00 1.00 0.50 1.17 1.00 1.00 1.00 1.00
4" above JT  Line 3.00 3.00 1.00 2 4 3 2.00 2.00 2.00 2,00
6" above JT  Line 3 4 0 4.00 2 4 0 3,00 3.00 3.00 3.00 3.00
8" above JT  Line 5.00 5.00 4.00 4.67 3.00 5.00 5.00 4,33
P e a k  T o rq u e : C o n c en tric E c cen tric
T reated U ntreated T reated U ntreated
S l /R l 28.61 57.09 61.43 89.63
S1/R2 47.19 72.27 86.24 105.5
S1/R3 70.51 78.78 78.51 111.46
A v erag e 48.77 69.38 75.39 102.20
D A Y S :
Treated U ntreated
ROM : 112.00 112.00 112.00 116.00 115.00 115.00
A v erag e
C ireu m fren ce :
Jo in t Line
112.00
45.30 45.40 45.40 45.37
115.33
43.80 43.70 43.80 43.77
2" above JT  Line 50.80 50.80 50.90 50.83 51.10 51.10 51.10 51.10
4" above JT  Line 60.10 60.20 60.10 60.13 58.10 58.20 58.20 58.17
6" above JT  Line 67.80 67.90 67.80 67.83 64.80 64.80 64.70 64.77















2" above JT  Line 1.00 1.00 1.00 0.50 0.50 0.50
4" above JT  Line 1 4 0 1.00 1.00 1.00 2.00 1.50
6" above JT  Line 2.00 2.00 2.00 2.00 3.00 2.50
8" above JT  Line 3.00 3.00 3.00 3.00 4.00 3.50
P e a k  T o rq u e : C o n c en tric E c cen tric
T reated U ntreated Treated U ntreated
S l /R l 46.78 54.10 99.67 126.65
S1/R2 96.00 97.09 108.21 128.82
S1/R3 97.90 105.77 133.29 122.85













ROM : 135 135 133
A verage 134.333
Cireum frence:
Joint Line 38.7 38 8 3 8 4
2" above JT  Line 42 j 42.5 4 2 6
4" above JT  Line 49.8 4 9 4 49.9
6" above JT  Line 54.5 54.6 54.6
8" above JT Line 58.4 5 8 4 58.5
Pain: Pre Ex Post Ex Post Tx
VM O 0.00 0.00
2" above JT  Line 0 00 0.50
4" above JT  Line 0.50 1,00
6" above JT  Line 0.50 1.00









































S l/R l 229.03 225.64 331.41 320.56
S1/R2 255.33 245.71 337.92 326.52
















2" above JT  Line 0.50 0.50 0.50
4" above JT Line 1.00 0.50 0.50
6" above JT  Line 1.00 0.50 0.50
8" above JT Line 2.00 1.00 1.00
D AY 3:
Untreated
RO M : 135.00 | 135.00 | 134.00
A verage 134.67 
Circum frence:
Joint Line 38.80 39.00 38.90
2" above JT Line 43.40 43.30 43.40
4" above JT  Line 49.60 49.60 49.70
6" above JT  Line 54.90 55.00 55.00
8" above JT Line 58.30 58.40 58.40
Pain: Pre Ex





2" above JT  Line 0.50 0.00 0 5 0
4" above JT Line 1.00 1.00 1.00
6" above JT Line 1.00 1.00 1.00













































1 0 0 2.00 3.00
1.17 
0.50 





















S l/R l 179.13 148.62 310.12 281.78
S1/R2 226.45 241.77 367.34 309.03
S1/R3 242.45 215.20 344.70 350.39
313.73
DAY 4:
R O M : 134.00
A verage 134.00 
Circum frence:
Joint Line 39.30 
2" above JT Line 42.70
4" above JT Line 49.30
6" above JT Line 55.70
































Pain: Pre Ex Post Ex P o stT x Pre Ex Post E x Post Tx
VM O 0.50 0.00 0.50 0.33 2.00 1.00 2.00
2' above JT Line 0.50 O jO 0.50 0.50 1.00 0.50 1.00
4' above JT Line 0.50 1.00 0.50 0.67 2.00 1.00 1.00
6' above JT Line 1.00 1.00 0.50 0.83 3.00 1.00 2.00






Peak Torque: C oncentric
U ntreater Treated





S l/R l 139.53 157.57 285.17 281.64
S1/R2 212.08 194.04 339.41 331.14




ROM : 134.00 133.00 135.00
A verage 134.00
Circum frence:
Joint Line 39.00 39.00 39.10
2" above JT Line 43.00 43.00 43.00
4" above JT Line 49.10 49.10 49.20
6" above JT  Line 55.10 55.20 55.10
8" above JT Line 58.60 58.60 58.60
Pain: Pre Ex Post Ex Post Tx
VM O 0.00 0.00
2" above JT  Line 0.50 0.50
4" above JT Line 1.00 0.50
6" above JT Line 1.00 1.00





























S l/R l 176.01 133.70 296.15 274.05
S1/R2 208.01 177.91 320.15 344.97























ROM : 150.00 151.00 151.00
A verage 150.67
C ircum frence:
Joint Line 33.10 33.10 33.20
2" above JT  Line 34.10 34.20 34.10
4" above JT  Line 38.20 38.30 38.20
6" above JT  Line 43.10 43.20 43.10
8" above JT  Line 47.70 47.80 47.70
Pain: Pre Ex Post Ex Post Tx
VMO 7.00 3.00
2" above JT  Line 0.00 2TW
4" above JT  Line 1.00 3.00
6" above JT  Line 4.00 5.00
8" above JT  Line 6.00 8 0 0
Peak Torque: Concentric



































S l/R l 73.09 93.70 135.33 149.43
S1/R2 79.05 100.21 144.01 156.75




























0.00 1 3 3
2" above JT  Line 1.00 2.00 1.00 1.33 1.00 1.00 1.00 1.00
4" above JT  Line 2.00 1.00 1.00 1.33 1.00 1.00 1.00 1.00
6" above JT  Line 4.00 2.00 2.00 2 67 3 00 2.00 2.00 2 J 3











33.30 33.40 33.30 33.33
149.00
33.60 33.60 33.70 33.63
2" above JT  Line 34.30 34.20 34.30 34.27 34.00 34.10 34.10 34.07
4" above JT  Line 37.70 37.80 37.70 37.73 38.70 38.80 38.70 38.73
6" above JT  Line 42.50 42.50 42.50 42.50 43.50 43.50 43.50 43.50














2.00 2 3 3
2" above JT Line 1.00 1.00 2.00 1.33 0.00 1.00 3.00 1.33
4" above JT  Line 2.00 3.00 1.00 2.00 2.00 1.00 1.00 1.33
6" above JT  Line 3.00 2.00 1.00 2.00 2.00 2.00 1.00 1.67
8" above JT  Line 4.00 5.00 1.00 3 33 3.00 4.00 2.00 3.00
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S l/R l 60.34 70.11 129.63 145.09
S1/R2 75.94 91.26 138.18 141.16




R O M : 145.00 145.00 145.00
A verage 145.00
C ircum frenee:
Joint Line 33.40 33.50 33.50
2" above JT Line 34.00 34.00 34.00
4" above JT Line 37.90 37.90 38.00
6" above JT  Line 42.70 42.80 42.70
8" above JT Line 47.10 47.20 47.20
Pain: Pre Ex Post Ex Post Tx
VM O 3.00 0.00 1.00
2" above JT  Line 2 ^ 0 2.00 1.00
4" above JT  Line 1.00 4.00 4.00
6" above JT  Line AOO 5.00 3.00





























S l/R l 46.10 70.78 139.26 138.85
S1/R2 73.90 79.33 145.36 143.33




















33.40 33.40 33.50 33.43
152.33
33.70 33.60 33.70 33.67
2" above JT  Line 33 90 33.90 33.90 33.90 34.10 34.10 34.10 34.10
4" above JT  Line 3&50 38.50 38.60 38.53 37.70 37.80 37.70 37.73
6" above JT  Line 43.20 43.20 43.20 43.20 43.90 43.90 44.00 43.93
8" above JT  Line 47.00 47.00 47.10 47.03 48.60 48.60 48.70 48.63
Pain:
VMO
above JT  Line 
i" above JT  Line 
I" above JT  Line 
































S l/R l 44.88 55 46 61.43 118.79
S1/R2 61.02 56.27 78.78 107.26













ROM : 155.00 155.00 155.00
Average 155.00
Circum frence:
Joint Line 38.80 38.90 38.80
2" above JT Line 40.80 40.90 40.80
4" above JT  Line 44.20 44.30 44.20
6" above JT Line 47.10 47.10 47.20
8" above JT Line 51.70 51.80 51.70
Pain: Pre Ex Post Ex Post Tx
VMO 4.00 4.00
2" above JT Line 0.00 0.00
4" above JT Line 0.00 0.00
6" above JT  Line 0.00 2.00



































U ntreated T reated
S l/R l 51.39 45.29 159,74 108.89
S1/R2 14.24 44.07 1.22 126.24






























2 "  above JT  Line 0.00 0.00 OTW 0.00 OTW 0.00 2 00
4" above JT  Line 6.00 2TW 0.00 2.67 4.00 0.00 4.00
6" above JT Line 4.00 5.00 3.00 4.00 6.00 5.00 8.00











39.30 39.20 39.20 39.23
150.33
38.50 38.50 38.60
2" above JT  Line 41.50 41.60 41.60 41.57 41.00 41.00 40.90
4" above JT Line 44.40 44.40 44.40 44.40 45.00 45.00 45.10
6" above JT Line 47.60 47.50 47.60 47.57 49.40 49.50 49.50
8" above JT Line 51.90 51.90 52.00 51.93 53.40 53.50 53.40
Pain: Pre Ex Post Ex Post Tx Pre Ex Post Ex Post Tx
VM O 7.00 5.00 6.00 6.00 8.00 8.00 8.00
2" above JT  Line 0.00 0.00 0.00 0.00 0.00 0.00 0.00
4" above JT  Line 0.00 0.00 0.00 0.00 0.00 0.00 2 4 0
6" above JT Line 5.00 4.00 4.00 4.33 5.00 4.00 5.00

















Peak T orque: Concentric
Untreater Treated
A verage 36.30 36.61
Eccentric
Untreated Treated
S l/R l 44.75 30.78 131.80 103.87
S1/R2 32.14 27.80 109.43 92.21








I 151.00 I 152.00
151.00
T reated 
151.00 I 152.00 I 152.00 
151.67
Join t Line 39.70 39.80 39.70 39.73 38.50 38.50 38.50
2' above JT  Line 41.40 41.40 41.50 41.43 41.00 41.00 41.10
4' above JT Line 43.90 43.90 43.87 44.80 44.80 44.90
6' above JT Line 48 00 48.10 48.00 48.03 49.20 49.20 49.30







V M O  5.00 
2" above JT Line 0.00
4" above JT Line 0.00
6" above JT Line 4.00
8" above JT Line 5.00
Peak Torque:


















Pre Ex Post Ex P o s tT x







U ntreated T reated
S l /R l 38.51 46.78 129.36 125.02
S1/R2 33.09 77.70 127.19 143.87







D A Y S:
Untreated Treated
ROM : 154.00 155.00 154.00 153.00 154.00 155.00
A verage 154.33 154.00
Circum frence:
Join t Line 39.20 39.20 39.20 39.20 38.00 38.00 38.10 38.03
2" above JT Line 41.40 41.30 41.30 41.33 41.10 41.10 41.00 41.07
4" above JT Line 44.00 44.00 44.10 44.03 44.40 44.40 44.40 44.40
6 "  above JT  Line 48.10 48.20 48.20 48.17 49.20 49.20 49.30 49.23
8" above JT Line 51.70 51.80 51.80 51.77 52.30 52.30 52.40 52.33
Pain: Pre Ex Post Ex Post T X Pre Ex Post Ex Post T X
VM O 5.00 8.00 6.50 7.00 8.00 7.50
2" above JT  Line 0.00 0.00 0.00 0.00 0.00 0.00
4" above JT Line 0.00 0.00 0.00 0.00 1.00 0.50
6" above JT Line 1.00 5.00 3.00 4.00 4.00 4.00
8" above JT  Line 5.00 8.00 6.50 4.00 8.00 6.00
Peak Torque: C oncentric
U ntreater T reated
Average 35.44 34.98
Eccentric
U ntreated T reated
S l/R l 49.77 1.90 130.99 5.56
S1/R2 29.70 57.90 130.31 116.07
S1/R3 26.85 45.15 154.72 146.18
138.67 89.27
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Subject: D 0 M S su b l2 Height: 182.88
Treatm ent: Lno/RJ Age:
M ale









2" above JT  Line 39.80 39.80 39.70
4" above JT  Line 44.50 44.50 44.60
6" above JT  Line 50.10 50.20 50.10








2" above JT  Line 0.00 0.00
4" above JT  Line 0.00 0.00
6" above JT  Line 0.00 0.00




































S l/R l 183.87 157.43 244.35 271.88
S1/R2 216.01 218.99 273.37 264.01
















2" above JT  Line 
4" above JT  Line 
6" above JT  Line 






DA Y  3:
ROM :
A verage  
Circum frence:
Joint Line 
2" above JT  Line 
4" above JT  Line 
6" above JT  Line 
8" above JT  Line
Pain:
VM O
2" above JT Line 
4" above JT  Line 
6" above JT  Line 
































































































S l/R l 130.45 162.72 166.79 244.76
S1/R2 152.41 197.03 163.94 243.81
S1/R3 132.62 197.43 198.52 238.38
242.32
DAY 4:








2" above JT Line 40.40 40.40 40.30
4" above JT Line 44.90 44.90 44.80
6" above JT Line 50.30 50.40 50.40
8" above JT  Line 55.10 55.00 55.00
Pain: Pre Ex Post Ex Post Tx
VM O 4.00 3.00 1.00
2" above JT Line 0.00 0.00 0.00
4" above JT  Line 0.00 0.00 0.00
6" above JT  Line 3.00 2.00 2.00
8" above JT Line 4.00 3.00 3.00




























S l/R l 92.34 5.15 177.23 21.97
S1/R2 121.23 196.76 212.49 273.78











A verage 106.58 137.54 204.76 188.71
D A Y S:





Joint Line 38.10 38.20 38.00
2" above JT Line 40.60 40.70 40.70
4" above JT Line 4 5 ^ 0 45.20 45.30
6" above JT Line 50.70 50.80 50.70
8" above JT Line 54.40 54.40 54.50
Pain: Pre Ex Post Ex Post Tx
VM O 1.00 1.00
2" above JT L ine 0.00 0.00
4" above JT Line 0.00 0 0 0
6" above JT Line 2 00 0 0 0










































S l/R l 142.24 183.33 208.00 292.35
S1/R2 194.86 215.06 248.55 280.69
S1/R3 181.70 222.52 308.35 273.91
Average 172.93 206.97 254.97 282.32
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D 0M S su b l3 172.72
T re a tm e n t:  R I/Lno A ge:
M ale 
DAY 1:








2" above JT Line 40.80 40.80 40 .80
4" above JT  Line 45 .40 45.50 45.50
6" above JT  Line 51.30 51.30 51.30
8" above JT Line 55.60 55.60 55.60
P ain:
VM O
P re Ex 
0 .00
P o st Ex 
0.00
P o st Tx
2" above JT  Line 0.00 0.00
4" above JT  Line 0.00 0.00
6" above JT  Line 0.00 0 .00
8" above JT  Line 0.00 0.00
P eak  T o rq u e : C o n c e n tric
T reated  U ntrea ted
29
W e ig h t:  













U ntrea ted  
I 137.00 1 136.00
136.33
38.00 38 .00 38.10
40.10 40 .10 40 .10
44.60 44 .70 44.70
51.00 51 .00 51.00
55.90 56.00 55.90






E c c e n tr ic
T reated U ntrea ted
S l/R l 259.67 250.86 326.80 318.39
S1/R2 224.69 251.27 297.10 3 18 .80
S1/R3 233 .10 223.06 322.86 3 06 .59
A verage  239.15 241.73
38.03 
40.10 













2" above JT  Line 
4" above JT  Line 
6" above JT  Line 
8" above JT Line
DA Y  3:
R O M :
A verage 
C ircu m fren ce :
Join t Line 
2" above JT  Line 
4" above JT  Line 
6" above JT  Line 





P o st Ex 
0.00












47.00 47 .00 47.00
52.40 52.20 52.20
57.10 57.10 57.10











U ntrea ted  














38.10 38.20 38 .00  38.10
40.10 40 .00 40 .2 0  40.10
45.20 45 .20 45 .2 0  45 .20
51.80 51.80 51 .80  51.80
56.70 56 .70 56 .80  56.73
Pre  E x  P o st E x  P o st T x
VM O 0.50 0.50 3.00 1.33 1.00 0 .50 2 .00 1.17
2" above JT Line 0.00 0.00 0.00 0.00 0.00 0 .00 0.00 0.00
4" above JT Line 0.00 0.00 3.00 1.00 1.00 0.00 2 .00 1.00
6" above JT Line 1.00 0.50 4.00 1.83 3.00 1.00 3 .00 2 J 3
8" above JT  Line 3.00 1.00 5.00 3.00 4.00 2.00 4 .00 3.33
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Peak Torque: C oncentric
Treated Untreated
A verage  172.48 176.69
E ccen tric
Treated U ntreated
S l/R l 121.36 127.06 173.03 160.28
S1/R2 186.31 201 .77 213 .30 160.01
S1/R3 209.77 201.23 246.93 203.13
211.09 174.47
DAY 4:
R O M :
A verage  
C ircu m fren ce :
Joint Line 
2" above JT  Line 
4" above JT  Line 
6" above JT  Line 






46.10 46.10 46 .10








87.00 I 9 2 .00  I 93 .00
90.67
38.00 38 .10 3 8 .10  38.07
41.10 41 .10 4 1 .10  41 .10
46.00 46 .00 4 6 .00  46 .00
51.60 51.60 51 .60  51.60
56.60 56.60 56 .00  56.40
P ain : Pre E x  P o st E x  P o st Tx P re  E x  P o st E x  P o st T x
VM O 5.00 1.00 2.00 2.67 5.00 2.00 2 .00
2" above JT  Line 0.00 0.00 0.00 0.00 0 .00 0 .00 0 .00
4" above JT  Line 3 .00 0.00 2.00 1.67 7.00 1.00 3.00
6" above JT Line 7.00 4.00 7.00 6.00 9 .00 5.00 4 .00






P e a k  T o rq u e : C on cen tric
T reated




T reated  U n trea ted
S l/R l 48.95 38.10 57.36 26.31
S1/R2 49.90 47.60 62 .24 4 6 .24
S1/R3 65.36 50.85 76 .34 4 9 .77
65.31 4 0 .77
D A Y S :
R O M :
A verage  
C ircu m fren ce :
Joint Line 
2" above .TT Line 
4" above JT  Line 
6" above JT  Line 
8" above JT  Line
P ain :





46.30 46 .30 46.30
52.00 52.10 52.10
57.10 57.10 57.20
P re  E x  P o st E x  P o st T x
VM O  2.00 1.00
2" above JT  L ine 0 .00 0.00
4" above JT  Line 4.00 1.00
6" above JT  L ine 7 .00 3.00














40.40 40 .40 40 .30
45.90 45 .90 45 .80
52.10 52.00 52.00
56.70 56.70 56.70
Pre E x  
2.00
P o st E x  
2 .00




















E ccen tr ic
T rea ted  U n trea ted
S l/R l 58.99 59.94 60.21 51 .26
S1/R2 61.43 76.48 71.60 79 .60





D 0 M S su b l4
Lno/RI
Female 





ROM : 135.00 135.00 135.00
A verage 135.00
Circum frence:
Joint Line 40.50 40.50 40.50
2" above JT Line 44.60 44.60 44.60
4" above JT Line 51.30 51.30 51.30
6" above JT  Line 58.30 58.30 58.40
8" above JT Line 62.60 62.70 62.70
Pain: Pre Ex Post Ex Post Tx
VM O 4.00 3.00
2" above JT Line 1.00 1.00
4" above JT Line 2.00 1.00
6" above JT Line 2.00 1.00





































S l/R l 68.07 59.53 247.33 277.98
S1/R2 120.14 120.01 244.89 255.61






























2" above JT  Line 1.00 1.00 0.50 0.83 1.00 1.00 1.00
4" above JT Line 2 00 1.00 0.50 1.17 2.00 1.00 1.00
6" above JT  Line 2.00 1.00 0.50 1.17 1.00 1.00 1.00











40.50 40.40 40.50 40.47
131.67
40.30 40.40 40.50
2" above JT Line 44.70 44.80 44.80 44.77 45.30 45.40 45.40
4" above JT  Line 52.80 52.80 52.80 52.80 51.80 51.80 51.90
6" above JT Line 58.80 58.90 58.90 58.87 58.70 58.80 58.70
8" above JT  Line 64.10 64.20 64.20 64.17 64.70 64.80 64.70
Pain: Pre Ex Post Ex Post Tx Pre Ex Post Ex Post Tx
VM O 5.00 5.00 4.00 4.67 5.00 4.00 5.00
2" above JT Line 2.00 0.50 0.50 1.00 1.00 1.00 1.00
4" above JT  Line 2.00 1.00 LOO 1.33 2.00 2.00 2.00
6" above JT  Line 2.00 2.00 2 0 0 2.00 3.00 3.00 3.00

















P eak T orque: Concentric
Treated Untreated
A verage  85.52 60.48
E ccentric
T reated Untreated
S l/R l 41.49 56.68 117.57 98.58
S1/R2 101.16 62.38 121.36 104.68
S1/R3 113.90 6 2 3 8 118.24 86.51
119.06 96.59
D AY 4:
R O M :
A verage






133.00 I 132.00 I 131.00
132.00
Joint Line 40.30 40.20 40.20 40.23 40.40 40.40 40.50
2" above JT Line 45.10 45.10 45.20 45.13 45.60 45.60 45.60
4" above JT Line 51.50 51.50 51.50 51.50 53.20 53.20 53.30
6" above JT Line 58.40 58.50 58.50 58.47 59.30 59.30 59.30











2" above JT Line
4" above JT L in e________
6" above JT Line 2.00
8" above JT Line 3.00




























T reated U ntreated
S l/R l 41.90 58.17 92.75 101.29
S1/R2 98.04 68.75 93 29 9 4 9 2







D A Y S :
Treated
R O M : 135.00 135.00 135.00
A verage 135.00
C ircu m fren ce :
Joint Line 40.50 40.60 40.60
2" above JT Line 45.50 45.50 45.60
4" above JT Line 52.00 52.00 52.00
6" above JT Line 58.70 58.80 58.80
8" above JT Line 65.50 65.50 65.50
P a in : Pre Ex Post Ex Post Tx
VM O 5.00 5.00
2" above JT Line 1.00 0.50
4" above JT Line 2.00 1.00
6" above JT Line 3.00 2.00
8" above JT Line 4.00 2.00



























T reated U ntreated
S l /R l 42.58 ' 43.39 134.38 134.38
S1/R2 69.43 76.89 136.68 141.84











Average 66.31 59.44 140.66 143.42
71
Subject: DOM SsubIS H eight: 172.72
T rea tm en t: LI/Rno Age:
Male 
DAY 1:








2" above JT Line 40.00 40.00 40.00
4" above JT Line 47.50 47.40 47.50
6" above JT Line 51.30 51.40 51.40








2" above JT Line 3.00 3.00
4" above JT Line 3.00 4.00
6" above JT Line 4.00 4.00
8" above, JT Line 4.00 5.00
24
W eight: 


































S l/R l 104.01 145.63 239.06 226.32
S1/R2 179.94 163.80 288.83 231.88
S1/R3 163.80 148.08 279.74 258.86




2" above JT Line 
4" above JT Line 
6" above JT Line 
8" above JT Line
Pre Ex
Untreated 
Post Ex Post T X
DAY 3:
R O M :
A verage 
C ircum frence :
Joint Line 
2" above JT Line 
4" above JT Line 
6" above JT Line 
8" above JT  Line
Pain:
VMO_ 
2" above JT Line 
4" above JT Line 
6" above JT Line 



























































































A verage 174.65 164.53
Eccentric
Untreated Treated
S l/R l 152.55 155.94 260.62 241.50
S1/R2 186.04 175.47 289.37 264.69
S1/R3 185.37 162.18 275.54 286.66
275.18 264.28
DAY 4:








2" above JT Line 39.80 39.90 39.90
4" above JT  Line 46.60 46.70 46.70
6" above JT Line 51.50 51.60 51.60
8" above JT Line 56.00 56.10 56.10
P ain: Pre Ex Post Ex Post Tx
VMO 3.00 3.00 3.00
2" above JT Line 3.00 3.00 3.00
4" above JT  Line 4.00 3TW 4.00
6" above JT  Line 6.00 5.00 6.00
8" above JT Line 7.00 7.00 8.00

























4.00 4.00 4 0 0
E ccen tric
Untreated Treated
S l/R l 155.53 156.62 251.54 256.83
SI/R 2 187.26 177.91 250.59 279.88











A verage 170.13 166.61 254.84 265.33
D A Y S:
Untreated Treated
R O M : 139.00 138.00 138.00 135.00 134.00 135.00
A verage
C ircum frence :
Joint Line
138.33
37.20 37.20 37.30 37.23
134.67
37.40 37.50 37.50 37.47
2" above JT Line 39.40 39.50 39.50 39.47 40.00 40.10 40.10 40.07
4" above JT Line 46.30 46.40 46.40 46.37 47.20 47.20 47.20 47.20
6" above JT Line 51.80 51.80 51.80 51.80 52.20 52.20 52.30 52.23
8" above JT Line 55.20 55.20 55.10 55.17 54.90 54.90 55.00 54.93
Pain:
VMO
2" above JT  Line 
4" above JT  Line 
6" above JT Line 
8" above JT  Line
































S l/R l 140.48 142.24 268.76 265.91
S1/R2 187.53 173.97 262.11 279.74
S1/R3 194.31 161.77 291.54 296.15
280.60
73
Subject: DOMSsubl6 Height: 175.26
T rea tm en t: RI/Lno Age:
Male 
DAY 1:








2" above JT Line 36.30 36.40 36.30
4" above JT  Line 39.50 39.60 39.50
6" above JT  Line 44.70 44.80 44.90








2" above JT Line 0.50 0.50
4" above JT Line 1.00 1.00
6" above JT Line 1.00 1.00
8" above JT Line 1.00 1.00












W eigh t: 
T a rg e t H R :
72.73
Untreated







Pre Ex Post Ex Post Tx
1.00 2.00






S l/R l 124.35 191.20 232.55 277.44
S1/R2 167.19 184.14 240.69 218.72
















2" above JT Line 
4" above JT Line 
6" above JT Line 







R O M :
A verage 
C ircum frence :
Joint Line 
2" above JT Line 
4" above JT Line 
6" above JT Line 
8" above JT Line
P ain :
VM O 
2" above JT Line 
4" above JT  Line 
6" above JT Line 
8" above JT Line
2.00 1.00 1.00
1.00 1.00 2.00

























































































S l/R l 97.23 108.21 190.25 195.94
S1/R2 107.80 75.26 213.71 205.98








Joint Line 35.50 35.40 35.40
2" above JT  Line 36.50 36.50 36.40
4" above JT  Line 41.10 41.00 41.00
6" above JT Line 46.50 46.50 46.50
8" above JT  Line 51.20 51.20 51.20
Pain:
VM O 5.00 5.00 7.00
2" above JT Line 3.00 3.00 3.00
4" above JT Line 4.00 4.00 4.00
6" above JT  Line 5.00 5.00 5.00



























S l/R l 58.83 7 2 6 8 141.84 133.84
S1/R2 76.21 77.43 177.09 150.92











Average 69.15 74.40 166.20 145.54
D A Y S:
Treated






2" above JT  Line 37.10 37.10 37.00
4" above JT  Line 41.00 40.90 40.90
6" above JT  Line 46.40 46.40 46.50








2" above JT Line 3.00 3.00
4" above JT Line 2 00 3.00
6" above JT Line 3.00 3.00































T reated U ntreated
S l/R l 75.80 99 80 168.69 165.57
S1/R2 85.83 106.04 182.25 168.96











A verage 81.31 1.94 179.58 168.42
75
Eccantric PT Eecantric PT 
Unraatti
6 5 %  o fT - H t W1
Sex HR (cm ) (k g ) P re 24 h 4 8 b 72k P re 24h 48h 7 2 h P re 2 4 k 48k 7 2 h P re 24 k 48h 7 2 k
D O M SstibO l Female 22 128.70 166.37 59.09 2.28 1.88 2.40 2.90 2.71 1.79 3.15 3.50 148.00 134.67 137.33 139.33 141.83 144.33 138.33 139.67
D O M Ssub 0 2 Female 24 127.40 162.56 61.36 3.61 358 3.63 4.04 3.50 3.23 3.33 3.48 140.00 138.00 142.67 145 33 142.33 139 00 142.33 146.33
D O M Ssub 03 23 126.75 172.72 92.27 2.32 186 2.09 3.39 1.98 1.41 0.90 2.88 120.67 124.67 119.33 124 33 120.00 118.67 105.33 120.67
D O M Ssub 04 21 129.85 186.69 84.09 3.00 2.82 236 2.22 3.16 2.19 2.11 2.38 129.67 125.33 12133 126.00 123.00 123.00 118.67 126.00
D O M Ssub 05 Female 23 128.05 154.94 50.00 3.89 3.11 3.17 3.66 4.40 3.58 3.52 3.83 144.33 131.67 140.00 142.00 140.00 140.00 140.00 144.00
D O M Ssub 0 6 31 122.85 169.55 66.60 4.82 3.71 3.29 3.48 4.71 3.74 2.22 2.98 140.67 139.67 135.33 137.00 144.33 136.33 129.33 130.33
D O M Ssub 07 Female 26 126.10 168.91 58 64 2-14 2.38 2.96 3.79 3.50 3.75 2.92 4,58 146.33 141.33 145.33 145.33 146.00 142.67 145.33 145.00
D O M Ssub 08 Female 37 118 95 157.48 104.55 1.60 1.17 0.72 1.09 1.51 1.10 0.98 1.21 123.67 110.33 100.67 112.00 124.33 105.00 110.33 115.33
D O M Ssub 09 Male 29 124.15 166.37 79.54 4.14 3.94 4.10 4.05 4.09 4.28 3.98 4.01 135.67 135.67 134.67 135.00 134.33 13467 134.00 134.00
DOM Ssub 10 Female 24 137.40 156.21 48.64 3.09 301 258 2-56 1.92 2.79 256 161 150.00 149.00 150.00 152.33 150.67 145.00 145.00 150.00
D O M Ssub 11 Female 23 128 05 165.10 6227 1.93 1.70 2.26 . .1.43, 1.81 1.84 2.18 2.23 154.67 150.33 151.67 154.00 155'00 150.00 151.00 154.33
D O M Ssub 12 Male 25 126.75 182.88 81.82 303 2.16 2.50 3.12 3.46 296 231 3.45 134.33 129.33 129.67 13133 134.67 127,33 130.67 130.00
D O M Ssub 13 Male 29 124.15 172.72 84.09 375 3.51 0.78 0.85 3.74 2.07 0,48 0.86 137.00 122.67 .80.67 93.33 136.33 123.00 90.67 100.00
D O M Ssub 14 Female 29 124.15 162.56 81.82 3.13 1.46 1.24 1.72 3.36 1.18 1.18 1.75 135.00 135.00 135.00 135.00 135.00 131.67 132.00 129.33
D O M Ssub 15 Male 24 127.40 172.72 75.91 3.15 3.48 350 3.70 3.55 3.63 336 3.61 133.67 136.33 13467 134.67 135.00 135 67 135.00 138.33
DOM Ssub 16 Male 37 118.15 175.36 72.73 3.50 2.86 2 29 2.47 3.60 2.78 2.00 2.32 140.00 135.00 0.00 135.00 145 33 136.33 0.00 134.67
Mean 26 A1 12.535 168:32 72.71 .li19 2 5 2 2.7ft .1.19 Î M 2 J 5 2.79 1 3 8 3 5 1.1.3/9 1 2 2 4 0 133«H 1.18DI \ . n . i 9 121 75 1 3 3 /.1
StUfK 4i<7 3 3 3 8.89 1 5 5 6 UJB7 0J15 Ui>« l i l 6 0 9 5 IXIi 1115 ID 7 9.19 9.94 37 J 9 15i)6 9.76 11 3 3 36.29 13.M«
S tF r r 1-12 Ü&1 3.89 0 J 2 O J l 0.24 0.26 0 J 4 (U 5 0 3 6 0 3 7 2 3 0 2.18 9 .15 3.76 2 A i i m 9 i r 3.4 7
Ranga o/Mi>ticn (iagraas) Ranga cf Motiox (iagraas) 
Utiraaiai
Joint Line GSrtk (cm) 
Treated
Joint Line Girtk (cm) 
Untreated
5 CM above J T  Line GUrtk (cm) 
Treated
S  cm above JT  Line Girth (cm) 
Untreated
PM 24h 48h 72h Pre 24h 48h 72H Pre 24h 4Sh 72h Pre 24h 48h 72h
DOMSsub 01 33.43 33.90 33.90 34.27 33.33 33.90 : 33.90 33.77 36.13 i 36.13 35.93 : 36.07 35.77 35.67 35.73 36.07
DÜMSsùb 02 33,20 33.57 33.47 . 33.17 33.27 33.37 33.33 33.07 36.50 36.83 36.93 ; 36.37 36.40 36.73 36.40 36.10
DOMSsub 03 41.43 41.37 41.73 41.63 41.80 42.00 41.40 42.20 44.73  ^ 44.40 44.80 : 44.50 45.03 45.40 45.50 45.43
DOMSsub 04 39.87 ■ 39.30 38.67 38.97 39.00 38.83 ; 38.97 38.90 40.27 : 40.13 40.07 40.27 40,07 40.23 40.47 40.30
DOMSsub 05 32.97 32.90 3300 32.33 34.07 33.13 33.30 33.33 35.43 ; 3547 35.33 ' 34.80 36.93 36.07 36.37 36.07
DOMSsub 06 36.73 36.43 36.83 36.77 36.37 36.03 36.37 36.67 37.47 : 36.67 37.83 37.63 38 00 37.23 38.23 38.47
DOMSsub 07 34,93 35.07 35.53 35.23 35.23 35.07 ' 36.43 36.30 37.13 ■ 37^43 38.40 : 37.63 37.17 37.37 38.37 38.53
DOMSsub 08 45.97 45.17 44.73 45.37 42,33 43.57 : 42.60 43.77 50.53 ' 50.50 50.63 : 50.83 51.13 51.47 50.73 51.10
DOMSsub 09 37.73 38.27 38.27 38.60 38.77 38.90 39.23 39.03 43.13 i 42.27 42.33 43.33 42.53 43.37 42.73 43.00
DOMSsub 10 34.00 33.63 33.70 33.67 33.13 33.33 33.47 33.43 34.10 1 34,07 34.03 : 34.10 34.13 34.27 34.00 33.90
DOMSsub 11 38.43 38.53 38.50 38.03 38.83 39.23 39.73 39.20 40.67 r 40.97 41.03 41.07 40.83 41.57 41.43 41.33
DOMSsub 12 38.07 38.07 38.13 38.10 38.03 37,67 38.10 38.27 39.77 : 39.90 40.37 40.67 39.47 38.93 39.10 40.00
DOMSsub 13 38.17 38.13 38.60 39.53 38.03 38.10 38.07 37.90 40.80 , 42.23 42.03 42.13 40.10 40.10 41.10 4037
DOMSsub 14 40.50 ■ 40.47 40.23 40.57 40.87 40.40 40.43 40.90 44.60 ! 44.77 45.13 ' 45.53 45.80 45.37 45.60 46.10
DOMSsub 15 37.20 : 36.97 3730 37.47 37.63 37.63 37.60 37.23 40.37 ' 39.80 40.67 40.07 40.00 40.10 39.87 39.47
DOMSsub 16 36.03 36.23 35.43 36.00 35.43 35.83 35.77 35.50 3623 ! 36.77 36.47 37.07 36.40 36.80 36.73 36.60
37,42 37 J 8 3738 37.48 37^6 37 37.43 ■ 37.47 39 M7 39370 ■10.13 40.13 3999 4044 10.1.9 40.18
347 3,28 321 3.42 3D0 3.16 i 2.95 321 429 1 4.26 4.29 4.44 4.40 452 4.36 4.47
0A7 0K2 njio nJÎ5 0.75 0.79 ; 0.74 04Î0 isrr 1416 1417 1.11 1.10 1.13 1119 1.12
J0em  abov* JTLina GtTlk(cm) 
Treatai
Id em  a bort JT  Lina Gtrtk(cm) 
Uniraatai
JS em abova JT L itit Girtk (cm) JSem abort J T L in t Oirtb (cm) 
IM iraatti
20em abort J T L ittt Girtk (cm) 20cm abort J T L in t Girtk (cm) 
U atrtatai
Pre 24h 48h 72k Pre 24h 48h 72k Pre 24k 48k 72h Pre 24h 48k 72k Pre 24k 46k 72k Pre 24k 48k 72k
DOMSs4lOI 41.70 41.10 41.03 40.73 40.00 40.70 40.43 40.70 4697 46.70 46.37 46.53 45.10 46.40 46.40 46.33 52.20 51.63 51.70 52.13 50.77 51.10 50-57 50.57
D 0M Ss4,02 40.73 40/7 40.93 . 40.50 40.37 40.53 40.27 45.80 4590 46.13 46.03 45/3 45.40 45.60 45.10 50,40 50.50 50.17 50.03 49 43 50.20 49.67 49.60
DOMSsdiO? 51.47 51.30 50.50 50.73 51.60 50.53 51.33 58.57 57.70 58.87 58.30 57.30 59 00 58.00 57,97 63.40 63.17 63.60 63.27 6243 62.57 63.00 63.20
DOMSsdi 01 45J3 44.90 45,43 ' 45.37 44.53 45.17 45.07 45 53 51.03 50.03 51.13 50.77 49.53 49.90 50.70 50.47 55.53 55.43 55.47 54.40 54.63 5513 5553 54.80
DOMSsvbGO 40.40 40.60 40.83 39.57 42.00 42.30 41.30 40.47 46.27 ' 46.37 46.07 45.37 47D7 47.03 4 7m 46.13 51.00 5177 50 53 50.50 4850 5303 5157 51.13
DOMSsub 06 42.70 42.47 43.80 : 43.57 42.67 4237 42.53 43.83 47.80 47.83 4853 43.83 47,67 47.60 48.07 49.23 51.00 5107 52.13 51.53 51.17 51.43 54.17 52.87
DOMSsub 07 40 73 41.43 42.67 41.83 41.03 41.13 42.43 43 37 45.27 46.07 47.27 46.80 46.77 46.23 48.73 50.53 5097 51.17 51.23 52.23 51.03 53.00 53 63
DOMSsub 08 6133 59.13 59.53 60.13 59.13 59.13 58.73 58.17 68.20 67 53 67.73 67.83 64.57 66.07 66.13 64.77 71-57 72.43 74.67 71.13 72.67 72.83 73.77 72.63
DOMSsub 09 49.47 49.67 48.83 . 49.53 49.83 49.63 49.27 49.13 55.67 55.43 56.50 55.73 54/7 5457 55.63 55.13 58.47 58.67 59.03 58.90 58.43 58.37 58.77 58.60
DOMSsub 10 39.13 38.73 3943 37.73 38.23 37.73 37,93 38.53 44.13 43-50 44.43 43.93 43.13 42.50 42.73 43.20 48.27 48.63 48.63 47.73 47.00 47.17 47.03
DOMSsub 11 4407 44.83 44.40 44.23 43.87 44.03 49.27 49.47 49.23 49.23 48.03 48.17 52.33 53.43 51.73 5193 52.40 52.77
DOMSsub 13 44.87 45.23 4407 43.33 44.73 50.13 50 40 50.37 50.73 48.83 49.83 49.33 51.03 55.27 55.33 55.03 54.43 54.00 54.27 53.40 53.87
DOMSsub 13 45.47 46.10 46.30 45 20 46.00 45.87 51.30 52 27 52.63 52.07 51.00 5180 51.60 52.03 5560 57.10 57.03 57.13 5593 56.73 56.40 56.70
DOMSsub 14 5130 51 50 52.00 51.83 53.23 53.27 58.33 58.87 58.47 58.77 57.67 58.73 59.30 59.87 62.67 64.17 65-» 6550 62.83 64.73 65.63 65.27
DOMSsub 15 46.77 46 43 47.20 47.47 47.43 46.67 46.37 52.63 52.43 52.63 52.23 51.37 51.57 51-57 51.80 55.57 55.77 55.93 54.93 56.33 55.57 56.07 55.17
D 0M Ssidil6 39 J3 41.03 40.93 39.93 40.57 41,33 40.77 44.80 46.00 46.50 46.43 46.07 46.57 46.73 4633 49.87 50.87 51.20 51.13 50.40 50.93 51.10 51.20
45.10 4540 15J5 4 5 DA •1.S.23 1.5-20 1541) 51D1 51 5 U 3 *1.23 60,21 50,70 50.94 SU12 MÂ9 5.«.97 /A,16 /■I .96 55.1.1 ./5 /«
5-83 5 / 8 5 58 563 .5.43 Û.4S 6 J 6 6 J 9 6JD 6.19 6 M 5J96 6 / 0 6J1 039 631 6 M 6 / 5 6 / J
137 i j i 142 1J9 138 136 I J 3 162 156 1 /7 iA 3 155 1.46 1 /5 1 /8 1 /8 1 /1 1 /4 1 69
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y/HO Prt Es: Pain 
TreaieA
VbfO Prt Ex Pain 
U nrta tti
y/HO Post Ex Pain VMO Post E x Pain 
V nrta ità
VMO Post Tx Pain VMO Post Tx Pain 
U analtd
Pre 24b 48h 72b 24h 48k 72k Pre 24k 48k 72h Pre 24h 48k 72k INT* 48h 72h INTx 24h 48k 72k
DOMSsiA 01 3.00 3.00 2.00 2.00 3.00 2.00 3.00 3.00 3.00 1.00 2.00 3.00 3.00 1.00 2.00 1.00 1.00 1.00 2.m 2.00 _
DOMSsub 02 0.00 3-00 1.00 2.00 0.00 3.00 2.00 2.00 0.00 2.00 1 00 1.00 0.00 3.00 1.00 1.00 0.00 3.00 3.00 i.m
DOMSsiA 03 1,00 . 200 ■ 0..50 0.50 100 3.00 2m 1.00 050 1.00 2.00 1.00 0.50 0.00 0.50 050 100 2.m i m
DOMSsub 04 100 2m 2.00 2.00 2.00 200 2.00 1.00 2.00 2.00 2.00 1.00 1.00 1.00 1.00 1.00 1.00 im
DOMSsub 05 1.00 1.00 0..50 050 1.00 3.00 1.00 1.00 0.50 0.50 2-00 lOO 100 0.50 2.00 1.00 1.00 1.00 0 50 0.50
DOMSsub 06 0.50 0.50 0.50 0.50 1.00 1.00 2.00 1.00 0.50 0.50 0.50 1.00 0.50 0.50 0-50 0.00 0.50 0.00 1.00 I.m 0.00
DOMSsub 07 300 1.00 1.00 0.50 2.00 1.00 0.50 0.50 2.00 100 1.00 0_50 2.00 1.00 1.00. . 0.50 0.00 0.00 0.50 i.m 1.00 i.m
DOMSsWi 08 1.00 2.00 1.00 0.00 2.00 1.00 1.00 pJO 2.00 2.00 1.00 0-50 1-00 1.00 ooo 2.00 2.00 i.m 2.m 2.00
DOMSsiAOP 2.00 2.00 1.00 0.00 0.00 0.50 000 Ï.00 1.00 1.00 0.00 0.00 0.50 000 2.00 2.00 2 m 0.50 1.00 0.50
DOMSsub 10 4.00 1.00 7.00 3.00 3.00 3.00 2.00 3.00 2.00 3.00 3.00 ooo 200 i m
DOMSsub 11 6.00 4.00 7.00 5.00 5.00 8.00 7.00 8.00 5.00 8.00 5.00 8.00 8.00 6.m 6.m
DOMSsub 12 4.00 6.00 3.00 0.00 6.00 3.00 1.00 500 0.00 3.00 5.00 i m 4.m 4.00 i.m
DOM Ss# 13 0.00 500 2.00 100 5.00 200 0.50 1 00 1.00 0-50 2 m 2.00 OOO 300 2.00 0.00 2.m 2m
DOMSsub 14 4.00 5.00 5.00 500 4.00 5.00 600 6.00 5.00 4.00 4.00 5.00 100 4.00 3.m 5.00 5.m
DOMSsub 15 3.00 : 3.00 3.00 3.00 2.00 3.00 300 400 3.00 3.00 4.00 . 3.00 3.00 3.00 300 3.00 3.00 3.m
DOMSstd) 16 1.00 300 5.00 1.00 3.00 1.00 4.00 5.00 5.00 4.00 5.00 1.00 100 3.00 5.00
2 /9 2 /6 I p i 2 /3 2.19 2 M 15»'' ■2At 14)1 1.19 1.72 2 J4
1 /5 2.15 2.ÎI Î44 1 -5.1 1.W 2.1» 2.27
0 /0 0.45 0 J9 0 /4 ÛJ8 0 / 4 0 /1 0 /7 - -
Je m  J T L in t P rt Ex Pain 5em  J T  L in t Prt E x Pain 
Unrtattà
S cm J T L in t Post Ex Pain S cm JT  Lint Post E x Pain 
U nrta tti
5 CM JT L in t Past Tx Pain 5  cm JT  Lint Post Tx Pain 
U nrta tti
24k 48h 72h Pre 24h 48k 72k Pre 24k 48k 72h Pre 24k 48k 72k INTx 24h 48k 72k INTx 24h 48h 72k
DOMSsub 01 2.m I.m 1.00 3.m 2m im 2.00 2.m 2.00 I.m I.m 3.00 2 m i.m i.m i.m I.m 100 - 1.00 100 I.m -
DOMSsub 02 o.m 0.00 0.00 o.m o.m 0.00 0.00 O.m o.m 0.00 o.m om O.m o.m o.m o.m o.m i.m o.m o.m O.m ooo
DOMSsub 03 0-50 0.50 0.50 050 050 050 0.50 050 0.50 0.50 0.50 0.50 0.50 0-50 0.50 0.50 o.m o.m 0.50 0.50 0-50 0.50
DOMSsub 04 0.50 !.m 1.00 I.m 1.00 I.m 1.00 0,50 050 1.00 i.m 050 1.00 I.m I.m 0.50 0.50 0.50 1.00 0.50 0.50 I.m
DOMSsub 05 I.m 0.50 0.50 : 0.50 1.00 2.00 2.00 0.50 2 m 1.00 0.50 0.50 2.m 1.00 I.m 0.50 3.m I.m 2.m I.m I.m I.m
DOMSsub 06 lOO 0.50 0.50 0.50 i m 0.50 050 0.50 1.00 0.50 0.50 0.50 im 0.50 0.50 050 o.m 0 50 o.m i.m o.m
DOMSsub 07 I.m 0.50 I.m 0.50 1.00 0.50 0.50 0.50 I.m 0.50 0.50 0.50 i m 0.50 I.m 0-50 o.m O.m 050 0.50 0.50
DOMSsWi 08 2.00 2.m 2.m : 1.00 1.00 2.m 1.00 0.50 I.m 2 m 1.00 1.00 I.m 2.m I.m 0.50 o.m 2.m 0.50 1.00 2.m i.m
DOMSsub 09 0 50 0.50 1.00 0-50 o.m 0.50 0.50 0.50 0.50 050 0.50 050 0.50 o.m 0.50 0.50 0.50 0.50 1.00 0.50 0.50 0.50
DOMSsub 10 3.00 o.m 2.m I.m 0.00 1.00 2.m 0-00 4.m I.m I.m 2.m I.m 2.m 1.00 3.m o.m I.m 2.m i.m
DOMSsub 11 om 000 0.00 0.00 o.m om 0.00 o.m o.m o.m o.m o.m 2.m o m o.m 0.00 o.m 0.00
DOMSsub 12 om 0.00 0.00 0.00 o.m 0.00 0.00 o.m o.m o.m O.m o.m o.m o.m o.m o.m
DOMSsub 13 0 00 0,00 o.m om O.m O.m o.m o.m o.m o.m o.m o m o.m o.m
DOMSsub 14 I.m 1.00 0.50 0.50 0.50 1.00 0.50
DOMSsub 15 3.m 3m 400 3m 3.m 3.m 3.m 3.m 2.m
DOMSsub 16 0.50 2 DO 3.m 2 m 3.m 2.m
1.13 11.91 0.7H 0.9» 0-91 (I-7H
039
n : . i 03fi 11.22
iOcm JT  Lint Prt Ex Pain tO em JT  L in t Prt Ex Pain 
Unrtattd
lO cm JT  Lint Post Ex Pain 19 cm JT  Lin t Post Ex Pain 
U nrta tti
Iff cm J T L in t Post Tx Pain Iff cm JT L in t Post Tx Pain 
U nrta tti
Pre 24k 48k 72h Pre 24k 48k 72h Pre 48k 72k 24k 48k 72h IN Tx 24h 48k 72k IN Tx 24k 46k 72k
DOMSsub 01 2.m 3.00 2.m 1.00 3 m 3.m 2.00 1 m 2.m 2.00 I.m i m 2.m I.m i.m 1.00 I.m I.m - 2.00 i.m I.m -
DOMSsub 02 om i.m 1.00 . om O.m 0.00 1.00 o.m om !.m o.m o.m o.m o.m I.m O.m 2,m i.m O.m o.m o m
DOMSsub 03 I.m 1.00 0.50 0.50 0.50 I.m 050 0.50 050 1.00 0.50 0.50 0.50 050 050 .050 o.m o.m 0.50 0.50 i.m 0.50
DOMSsub 04 050 2.m I.m i.m 0.50 3.m I.m 1.00 0.50 I.m im 0.50 i.m 2.m I.m i.m 0.50 I.m I.m 0.50 i.m I.m
DOMSsub 05 0.50 I.m 0.50 I.m 2.m I.m 050 2.m I.m 0.50 0-50 2.m 2.m 2 m 0.50 2.m I.m i m - I.m I.m 0.50
DOMSsub 06 0.50 050 I.m 0.50 0.50 050 0.50 050 0.50 I.m 0-50 0.50 050 0.50 0.50 o.m 0.50 0.00 0.50 0.50 o.m
DOMSnA 07 0.50 0.50 0.50 050 050 1.00 0.50 0.50 0.50 I.m 0.50 0 50 050 i.m 0.50 o.m o m 0.50 0.50 0.50 0.50
DOMSsiA 08 2.m 3.00 3 m I.m 2.00 4m 2.00 1.00 2.00 3.m I.m 400 2.m 2.00 o.m 2.00 I.m 2.00 4-00 2.m
DOMSsub 09 0.50 i.m 2.m I.m 0.50 i.m 0.50 I.m 1.00 1.00 1.00 100. 1-00 I.m I.m 0.50 I.m I.m im 0.50 1.00 0.50
DOMSsub 10 4.m 2.00 2.00 1 m I.m 2.00 1.00 2.m 2.m I.m 5.m I.m 3.m 3.m 4.m 3.m I.m I.m I.m i m
DOMSsub 11 0.00 o.m 0.00 o.m o.m 0.00 0.00 o.m o m o.m i m o.m o.m o.m
DOMSstA 12 o.m o.m o m o.m o.m o.m I.m o.m om o.m o m 0.00
DOMSsub 13 o.m 7.00 o.m o.m o.m i.m I.m I.m o.m 2.m 3.m
DOMSsub 14 2.m 2.00 i.m 2.m 2.m I.m I.m 1.00 2.m I.m im 0.50 i.m I.m 2.m I.m
DOMSsub 15 3.m 4.m 3 m • 3.m 4.m 4.m 3.m 3.m 3.00 3.m 3.00 4.m 4.m 5.m 4.m
DOMSsub 16 i m 3.00 400 2.00 300 1.00 200 3,m 2.00 2.m 3 m 4.m
1 /0 1-S6 1 /9 1.72 131 i . i j 138 097 131 138 132 054 l .U 1.19 0-91 138 138 -
1.19 1.2(1 1.11 i.tv 1 A4 13.1 1 /1 087 " m t  " 130 1.17 1.17 131 1 /2
0.10 0-28 035 038 032 032 039 031 030 ~ 0:26 035 -
IS c m J T  Lint Prt Ex Pain 15 cm J T L in t Prt E x Pain 
U nrta tti
15 cm JT  L in t Post E x Pain 15 cm J T L in t Post E x Pain 
U n rta tti
15 em J T L in t Post Tx Pain 15cm J T L in t Post Tx Pain 
U nrta tti
Pre 24h 46k Pre 4Bh 72k Pre 24k 48k 72k P rt 24k 48k 72k INTx 24k INTx 24k 48k 72h
DOMSsub 01 3.00 3.m 4.m 2.m 3.m 400 3.m 2.m 2.m 2.m i m 2.00 3.m 3.m 2.m i.m I.m I.m 100 2.00 3.00 -
DOMSsub 02 O.m 5.m 0.00 4.m 4 m o.m 2.m I.m 2.ra O.m 2.m 2.m 0.50 4.m 4 m 0.50 2.m 3 m
DOMSsub 03 i m 3 m 050 I.m 2 00 I.m i.m 2m im 050 050 2C0 2m o m 050 I.m 0.50 200 i m
DOMSsub 04 0-50 3.m 300 3.m 0 50 3.m 3 m 3.m 0.50 2.ra 3.m 2.m I.m 3 m 3.m 3 m I.m 2.00 3 m 0.50 2.m 400
pOMSsdb 05 0.50 I.m 2.00 0.50 0.50 .2-00 3 m I.m I.m 100 i,m 0.50 2.00 2,m 3.m 1.00 3.m i m 2.m 1.00 2.m I.m
DOMSsub 06 I.m 1.00 I.m 2.m I.m I.m 300 I.m im I.m I.m I.m I.m 1.00 I.m I.m o.m I.m o.m i.m o.m
DOMSs«A07 0.50 2.m 4,m  ^ 3m 0.50 0.50 2.m 1 m 0.50 im 3.m I.m 0.50 2.m i.m 050 0.50 2.m 050
DOMSsd, 08 2m 5m 2.m 2.00 5.m 3.m 200 2m 3.00 2.m i.m 5.m 300 3.m o m 4.m 2.m . ,2m 5.m 5.m
DOMSsub 09 i.oo 3.m 2.m 0.50 i.m I.m I.m 2.m I.m . I.W 2.m i m i.m 1X0 I.m I.m 3m 0.50 i.m 0.50
DOMSsub 10 2.m 4.m 3.m 4.m 6 m 2m 4.m 3.00 5.00 2X0 5.00 3.00 3.m tm 2.m i.m 3m
DOMSsub U 4.m 5.m o.m 5.m 4.m I.m o.m 4.00 2.m 4,m 4.m 2.00 5.m 5.m 4.00
DOMSsub 12 o.m i.m o.m i.m i m I.m o.m 1.00 2.m o m I.m 3 m 0.00 2.m i m i m
DOMSsub 13 0 00 i.m 7.m o m 3.m 900 5.m o.m 050 4.00 i m 5.m 4.m 700 3.m 7.m
DOMSsub 14 2.m 2.00 3.m 2.m 3.m 3.m i.m 2.m 2.00 2 m 3.m 2.m 2.m 2.00 I.m 2.m
DOMSsiA 15 4.m 5.m 4.m 3.m 4,m 5.m 6 m 5.m 4.m 4m 3m 3.m 4.m 5.m 5.m 5.m 3.m 5 m 4,m 4.m 5.m 6.m
DOMSstA 16 I.m 2.m 5.m 3.m 0.50 3.m 5.00 5.m 1.00 2.m 5m 3.m 050 3.m 5.m 4.m 3.m 3.m 5.m I.m 2 m 5.00
1 66 2 /3 .131 2.78 3 /6 2-63 138 191 2X4 134 2.41 2.94 2.44 1X7 3/11 1.16 228 2.9'’ -
1 3 / 197 131 141 14(1 1 3 / ' : x r 162 139
0-16 ÜM 0 19 n..<2 0.19 1)32 (141 - 0 3 / 11/2 -
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JO em JT  Lint P n  Ex Pain 20 em J T L in t Prt Ex Pain 
U nrta tti
20em  J T L in t Post Ex Pain 2 Oem J T L in t Post Ex Pain 
U nrta tti
29cm  J T L in t Post Tx Pain 20cm J T L in t Post Tx Pain 
U nrta tti
Pre 24k 48k 72k Pre 24k 48k 72k Pre 24k 48k 72k Pre 24h 48h 72k INTx 24k 48k INTx 72h
DOMSstAOl 3.00 400 5 m 1.00 3.00 4.00 5.00 3.00 2.00 3.00 3.00 3.00 2 00 3.00 4.00 3.00 1.00 2.00 2.00 2.00 3.00
DOMSsub 02 0.00 5.00 6.00 7.00 0.00 4.00 7.00 8.00 0.00 4.00 3.00 5.00 0 00 4.00 4.00 3.00 I.OO 6.00 7.00 0.50 4,00
DOMSsub 03 1.00 3.00 . 0.50 0.50 3.00 2.00 1,00 1.00 2X0 J.OO 0.50 3.00 2.00 0.50 1.00 2.00
DOMSsub 04 3.00 0.50 3.00
DOMSsub 05 2.00
DOMSsub 06 200
DOMSsub 07 3.00 5.00 2.00 2.00 3.00 2.00 2.00 500 3.00 1.00 3.00 1.00 0.50 3.00 2.00
DOMSsub 08 4.00 3.00 5.00 3.00 3.00 6.00 300 3.00 4.00 5,00 5.00 3.00 2.00 5.00 4.00 0.00 500 4.00 3.00
DOMSsub 09 2.00 ; 3.00 3.00 2.00 1.00 2.00 1.00 2.00 1.00 '2,00 2.00 ioo 1.00 ICO 2.1X1 I.m 2.00 3.00 3.00 1.00 2.00
DOMSsub 10 6.00 4.00 400 7.00 6.00 7.00 4,00 3.00 8.00 5.00 5.00 5.00 2.00 1.00
DOMSsub U 5.0Û 7.00 5.00 5.00 0.00 5.00 7.00 8.00 4.00 5.00 5.00 800 6.00 4.00 5.00
DOMSsub 12 4.00 I.OO 050 0.00 2.00 I.OO 0.00 2.00 3.00 0.00 5.00 0.00
DOMSsub 13 3.00 700 0.00 4.00 10 00 lOOO 0.00 1.00 5.00 000 200 7.00 7,00 5.00 10.00 0.00
DOMSsub 14 4.00 . 3.(30 2.00 400' 4.00 5.00 050 2.00 2.00 3.00 2.00 2.00 2.00 2.00 1.00
DOMSsub 15 3.00 5.00 4.00 4.00 4.00 6.00 7.00 700 5X30 5.00 4,00 4.00 5.00 6.00 7.00 7.00 3.00 5.00 4.00 4.00 6.00
DOMSsub 16 1J30 2.00 6.00 4.00 100 4.00 6,00 3.00 im 3.00 5.M 5.00 1.00 3.00 5.00 5.00 2.00 3.00 6.00 3.00 3.00
1.7/ 3 2 / 4.19 359 184 369 4X1 UIV 163 288 363 334 184 3-13 3.7,5 1J1 -U19 .169 1.78 .106
134 :.3K 255 211: 136 1.9(3 167 2.32 I 34 199 169 16.«














































4 * p = , .0 2 9
A
Day 1 Day 3 Day 4 Day 5
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Knee Joint AROM (Flexion)





g  125.00 - 
S  120.00 -o
115.00 -
110.00








?  38.00 4 
-  37.50 







Day 1 Day 3 Day 4 Day 5






- 3 9 .5 0  4 







Day 1 Day 3 Day 4 Day 5
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e  51.00 
— 50.50 





15 cm above Joint Line Girth
♦ p = .037*p =  .0 2 6
-#— Treated 
Untreated
Day 1 Day 3 Day 4 Day 5




















15cm above Jt Line Girth
* p =  .001
Day 3 Day 4 Day 5
Day 1
20cm above Jt Line Girth
























Day 1 Day 3 Day 4 Day 5
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5 cm above Joint Line Pre-exercise Pain
Day 1 Day 3 Day 4 Day 5
■Treated 
□ Untreated








Day 1 Day 3 Day 4 Day 5
■ Treated 
□ Untreated















Day 1 Day 3 Day 4 Day 5
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5 cm above Joint Line Post-exercise Pain






































15 cm above Joint Line P ost-exercise Pain
*p = ,.0 0 6 :
1.?8 1.A4











20 cm above Joint Line Post-exercise Pain
*p  =  .0 4 4  3.H3
 A  T ,* *














































5 .0 0  1
4.00
10 cm above Joint Line Post-treatment Pain
























*p =  .013
A"
*p =  .024
■ Treated 
□ Untreated











20 cm above Joint Line Pain
*p =  .004
*p =  .026
■ Treated 
□ Untreated












VMO Post-treatment Pain Interaction
Day 2 Day 3 Day 4














5 .0 0  1
5cm above Joint Line Pain Throught Experiment
4 . 0 0  -






10cm above Joint Line Pain Throughout Experiment
4 .0 0  -























20cm above Joint Line Pain Throughout Experiment5 .0 0  -
4 .0 0  -
3 .0 0  -
♦— T reated







DEPENDENT VARIABLES d / F p-value DEPENDENT VARL4BLES d / F p-value
C oncentric P eak  T orque
T reatm ent 1.000 .017 .897
5cm  P re-exercise  Pain
T reatm ent 1.000 .031 .863
Tim e 1.549 3.787 .047 T im e 2.169 .591 .573
T reatm ent*T im e 3.000 1,919 .140 T reatm ent*T im e 1.414 .247 .706
E ccentric P eak  T orque
T reatm ent 1.000 .001 .979
5cm  P ost-exercise  Pain
T reatm ent 1.000 .050 .827
T im e 1.965 4.480 .020 T im e 1.621 1.332 .278
T reatm ent*T im e 3.000 1.742 .172 T reatm ent*T im e 1.338 .672 .464
R ange o f  M otion
T reatm ent 1.000 .405 .534
5cm  P ost-treatm ent Pain
T reatm ent 1.000 .149 .705
T im e 1.162 2.408 .136 T im e 2.000 .961 .394
T reatm ent*T im e 3.000 .031 .993 T reatm ent*T im e 2.000 .063 .939
Join t L ine G irth
T reatm ent 1.000 .070 .795
10cm  P re-exercise  Pain
T reatm ent 1.000 .487 .496
T im e 3.000 1.037 .385 T im e 1.730 2.384 .118
T reatm ent* T im e 3.000 .561 .644 T reatm ent*T im e 3 .000 .771 .516
5cm  above Jo in t L ine G irth
T reatm ent 1.000 .286 .601
10cm  P ost-exercise  Pain
T reatm ent 1.000 2.442 .139
Tim e 3.000 2.409 .079 Tim e 3.000 .973 .414
T reatm ent* T im e 3.000 .314 .815 T reatm ent*T im e 3.000 .791 .505
10cm  above J o is t  L ine G irth
T reatm ent 1.000 1.349 .264
10cm  P ost-treatm ent Pain
T reatm ent 1.000 .039 .847
Tim e 2.173 .718 .506 Tim e 2.000 2.180 .131
T reatm ent* T im e 3.000 .858 .471 T reatm ent*T im e 2.000 .346 .711
15cm  above Jo in t L ine G irth
T reatm ent 1.000 4.330 .055
15cm  P re-exercise  Pain
T reatm ent 1.000 .034 .855
Tim e 3.000 7.415 .000 Tim e 1.986 7.595 .002
T reatm ent*T im e 3.000 2.827 .049 T reatm ent*T im e 3.000 1.301 .286
20cm  above Jo in t L ine G irth
T reatm ent 1.000 .806 .383
15cm  P ost-exercise  Pain
T reatm ent 1.000 10.281 .006
Tim e 3.000 4.848 .005 T im e 3.000 4.749 .006
T reatm ent*T im e 3.000 .726 .542 T reatm ent*T im e 3.000 2.644 .061
V M O  P re-exercise Pain
T reatm ent 1.000 .011 .916
15cm  P ost-treatm ent Pain
T reatm ent 1.000 .305 .589
Tim e 3.000 1.274 .295 T im e 2.000 8.498 .001
T reatm ent*T im e 3.000 .706 .554 T reatm ent*T im e 2.000 .559 .578
V M O  P ost-exercise  Pain
T reatm ent 1.000 .685 .421
20cm  P re-exercise  Pain
T reatm ent 1.000 1.291 .274
Tim e 2.150 1.326 .281 T im e 1.751 8.494 .002
T reatm ent*T im e 3.000 .847 .475 T reatm ent*T im e 2.202 .416 .682
V M O  P ost-treatm ent Pain
T reatm ent 1.000 .000 1.000
20cm  P ost-exercise  Pain
T reatm ent 1.000 2.945 .107
T im e 2.000 4.650 .017 T im e 2.101 7.987 .001
T reatrnent*Tim e 1.405 6.072 .015 T reatm ent*T im e 2.245 .099 .924
20cm  P ost-treatm ent Pain
T reatm ent
T im e



































Mean Std. Deviation N
E c c P T P r e T 3 .0 8 6 2 .86961 16
Ecc_PT_24T 2.6019 .84763 16
Ecc_PT_48T 2 .5 1 6 9 .97847 16
Ecc_PT_72T 2 .7 7 9 4 1.05889 16
E c c P T P r e N 3.1875 .94916 16
Ecc_PT_24N 2 .6 4 5 0 1.01304 16
Ecc PT 48N 2 .3 4 8 8 1.04613 16
Ecc__PT_72N 2 .7 9 2 5 1.07407 16
M auehly's Test o f Sphericity
Measure:MEASURE 1
Within Subjects Effect Mauehly's W
Approx.




Treatment 1.000 .000 0 1.000 1.000 1.000
Time .2 5 8 18 .585 5 .002 .5 8 4 .655 .333
Treatment * Time .6 2 8 6 .3 8 5 5 .272 .786 .9 4 2 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalizcd transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time
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1 .000 .001 .979 .000 .001 .050
Greenhouse-
Geisser .000 1.000 .000 .001 .979 .000 .001 .050
Huynh-Feldt .000 1.000 .000 .001 .979 .000 .001 .050




















Assumed 8.559 3 2 .8 5 3 4.480 .008 .230
13.441 .851
Greenhouse-
Geisser 8.559 1.752 4.885 4.480 .025 .230 7.851 .679
Huynh-Feldt 8.559 1 .965 4.355 4.480 .020 .230 8 .8 0 6 .717







2 8 .6 5 6
28.656
2 8 .6 5 6
28.656
45







Treatment * Time Sphericity
Assumed .324 3 .108 1.742 .172
.104 5 .2 2 5 .424
Greenhouse-
Geisser .324 2 .3 5 7 .138
1.742 .185 .104 4.105 .3 6 9
Huynh-Feldt .324 2 .8 2 5 .115 1.742 .176 .104 4.920 .409


































R O M 48T





R O M PreN
ROM_24N
ROM_48N
R 0 M 7 2 N
Descriptive Statistics
Mean Std. Deviation N
R O M PreT 138.3550 9.19120 16
R0M_24T 133.6875 9.93561 16
ROM_48T 122.3962 37.39308 16
R0M_72T 133.8738 15.05549 16
R O M PreN 138.0094 9.75007 16
ROM_24N 133.2919 11.52932 16
R O M 48N 121.7494 36.28581 16
ROM_72N 133.6244 13.87795 16









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .011 62.267 5 .000 .377 .387 .333
Treatment * Time .509 9.255 5 .100 .787 .943 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time
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Assumed 5.363 1 5.363 .405 .534 .026 .405 .092
Greenhouse
-Geisser 5.363 1.000 5.363 .405 .534 .026 .405 .092
Huynh-
Feldt 5.363 1.000 5.363 .405 .534 .026 .405 .092
Lower-
bound




































































Treatment * Time Sphericity
Assumed
.690 3 .230 .031 .993 .002 .093 .055
Greenhouse
-Geisser
.690 2.360 .292 .031 .982 .002 .073 .055
Huynh-
Feldt
.690 2.830 .244 .031 .991 .002 .088 .055
Lower-
bound






-Geisser 334.052 35.405 9.435
Huynh-

















Girth J t_ 2 4 T  











Mean Std. Deviation N
Girth Jt PreT 37.4163 3.47041 16
Girth Jt 24T 37.3756 3.28106 16
Girth Jt 48T 37.3763 3.20924 16
Girth Jt 72T 37.4819 3.41626 16
Girth_Jt_PreN 37.2575 3.00337 16
Girth Jt 24N 37.3119 3.15620 16
Girth Jt 48N 37.4188 2.94579 16
Girth_Jt_72N 37.4669 3.21022 16
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Treatment . 1.000 .000 0 1.000 1.000 1.000
Time .782 3.371 5 .644 .866 1.000 .333
Treatment * Time .771 3.569 5 .614 .850 1.000 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time




o f Mean Eta Noncent. Observed
Source Squares df Square F Sig. Squared Parameter Power"
Treatment Sphericity
Assumed
.076 1 .076 .070 .795 .005 .070 .057
Greenhouse-
Geisser .076
1.000 .076 .070 .795 .005 .070 .057
Huynh-Feldt .076 1.000 .076 .070 .795 .005 .070 .057




















Assumed .388 3 .129 1.037
.385 .065 3.112 .263
Greenhouse-
Geisser .388
2.598 .149 1.037 .379 .065 2.695 .244
Huynh-Feldt .388 3.000 .129 1.037 .385 .065 3.112 .263








Huynh-Feldt 5.610 45.000 .125
Lower-bound 5.610 15.000 .374
Treatment * Time Sphericity
Assumed .174 3 .058 .561 .644 .036 1.682 .156
Greenhouse-
Geisser
.174 2.551 .068 .561 .617 .036 1.430 .147
Huynh-Feldt .174 3.000 .058 .561 .644 .0 3 6 1.682 .156












































Mean Std. Deviation N
Girth 5cm PreT 39.8725 4.29209 16
Girth 5cm 24T 3 9 .8 9 6 2 4.25960 16
Girth 5cm 48T 40.1238 4.29325 16
Girth 5cm 72T 40.1294 4.43802 16
Girth 5 cm PreN 39.9850 4.39624 16
Girth 5 cm 24N 40.0425 4.52488 16
Girth 5cm 48N 40.1475 4.35892 16
Girth_5cm_72N 40.1775 4.47250 16
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Treatment 1.000 .000 0 1.000 1.000 1.000
Time .840 2.388 5 .794 .892 1.000 .333
Treatment * Time .723 4.455 5 .487 .810 .978 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time


















1 .219 .286 .601 .019 .286 .079
Greenhouse-
Geisser
.219 1.000 .219 .286 .601 .019 .286 .079
Huynh-Feldt .219 1.000 .219 .286 .601 .019 .286 .079





















1.254 3 .418 2.409 .079 .138 7.226 .564
Greenhouse-
Geisser
1.254 2.676 .469 2.409 .088 .138 6.446 .529
Huynh-Feldt 1.254 3.000 .418 2.409 .079 .138 7.226 .564
















Lower-bound 7.810 15.000 .521
Treatment * Time Sphericity
Assumed .077 3 .026 .314 .815 .020 .941 .106
Greenhouse-
Geisser .077 2.429
.032 .314 .773 .020 .762 .100
Huynh-Feldt .077 2.933 .026 .314 .811 .020 .920 .105































G ir th l OcmPreT  












Mean Std. Deviation N
G ir th l Ocm PreT 45.3038 5.82883 16
Girth_10cm_24T 45.4025 5.47236 16
Girth_10cm_48T 45.5275 5.22100 16
Girth_10cm_72T 45.3450 5.67652 16
G ir th l O cm PreN 45.0300 5.57476 16
G ir th l Ocm_24N 45.2269 5.53333 16
Girth_10cm_48N 45.1988 5.43447 16
Girth_10cm_72N 45.3981 5.32618 16
1 0 1









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .420 11.897 5 .037 .635 .724 .333
Treatment * Time .858 2.108 5 .834 .920 1.000 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design; Intercept Within Subjects Design; Treatment + Time + Treatment * Time


















1.051 1 1.051 1.349 .264 .083 1.349 .193
Greenhouse-
Geisser
















































































Treatment * Time Sphericity
Assumed .682 3 .227 .856 .471 .054 2.567 .221
Greenhouse-
Geisser .682 2.760 .247 .856 .464 .054 2.361 .212
Huynh-Feldt .682 3.000 .227 .856 .471 .054 2.567 .221































G ir th l 5cm_PreT 
Girth_15cm_24T 






G ir th l 5cm_PreN 
Girth_15cm_24N  
Girth 15 cm_48N  
Girth_15cm_72N
Descriptive Statistics
Mean Std. Deviation N
Girth 15 cm PreT 51.0106 6.47839 16
Girth 15 cm 24T 51.0312 6.26374 16
Girth 15cm 48T 51.4288 6.25400 16
Girth 15cm 72T 51.2238 6.29284 16
G ir th l 5cm_PreN 50.2069 5.70606 16
Girth_15cm_24N 50.6981 6.19106 16
Girth_15cm_48N 50.9388 6.05497 16
Girth_15cm_72N 51.0181 5.86051 16
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Treatment 1.000 .000 0 1.000 1.000 1.000
Time .566 7.812 5 .168 .715 .838 .333
Treatment * Time .751 3.930 5 .560 .849 1.000 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design; Intercept Within Subjects Design: Treatment + Time + Treatment * Time


















6.716 1 6.716 4.330 .055 .224 4.330 .495
Greenhouse-
Geisser
6.716 1.000 6.716 4.330 .055 .224 4.330 .495
Huynh-Feldt 6.716 1.000 6.716 4.330 .055 .224 4.330 .495





















6.639 3 2.213 7.415 .000 .331 22.244 .977
Greenhouse-
Geisser 6.639 2.146 3.094
7.415 .002 .331 15.909 .930
Huynh-Feldt 6.639 2.515 2.640 7.415 .001 .331 18.648 .957




















Treatment * Time Sphericity
Assumed 1.599 3 .533 2.827 .049 .159 8.481 .640
Greenhouse-
Geisser 1.599 2.548 .627 2.827 .059 .159 7.204 .587
Huynh-Feldt 1.599 3.000 .533 2.827 .049 .159 8.481 .640



















a. Computed using alpha = .05




Treatme 95% Confidence Interval
nt Mean Std. Error Lower Bound Upper Bound
1 51.174 1.578 47.810 54.537






(I-J) Std. Error Sig.'
95% Confidence Interval for 
Difference"
Lower Bound Upper Bound
1 2 .458 .220 .055 -.011 .927
2 1 -.458 .220 .055 -.927 .011
Based on estimated marginal means




Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 50.609 1.517 47.374 53.843
2 50.865 1.554 47.553 54.176
3 51.184 1.535 47.912 54.456




(I) Time (J) Time
Mean Difference 
(I-J) Std. Error Sig."
95% Confidence Interval for 
Difference"
Lower Bound Upper Bound
1 2 -.256 .107 .180 -.580 .068
3 -.575* .120 .001 -.938 -.212
4 -.512 .176 .065 -1.047 .023
2 3 -.319 .122 .115 -.688 .050
4 -.256 .161 .791 -.744 .232
3 4 .063 .120 1.000 -.303 .428
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Bonferroni. 

























Mean Std. Deviation N
Girth 20cm PreT 55.2300 6.19627 16
Girth_20cm_24T 55.6925 6.31293 16
Girth_20cm_48T 55.9725 6.88511 16
Girth 20cm  72T 55.4563 6.31066 16
Girth_20cm_PreN 54.9506 6.54449 16
Girth_20cm_24N 55.4281 6.54627 16
Girth_20cm_48N 55.7638 6.77201 16
Girth_20cm_72N 55.5025 6.60936 16
106









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .854 2.160 5 .827 .901 1.000 .333
Treatment * Time .549 8.230 5 .145 .703 .822 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time
Tests of Within-Subjects Effects
M e asu re :M E A S U R E
S o u rce
T y p e  III 
Sum  
o f  S quares d f
M ean
S q u are F Sig.
P artia l
E ta
S q u ared
N o n cen t.
P aram e te r
O b serv ed
Pow er"
T rea tm en t S pheric ity
A ssu m ed
.998 1 .998 .808 .383 .051 .808 .134
G reen h o u se -
G eisse r
.998 1.000 .998 .808 .383 .051 .808 .134
H u y n h -F e ld t .998 1.000 .998 .808 .383 .051 .808 .134
L o w er-b o u n d .998 1.000 .998 .808 .383 .051 .808 .134
E rro r(T rea tm en t) S p h eric ity
A ssu m ed
G reen h o u se -
G eisse r
H u y n h -F e ld t













T im e S p h eric ity
A ssu m ed
9.838 3 3.279 4.848 .005 .244 14.545 .880
G reen h o u se -
G e isse r
9.838 2.702 3.641 4.848 .007 .244 13.100 .851
H u y n h -F e ld t 9.838 3.000 3.279 4.848 .005 .244 14.545 .880
L o w er-b o u n d 9.838 1.000 9.838 4.848 .044 .244 4.848 .540
E rro r(T im e) S p h eric ity
A ssu m ed
G reen h o u se -
G eisse r
H u y n h -F e ld t













T re a tm e n t * T im e S p h eric ity
A ssu m ed
.552 3 .184 .726 .542 .046 2.177 .192
G reen h o u se -
G e isse r
.552 2.110 .261 .726 .499 .046 1.532 .165
107
H u y n h -F e ld t .552 2 .465 .224 .726 .518 .046 1.789 .176
L o w er-b o u n d .552 1.000 .552 .726 .408 .046 .726 .126
E rro r(T rea tm en t* T im e) S pheric ity  
A ssu m ed
11.403 45 .253
G reen h o u se -
G e isse r 11.403 31 .657 .360
H u y n h -F e ld t 11.403 36 .968 .308
L o w er-b o u n d 11.403 15.000 .760

























Mean Std. Deviation N
VM O prexPreT 2.1562 1.92976 16
VMOprex_24T 2.6875 1.98221 16
VMOprex_48T 2.7188 1.87055 16
VMOprex_72T 2.1250 1.94508 16
VMOprex PreN 2.0625 2.01556 16
VMOprex 24N 2.8750 1.85742 16
VMOprex_48N 2.5625 1.81544 16
VMOprex_72N 2.1250 1.88414 16
MeasureiMEASURE 1








Treatment 1.000 .000 0 1.000 1.000 1.000
Time .503 9.419 5 .094 .702 .820 .333
Treatment * Time .960 .559 5 .990 .974 1.000 .333
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Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  signifleanee. Correeted tests are 
displayed in the Tests o f  Within-Subjeets Effeets table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time

















Assumed .008 1 .008 .011 .916 .001 .011 .051
Greenhouse-
Geisser .008 1.000 .008 .011 .916 .001 .011 .051
Huynh-Feldt .008 1.000 .008 .011 .916 .001 .011 .051




















Assumed 11.602 3 3.867
1.274 .295 .078 3.821 .317
Greenhouse-
Geisser
11.602 2.107 5.507 1.274 .295 .078 2.683 .262
Huynh-Feldt 11.602 2.459 4.718 1.274 .296 .078 3.132 .284



















Treatment * Time Sphericity
Assumed .539
3 .180 .706 .554 .045 2.117 .188
Greenhouse-
Geisser .539
2.921 .185 .706 .550 .045 2.061 .185
Huynh-Feldt .539 3.000 .180 .706 .554 .045 2.117 .188
Lower-bound .539 1.000 .539 .706 .414 .045 .706 .123
Error(Treatment*Time) Spherieity
Assumed 11.461 45 .255
109
Greenhouse-
Geisser 11.461 43.819 .262
Huynh-Feldt 11.461 45.000 .255
Lower-bound 11.461 15.000 .764

























Mean Std. Deviation N
VMOpstex_PreT 1.9062 1.55154 16
VMOpstex_24T 2.6250 2.14864 16
VMOpstex_48T 2.1875 1.82460 16
VMOpstex_72T 2.0000 2.20605 16
V M O pstexPreN 1.9688 1.44301 16
VMOpstex_24N 2.4687 1.53263 16
VMOpstex_48N 1.9062 1.93407 16
VMOpstex_72N 2.0000 2.17562 16
Measure:MEASURE I








Treatment 1.000 .000 0 1.000 1.000 1.000
Time .379 13.304 5 .021 .629 .717 .333
Treatment * Time .562 7.897 5 .163 .741 .876 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
1 1 0
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time
Tests of Within-Subjects Effects
M e asu re :M E A S U R E  1
S ource
T yp e  III 
S um  
o f  S quares d f
M ean
S quare F Sig.
P artia l
E ta
S q u ared
N o n cen t.
P aram e te r
O b serv ed
Pow er"
T rea tm en t S p h eric ity
A ssu m ed
.281 1 .281 .685 .421 .044 .685 .121
G reen h o u se -
G e isse r
.281 1.000 .281 .685 .421 .044 .685 .121
H u y n h -F e ld t .281 1.000 .281 .685 .421 .044 .685 .121
L o w er-b o u n d .281 1.000 .281 .685 .421 .044 .685 .121
E rro r(T rea tm en t) S p h eric ity
A ssu m ed
G reen h o u se -
G e isse r
H u y n h -F e ld t
L o w er-b o u n d
6 .1 5 6
6 .156
6 .1 5 6









T im e S p h eric ity
A ssu m ed
7 .508 3 2 .503 1.326 .278 .081 3 .978 .329
G reen h o u se -
G eisse r 7 .508
1.887 3.979 1.326 .280 .081 2 .502 .256
H u y n h -F e ld t 7 .5 0 8 2 .1 5 0 3 .493 1 .326 .281 .081 2 .850 .274
L o w er-b o u n d 7 .508 1.000 7 .508 1.326 .268 .081 1.326 .190
E rro r(T im e) S p h eric ity
A ssu m ed
G reen h o u se -
G eisse r
H u y n h -F e ld t











2 .6 3 4
5 .662
T rea tm en t * T im e S pheric ity
A ssu m ed
.578 3 .193 .847 .475 .053 2 .542 .219
G reen h o u se -
G eisse r .578 2.223 .260 .8 4 7 .448 .053 1.883 .190
H u y n h -F e ld t .578 2 .6 2 7 .220 .847 .463 .053 2.226 .206
L o w er-b o u n d .578 1.000 .578 .847 .372 .053 .847 .139
E rro r(T rea tm en t* T im e) S p h eric ity
A ssu m ed
G reen h o u se -
G eisse r
H u y n h -F e ld t



































Mean Std. Deviation N
V M O psttxPreT 1.1875 1.47054 16
VMOpsttx_24T 2.5000 2.05751 16
VMOpsttx_48T 2.3750 2.26936 16
V M O psttxPreN 1.7188 1.26450 16
VMOpsttx 24N 2.3438 1.53535 16
VMOpsttx_48N 2.0000 1.81659 16
Measure;MEASURE 1








Treatment 1.000 .000 0 1.000 1.000 1.000
Time .730 4.401 2 .111 .788 .864 .500
Treatment * Time .491 9.952 2 .007 .663 .702 .500
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time
Measure:MEASURE 1
Tests o f  W ithin-Subjects Effects
Type III
Sum Partial
o f Mean Eta Noncent. Observed




.000 1 .000 .000 1.000 .000 .000 .050
Greenhouse-
Geisser .000 1.000 .000
.000 1.000 .000 .000 .050
Huynh-Feldt .000 1.000 .000 .000 1.000 .000 .000 .050





















16.349 2 8.174 4.650 .017 .237 9.301 .740
Greenhouse-
Geisser 16.349
1.575 10.379 4.650 .027 .237 7.325 .662
Huynh-Feldt 16.349 1.728 9.459 4.650 .023 .237 8.037 .692



















Treatment * Time Sphericity
Assumed
3.578 2 1.789 6.072 .006 .288 12.145 .852
Greenhouse-
Geisser 3.578 1.326 2.699 6.072 .016 .288 8.050
.725
Huynh-Feldt 3.578 1.405 2.547 6.072 .015 .288 8.530 .744



















a. Computed using alpha = .05 '
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Treatme 95% Confidence Interval
nt Mean Std. Error Lower Bound Upper Bound
1 2.021 .433 1.099 2.943







(I-J) Std. Error Sig."
95% Confidence Interval for 
Difference"
Lower Bound Upper Bound
1 2 .000 .230 1.000 -.491 .491
2 1 .000 .230 1.000 -.491 .491
Based on estimated marginal means




Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1.453 .301 .811 2.095
2 2.422 .437 1.490 3.353


























Mean Std. Deviation N
Prex_5cm_PreT .9375 .89209 16
Prex_5cm_24T .9062 .96986 16
Prex_5cm_48T 1.0312 .99111 16
Prex_5cm_72T .8438 .92590 16
Prex_5cm_PreN .8750 1.00830 16
Prex_5cm_24N 1.0000 .93095 16
Prex_5cm_48N 1.0000 1.00000 16
Prex_5cm_72N .7812 .99948 16
Measure:MEASURE 1








Treatment 1.000 .000 0 1.000 1.000 1.000
Time 398 12.626 5 .028 .634 .723 333
Treatment * Time .081 34.471 5 .000 .444 .471 333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time


















.008 1 .008 .031 363 .002 .031 .053
Greenhouse-
Geisser .008 1.000
.008 .031 363 .002 .031 .053
Huynh-Feldt .008 1.000 .008 .031 .863 .002 .031 .053






















.703 3 .234 .591 .624 .038 1.772 .163
Greenhouse-
Geisser .703 1.901 .370 .591 .552 .038 1.123 .136
Huynh-Feldt .703 2.169 .324 .591 .573 .038 1.281 .143



















Treatment * Time Sphericity
Assumed
.133 3 .044 .247 .863 .016 .742 .093
Greenhouse-
Geisser .133
1.333 .100 .247 .692 .016 .330 .079
Huynh-Feldt .133 1.414 .094 .247 .706 .016 .350 .080













































Mean Std. Deviation N
Pstex Scm PreT 1.1250 1.28452 16
Pstex_5cm_24T .9062 .89849 16
Pstex_5cm_48T .8125 .92871 16
Pstex_5cm_72T .7812 .93039 16
Pstex_5cm_PreN 1.0625 .98107 16
Pstex_5cm_24N .9062 .91686 16
Pstex_5cm_48N .9375 .96393 16
Pstex_5cm_72N .7500 .93095 16









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .083 34.120 5 .000 .498 .540 .333
Treatment * Time .075 35.515 5 .000 .424 .446 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design; Intercept Within Subjects Design; Treatment + Time + Treatment * Time

















Assumed .002 1 .002
.050 .827 .003 .050 .055
Greenhouse-
Geisser .002 1.000 .002 .050 .827
.003 .050 .055
Huynh-Feldt .002 I.OOO .002 .050 .827 .003 .050 .055












































































Treatment * Time Sphericity
.162 3 .054 672 574 .043 2.016 .180Assumed
Greenhouse-
Geisser
.162 1.273 .127 .672 .457 .043 .855 .129
Huynh-Feldt .162 1.338 .121 .672 .464 .043 .899 .132









































Mean Std. Deviation N
Psttx_5cm_PreT .7813 .96555 16
Psttx_5cm_24T 1.0000 1.12546 16
Psttx_5cm_48T .8125 1.01448 16
Psttx_5cm_PreN .7188 .72958 16
Psttx_5cm_24N .9375 .89209 16
Psttx_5cm_48N .8125 .94648 16
Measure;MEASURE 1








Treatment 1.000 .000 0 1.000 1.000 1.000
Time .919 1.181 2 .554 .925 1.000 .500
Treatment * Time .955 .650 2 .722 .957 1.000 .500
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time





















.042 1.000 .042 .149 .705 .010 .149 .065
Huynh-Feldt .042 1.000 .042 .149 .705 .010 .149 .065





















.813 2 .406 .961 .394 .060 1.921 .201
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Greenhouse-
Geisser .813 1.850 .439
.961 .389 .060 1.777 .194
Huynh-Feldt .813 2.000 .406 .961 .394 .060 1.921 .201



















Treatment * Time Sphericity
Assumed .021
2 .010 .063 .939 .004 .126 .059
Greenhouse-
Geisser
.021 1.913 .011 .063 .933 .004 .120 .058
Huynh-Feldt .021 2.000 .010 .063 .939 .004 .126 .059































P rex lO cm P reT  
Prex_10cm_24T 






Prex_ 1 Ocm_PreN 





Mean Std. Deviation N
P rex lO cm P reT 1.0938 1.18629 16
Prex_10cm_24T 1.5000 1.25167 16
Prex_10cm_48T 1.5625 1.19548 16
Prex_10cm_72T 1.1562 1.10633 16
P r e x l  O cm PreN .8750 .97468 16
Prex_10cm_24N 1.6875 1.38894 16
Prex_10cm_48N 1.7188 1.85264 16
Prex lOcm 72N 1.3125 1.32759 16









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .208 21.554 5 .001 .525 .577 .333
Treatment * Time .612 6.745 5 .241 .789 .947 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time

















.158 1 .158 .487 .496 .031 .487 .100
Greenhouse-
Geisser
.158 1.000 .158 .487 .496 .031 .487 .100
Huynh-Feldt .158 1.000 .158 .487 .496 .031 .487 .100
Lower-
































































































































































Mean Std. Deviation N
Pstex_ 1 OcmPreT 1.0625 1.09354 16
Pstex_10cm_24T 1.1250 .78528 16
Pstex_10cm_48T 1.3750 1.53297 16
Pstex_10cm_72T .9688 .86542 16
P s te x l  O cm PreN 1.0625 1.15289 16
P s t e x l  Ocm_24N 1.4062 1.26779 16
Pstex_10cm_48N 1.3750 1.29743 16
Pstex_10cm_72N 1.2188 1.16860 16
M auchly's Test o f Sphericity
Measure: MEASURE 1
Epsilon"





Treatment 1.000 .000 0 1.000 1.000 1.000
Time .637 6.179 5 .290 .760 .904 .333
Treatment * Time .511 9.217 5 .101 .715 .837 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time

















.564 1 .564 2.442 .139 .140 2.442 .310
Greenhouse-
Geisser









































































































































































P s t tx l  O cm PreN  




Mean Std. Deviation N
Psttx l Ocm PreT .9375 1.22304 16
P s t tx l  0cm_24T 1.4062 1.17216 16
Psttx_10cm_48T 1.1875 1.20934 16
Psttx_ 10cm PreN .9062 1.03632 16
Psttx_10cm_24N 1.3750 1.39642 16
Psttx_10cm_48N 1.3750 1.52206 16









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .804 3.052 2 .217 .836 .929 .500
Treatment * Time .741 4.200 2 .122 .794 .873 .500
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time


















.042 1 .042 .039 .847 .003 .039 .054
Greenhouse-
Geisser .042 1.000 .042 .039 .847
.003 .039 .054
Huynh-Feldt .042 1.000 .042 .039 .847 .003 .039 .054





















1.924 2.180 .131 .127 4.360 .410
125
Greenhouse-
Geisser 3.849 1.672 2.301 2.180 .141 .127 3.646 .371
Huynh-Feldt 3.849 1.858 2.072 2.180 .135 .127 4.050 .393



















Treatment * Time Sphericity
Assumed .255 2 .128 .346 .711 .023 .691 .100
Greenhouse-
Geisser .255 1.588 .161 .346 .662 .023 .549 .095
Huynh-Feldt .255 1.746 .146 .346 .682 .023 .603 .097













































Mean Std. Deviation N
Prex_15cm_PreT 1.6563 1.74851 16
Prex_15cm_24T 2.6250 1.45488 16
Prex_15cm_48T 3.3125 1.49304 16
Prex_15cm_72T 2.7500 1.60208 16
Prex_l S cm P reN 1.2188 1.37803 16
Prex_15cm_24N 2.7812 1.47161 16
Prex_15cm_48N 3.5625 1.96532 16
Prex_15cm_72N 2.6250 1.66833 16









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .288 17.095 5 .004 .589 .662 .333
Treatment * Time .807 2.950 5 .708 .895 1.000 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time


















.049 1 .049 .034 .855 .002 .034 .053
Greenhouse-
Geisser .049 1.000 .049
.034 .855 .002 .034 .053
Huynh-Feldt .049 1.000 .049 .034 .855 .002 .034 .053






















66.131 3 22.044 7.596 .000 .336 22.788 .980
Greenhouse-
Geisser
66.131 1.767 37.419 7.596 .003 .336 13.425 .896
Huynh-Feldt 66.131 1.986 33.303 7.596 .002 .336 15.084 .921



















Treatment * Time Sphericity
Assumed
2.303 3 .768 1.301 .286 .080 3.904 .324
Greenhouse-
Geisser 2.303 2.686
.857 1.301 .287 .080 3.495 .304
Huynh-Feldt 2.303 3.000 .768 1.301 .286 .080 3.904 .324













































Mean Std. Deviation N
Pstex_ 15cm_PreT 1.3750 1.61761 16
Pstex_15cm_24T 1.9062 1.03632 16
Pstex_15cm_48T 2.4375 1.31498 16
Pstex_15cm_72T 1.8750 1.13284 16
P s t e x l  5cm_PreN 1.3438 1.41090 16
Pstex_15cm_24N 2.4062 1.40498 16
Pstex_15cm 48N 2.9375 1.38894 16
Pstex_15cm_72N 2.4375 1.54785 16









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .681 5.275 5 .384 .838 1.000 .333
Treatment * Time .680 5.285 5 .383 .845 1.000 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment -+- Time + Treatment * Time


















4.689 1 4.689 10.281 .006 .407 10.281 .850
Greenhouse-
Geisser
4.689 1.000 4.689 10.281 .006 .407 10.281 .850
Huynh-Feldt 4.689 1.000 4.689 10.281 .006 .407 10.281 .850






















28.787 3 9.596 4.749 .006 .240 14.246 .872
Greenhouse-
Geisser 28.787 2.513 11.455 4.749 .010 .240 11.934 .822
Huynh-Feldt 28.787 3.000 9.596 4.749 .006 .240 14.246 .872



















Treatment * Time Sphericity
Assumed
1.850 3 .617 2.644 .061 .150 7.931 .608
Greenhouse-
Geisser 1.850 2.535 .730 2.644 .072 .150 6.702 .554
Huynh-Feldt 1.850 3.000 .617 2.644 .061 .150 7.931 .608






























P s t t x l  5cm_PreT 
Psttx_15cm_24T 




P sttx_ 15 cm P reN  




Mean Std. Deviation N
P s t tx l  S cm PreT 1.4687 2.06937 16
Psttx_15cm_24T 2.5000 1.62275 16
Psttx_15cm_48T 2.8750 1.74642 16
P s t tx l  5cm_PreN 1.1562 1.09116 16
P s t tx l  5cm_24N 2.2813 1.39007 16
Psttx_15cm_48N 2.9688 2.06937 16









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .793 3.244 2 .197 .829 .919 .500
Treatment * Time .905 1.396 2 .498 .913 1.000 .500
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Design: Intercept Within Subjects Design: Treatment + Time + Treatment * Time

















Assumed .510 1 .510 .305 .589 .020 .305 .081
Greenhouse-
Geisser .510 1.000 .510 .305 .589 .020 .305 .081
Huynh-Feldt .510 1.000 .510 .305 .589 .020 .305 .081

























43.036 1.657 25.969 8.498 .003 .362 14.083 .914
Huynh-Feldt 43.036 1.837 23.423 8.498 .002 .362 15.614 .934



















Treatment * Time Sphericity
Assumed
.724 2 .362 .559 .578 .036 1.117 .134
Greenhouse-
Geisser
.724 1.827 .396 .559 .563 .036 1.020 .130
Huynh-Feldt .724 2.000 .362 .559 .578 .036 1.117 .134













































Mean Std. Deviation N
Prex_20cm_PreT 1.7500 1.65328 16
Prex_20cm_24T 3.2500 1.34164 16
Prex_20cm_48T 4.1875 1.68201 16
Prex_20cm_72T 3.5938 2.37500 16
Prex_20cm_PreN 1.8438 1.75802 16
Prex_20cm_24N 3.6875 1.66208 16
Prex_20cm_48N 4.4062 2.55094 16
Prex 20cm _72N 4.0938 2.59627 16









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .231 20.091 5 .001 .531 .584 .333
Treatment * Time .441 11.229 5 .048 .642 .734 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Designi Intercept Within Subjects Designi Treatment + Time + Treatment * Time

















Assumed 3.125 1 3.125 1.291
.274 .079 1.291 .187
Greenhouse-
Geisser







































Assumed 114.133 3 38.044 8.494 .000 .362 25.482 .989
Greenhouse-
Geisser 114.133 1.592 71.676 8.494 .003 .362 13.525 .905
Huynh-Feldt 114.133 1.751 65.180 8.494 .002 .362 14.873 .925



















Treatment * Time Sphericity
Assumed .859
3 .286 .416 .742 .027 1.249 .126
Greenhouse-
Geisser
.859 1.925 .447 .416 .656 .027 .802 .110
Huynh-Feldt .859 2.202 .390 .416 .682 .027 .917 .114













































Mean Std. Deviation N
Pstex_20cm_PreT 1.6250 2.02073 16
Pstex_20cm_24T 2.8750 1.36015 16
Pstex_20cm_48T 3.6250 1.78419 16
Pstex_20cm 72T 3.3437 1.90367 16
Pstex_20cm_PreN 1.8438 2.17347 16
Pstex_20cm_24N 3.1250 1.66833 16
Pstex_20cm_48N 3.9375 1.73085 16
Pstex_20cm_72N 3.7500 2.32379 16









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .400 12.575 5 .028 .617 .700 .333
Treatment * Time .443 11.165 5 .049 .652 .748 .333
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.
b. Designi Intercept Within Subjects Designi Treatment + Time + Treatment * Time


















2.820 1 2.820 2.945 .107 .164 2.945 .362
Greenhouse-
Geisser 2.820 1.000 2.820 2.945 .107 .164 2.945 .362
Huynh-Feldt 2.820 1.000 2.820 2.945 .107 .164 2.945 .362






















80.328 3 26.776 7.987 .000 .347 23.961 .985
Greenhouse-
Geisser 80.328 1.852 43.378 7.987 .002 .347 14.791 .920
Huynh-Feldt 80.328 2.101 38.227 7.987 .001 .347 16.784 .944



















Treatment * Time Sphericity
Assumed .164 3 .055 .099 .960 .007 .297 .066
Greenhouse-
Geisser
.164 1.955 .084 .099 .902 .007 .193 .064
Huynh-Feldt .164 2.245 .073 .099 .924 .007 .222 .064









































Mean Std. Deviation N
Psttx_20cm_PreT 1.3125 1.34009 16
Psttx_20cm_24T 3.0938 1.99348 16
Psttx_20cm_48T 3.6875 2.41437 16
Psttx_20cm_PreN 1.7813 1.69282 16
Psttx_20cm_24N 3.0625 1.65202 16
Psttx_20cm_48N 3.8750 2.52653 16









Treatment 1.000 .000 0 1.000 1.000 1.000
Time .933 .965 2 .617 .938 1.000 .500
Treatment * Time .885 1.712 2 .425 .897 1.000 .500
Tests the null hypothesis that the error covariance matrix o f  the orthonormalized transformed dependent 
variables is proportional to an identity matrix.
a. May be used to adjust the degrees o f  freedom for the averaged tests o f  significance. Corrected tests are 
displayed in the Tests o f  Within-Subjects Effects table.





o f Mean Eta Noncent. Observed
Source Squares df Square F Sig. Squared Parameter Power"
Treatment Sphericity
Assumed
1.042 1 1.042 .526 .479 .034 .526 .104
Greenhouse-
Geisser
1.042 1.000 1.042 .526 .479 .034 .526 .104
Huynh-Feldt 1.042 1.000 1.042 .526 .479 .034 .526 .104
























Geisser 83.536 1.875 44.550 10.081 .001 .402 18.903 .969
Huynh-Feldt 83.536 2.000 41.768 10.081 .000 .402 20.162 .976



















Treatment * Time Sphericity
Assumed 1.005
2 .503 .754 .479 .048 1.508 .166
Greenhouse-
Geisser
1.005 1.794 .560 .754 .467 .048 1.353 .159
Huynh-Feldt 1.005 2.000 .503 .754 .479 .048 1.508 .166
Lower-bound 1.005 1.000 1.005 .754 .399 .048 .754 .129


















a. Computed using alpha = .05
T-Test
Paired Samples Statistics
Mean N Std. Deviation Std. Error Mean
Pair 1 Girth_15cm_PreT 51.0106 16 6.478 1.620
Girth 15cm PreN 50.207 16 5.706 1.427
Pair 2 Girth 15cm 24T 51.031 16 6.264 1.566
Girth_15cm_24N 50.698 16 6.191 1.548
Pair 3 Girth_15cm_48T 51.429 16 6.254 1.564
Girth_15cm_48N 50.939 16 6.055 1.514
Pair 4 Girth_15cm_72T 51.224 16 6.293 1.573




Pair 1 Girth 15 cm PreT &
16 .985 .000Girth 15cm_PreN
Pair 2 Girth 15cm 24T &
16 .992 .000
G ir th l 5cm_24N
Pair 3 Girth 15cm 48T &
16 .991 .000
Girth_15cm_48N








o f the Difference
Sig. (2-
Mean Deviation Mean Lower Upper t df tailed)
Pair 1 Girth l Scm PreT -  
Girth_15cm_PreN .804 1.301 .325 .111 1.497 2.471 15 .026
Pair 2 Girth lScm  2 4 T -  
Girth_15cm_24N .333 .790 .198 -.088 .754 1.686 15 .112
Pair 3 Girth lScm  4 8 T -  
Girth_15cm_4SN .490 .856 .214 .034 .946 2.291 15 .037
Pair 4 Girth lScm  7 2 T -  
Girth_lScm _72N .206 1.089 .272 -.374 .786 .756 15 .461
T-Test
Paired Samples Statistics
Mean N Std. Deviation Std. Error Mean
Pair 1 V M O psttxPreT 1.188 16 1.471 .368
VMOpsttx_PreN 1.719 16 1.265 .316
Pair 2 VMOpsttx 24T 2.500 16 2.058 .514
VMOpsttx_24N 2.344 16 1.535 .384
Pair 3 VMOpsttx_48T 2.375 16 2.269 .567
VMOpsttx_48N 2.000 16 1.817 .454
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Paired Sam ples Correlations
N Correlation Sig.
Pair 1 VMOpsttx PreT & 
V M O psttxPreN 16 .550 .027
Pair 2 VMOpsttx_24T & 
VMOpsttx_24N 16 .000











Mean Lower Upper t df Sig. (2-tailed)










.156 .978 .245 -.365 .678 .639 15 .533
VMOpsttx_48N


























Mean Std. Deviation N
E c c P T P r e T 3.0862 .86961 16
Ecc_PT_24T 2.6019 .84763 16
Ecc_PT_48T 2.5169 .97847 16
Ecc_PT_72T 2.7794 1.05889 16
E c c P T P r e N 3.1875 .94916 16
Ecc_PT_24N 2.6450 1.01304 16
Ecc_PT_48N 2.3488 1.04613 16





Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 3.137 .218 2.672 3.601
2 2.623 .225 2.145 3.102
3 2.433 .246 1.908 2.958
4 2.786 .260 2.233 3.339
Pairwise Comparisons
Measure:MEASURE 1
(I) Time (J) Time
Mean Difference 
(I-J) Std. Error Sig."
95% Confidence Interval for 
Difference^
Lower Bound Upper Bound
1 .513* .156 .029 .040 .987
3 .704 .253 .084 -.064 1.472
4 .351 .266 1.000 -.456 1.158
2 3 .191 .143 1.000 -.244 .625
4 -.163 .195 1.000 -.755 .430
3
4 -.353 .146 ,174 -.797 .091
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
a. Adjustment for multiple comparisons: Bonferroni.
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Mean Std. Deviation N
Girth_l 5cm_PreT 51.0106 6.47839 16
Girth_15cm_24T 51.0312 6.26374 16
Girth_15cm_48T 51.4288 6.25400 16
Girth_15cm_72T 51.2238 6.29284 16
G ir th l S cm P reN 50.2069 5.70606 16
Girth_15cm_24N 50.6981 6.19106 16
Girth_15cm_48N 50.9388 6.05497 16





Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 50.609 1.517 47.374 53.843
2 50.865 1.554 47.553 54.176
3 51.184 1.535 47.912 54.456




(1) Time (J) Time
Mean Difference 
(I-J) Std. Error Sig."
95% Confidence Interval for 
Difference®
Lower Bound Upper Bound
1 2 -.256 .107 .180 -.580 .068
3 -.575* .120 .001 -.938 -.212
4 -.512 .176 .065 -1.047 .023
2 1 .256 .107 .180 -.068 .580
3 -.319 .122 .115 -.688 .050
4 -.256 .161 .791 -.744 .232
3 1 .575* .120 .001 .212 .938
2 .319 .122 .115 -.050 .688
4 .063 .120 1.000 -.303 .428
4 1 .512 .176 .065 -.023 1.047
2 .256 .161 .791 -.232 .744
3 -.063 .120 1.000 -.428 .303
Based on estimated marginal means
a. Adjustment for multiple comparisons; Bonferroni.


























Mean Std. Deviation N
Girth_20cm_PreT 55.2300 6.19627 16
Girth_20cm_24T 55.6925 6.31293 16
Girth_20cm_48T 55.9725 6.88511 16
Girth_20cm_72T 55.4563 6.31066 16
Girth_20cm_PreN 54.9506 6.54449 16
Girth 20cm 24N 55.4281 6.54627 16
Girth_20cm_48N 55.7638 6.77201 16





Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 55.090 1.588 51.706 58.474
2 55.560 1.605 52.140 58.981
3 55.868 1.702 52.241 59.495
4 55.479 1.610 52.047 58.911
Pairwise Comparisons
Measure; MEASURE 1
(I) Time (J) Time
Mean Difference
(I-J) Std. Error Sig.'
95% Confidence Interval for 
Difference®
Lower Bound Upper Bound
1 2 -.470 .199 .193 -1.074 .134
3 -.778* .233 .027 -1.484 -.071
4 -.389 .224 .620 -1.070 .292
2 1 .470 .199 .193 -.134 1.074
3 -.308 .206 .937 -.934 .318
4 .081 .195 1.000 -.510 .672
3 1 .778* .233 .027 .071 1.484
2 .308 .206 .937 -.318 .934
4 .389 .171 .227 -.129 .907
4 1 .389 .224 .620 -.292 1.070
2 -.081 .195 1.000 -.672 .510
3 -.389 .171 .227 -.907 .129
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Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.





















Mean Std. Deviation N
VM O psttxPreT 1.1875 1.47054 16
VMOpsttx_24T 2.5000 2.05751 16
VMOpsttx_48T 2.3750 2.26936 16
VM O psttxPreN 1.7188 1.26450 16
VMOpsttx_24N 2.3438 1.53535 16





Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1.453 .301 .811 2.095
2 2.422 .437 1.490 3.353




(I) Time (J) Time
Mean Difference 
(I-J) Std. Error Sig.'
95% Confidence Interval for 
Difference®
Lower Bound Upper Bound
1 2 -.969* .287 .012 -1.741 -.196
3 -.734 .409 .277 -1.835 .366
2 1 .969* .287 .012 .196 1.741
3 .234 .284 1.000 -.530 .998
3 1 .734 .409 .277 -.366 1.835
2 -.234 .284 1.000 -.998 .530
Based on estimated marginal means
*. The mean difference is significant at the .05 level.























Prex_ 15 cm 7 2N
Descriptive Statistics
Mean Std. Deviation N
Prex 15 cm PreT 1.6563 1.74851 16
Prex 15cm 24T 2.6250 1.45488 16
Prex_15cm_48T 3.3125 1.49304 16
Prex 15 cm 72T 2.7500 1.60208 16
Prex_15cm_PreN 1.2188 1.37803 16
Prex_15cm_24N 2.7812 1.47161 16
Prex_15cm_48N 3.5625 1.96532 16
Prex_15cm_72N 2.6250 1.66833 16
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Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1.438 .370 .649 2.226
2 2.703 .342 1.973 3.433
3 3.438 .403 2.579 4.296
4 2.688 .361 1.918 3.457
Pairwise Comparisons
Measure:MEASURE 1
(1) Time (J) Time
Mean Difference
(I-J) Std. Error Sig.'
95% Confidence Interval for 
Difference®
Lower Bound Upper Bound
1 2 -1.266’ .351 .016 -2.331 -.200
3 -2.000* .528 .011 -3.603 -.397
4 -1.250 .501 .149 -2.771 .271
2 1 1.266* .351 .016 .200 2.331
3 -.734 .454 .759 -2.112 .644
4 .016 .436 1.000 -1.309 1.340
3 1 2.000* .528 .011 .397 3.603
2 .734 .454 .759 -.644 2.112
4 .750* .198 .011 .150 1.350
4 1 1.250 .501 .149 -.271 2.771
2 -.016 .436 1.000 -1.340 1.309
3 -.750* .198 .011 -1.350 -.150
Based on estimated marginal means 
*. The mean difference is significant at the .05 level, 
a. Adjustment for multiple comparisons: Bonferroni.
1 4 7
























Mean Std. Deviation N
Pstex_15cm_PreT 1.3750 1.61761 16
Pstex_15cm_24T 1.9062 1.03632 16
Pstex _15cm _48T 2.4375 1.31498 16
Pstex_15cm_72T 1.8750 1.13284 16
P s te x l  S cm P reN 1.3438 1.41090 16
P s t e x l  5cm_24N 2.4062 1.40498 16
Pstex_15cm_48N 2.9375 1.38894 16





Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1.359 .367 .577 2.142
2 2.156 .297 1.522 2.790
3 2.688 .319 2.007 3.368




(I) Time (J) Time
Mean Difference 
(I-J) Std. Error Sig."
95% Confidence Interval for 
Difference®
Lower Bound Upper Bound
1 2 -.797 .374 .302 -1.934 .340
3 -1.328’ .387 .022 -2.503 -.153
4 -.797 .411 .429 -2.045 .451
2 1 .797 .374 .302 -.340 1.934
3 -.531 .371 1.000 -1.659 .596
4 .000 .268 1.000 -.814 .814
3 1 1.328* .387 .022 .153 2.503
2 .531 .371 1.000 -.596 1.659
4 .531 .298 .571 -.375 1.437
4 1 .797 .411 .429 -.451 2.045
2 .000 .268 1.000 -.814 .814
3 -.531 .298 .571 -1.437 .375
Based on estimated marginal means 
a. Adjustment for multiple comparisons; Bonferroni. 




T reatme 95% Confidence Interval
nt Mean Std. Error Lower Bound Upper Bound
1 1.898 .228 1.412 2.384







(I-J) Std. Error Sig."
95% Confidence Interval for 
Difference®
Lower Bound Upper Bound
1 2 -.383* .119 .006 -.637 -.128
2 1 .383* .119 .006 .128 .637
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
a. Adjustment for multiple comparisons: Bonferroni.
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Psttx_l 5cm_24N  
Psttx_15cm_48N
Descriptive Statistics
Mean Std. Deviation N
Psttx l 5cm PreT 1.4687 2.06937 16
Psttx_15cm_24T 2.5000 1.62275 16
Psttx_15cm_48T 2.8750 1.74642 16
Psttx_l 5cm_PreN 1.1562 1.09116 16
Psttx_15cm 24N 2.2813 1.39007 16





Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1.312 .362 .541 2.084
2 2.391 .345 1.655 3.127




(1) Time (J) Time
Mean Difference 
(I-J) Std. Error S ig .'
95% Confidence Interval for 
Difference®
Lower Bound Upper Bound
1 2 -1.078* .3 5 3 .024 - 2 .0 2 8 -.128
3 -1.609* .480 .013 -2 .9 0 2 -.317
2 1 1.078* .3 5 3 .024 .128 2 .0 2 8
3 -.531 .347 .439 -1.465 .403
3 1 1.609* .480 .013 .317 2 .9 0 2
2 .531 .347 .4 3 9 -.403 1.465
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
a. Adjustment for multiple comparisons: Bonferroni.
G e n e r a l  L in e a r  M o d e l























Mean Std. Deviation N
Prex_20cm_PreT 1.7500 1.65328 16
Prex_20cm_24T 3.2500 1.34164 16
Prex_20cm_48T 4.1875 1.68201 16
Prex_20cm_72T 3 .5 9 3 8 2.37500 16
Prex_20cm_PreN 1.8438 1.75802 16
Prex_20cm_24N 3.6875 1.66208 16
Prex 20cm 48N 4.4062 2.55094 16
Prex_20cm_72N 4.0938 2.59627 16
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Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1.797 .402 .940 2.654
2 3 .4 6 9 .355 2.712 4.225
3 4.297 .476 3 .2 8 2 5.312
4 3.844 .591 2 .5 8 5 5.103
P a ir w is e  C o m p a r is o n s
MeasureiMEASURE 1
(I) Time (J) Time
Mean Difference 
(I-J) Std. Error S ig .'
95% Confidence Interval for 
Difference®
Lower Bound Upper Bound
1 2 -1.672* .4 2 8 .008 -2.971 - .3 7 2
3 -2.500* .602 .005 -4 .3 2 8 - .6 7 2
4 -2.047 .750 .093 -4 .3 2 3 .230
2 1 1.672* .4 2 8 .008 .3 7 2 2.971
3 - .8 2 8 .4 3 5 .457 -2.148 .4 9 2
4 -.375 .5 4 5 1.000 -2.031 1.281
3 1 2.500* .602 .005 .672 4 .3 2 8
2 .8 2 8 .435 .457 - .4 9 2 2.148
4 .4 5 3 .2 9 2 .853 -.435 1.341
4 1 2.047 .7 5 0 .093 - .2 3 0 4 .3 2 3
2 .3 7 5 .545 1.000 -1.281 2.031
3 -.453 .2 9 2 .8 5 3 -1.341 .4 3 5
Based on estimated marginal means 
*. The mean difference is significant at the .05 level, 
a. Adjustment for multiple comparisons; Bonferroni.
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Pstex 20cm _48N  
Pstex_20cm_72N
D e s c r ip t iv e  S t a t is t ic s
Mean Std. Deviation N
Pstex_20cm_PreT 1.6250 2 .0 2 0 7 3 16
Pstex_20cm_24T 2 .8 7 5 0 1.36015 16
Pstex_20cm_48T 3 .6 2 5 0 1.78419 16
Pstex_20cm_72T 3 .3 4 3 7 1.90367 16
Pstex_20cm_PreN 1.8438 2.17347 16
Pstex_20cm_24N 3.1250 1.66833 16
Pstex_20cm_4 8N 3 .9 3 7 5 1.73085 16
Pstex_20cm_72N 3.7500 2 .3 2 3 7 9 16
1. T im e
E s t im a te d  M a r g in a l  M e a n s
E s t im a te s
MeasureiMEASURE 1
Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1.734 .5 0 2 .6 6 5 2.804
2 3.000 .371 2.210 3 .7 9 0
3 3.781 .406 2.917 4.646




(1) Time (J) Time
Mean Difference 
■ (I-J) Std. Error Sig."
95% Confidence Interval for 
Difference®
Lower Bound Upper Bound
1 2 -1.266* .408 .044 -2.504 -.027
3 -2.047* .560 .014 -3.747 -.346
4 -1.812 .603 .053 -3.644 .019
2 1 1.266* .408 .044 .027 2 .5 0 4
3 -.781 .3 9 5 .400 -1.981 .419
4 -.547 .426 1.000 -1 .8 4 0 .746
3 1 2.047* .560 .014 .346 3.747
2 .781 .3 9 5 .400 -.419 1.981
4 .234 .275 1.000 -.601 1.070
4 1 1.812 .603 .053 -.019 3 .6 4 4
2 .547 .426 1.000 -.746 1.840
3 -.234 .275 1.000 -1.070 .601
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
a. Adjustment for multiple comparisons; Bonferroni.
G e n e r a l  L in e a r  M o d e l


















D e s c r ip t iv e  S t a t is t ic s
Mean Std. Deviation N
Psttx 20cm  PreT 1.3125 1.34009 16
Psttx_20cm_24T . 3 .0 9 3 8 1.99348 16
Psttx_20cm_48T 3.6875 2.41437 16
Psttx 20cm PreN 1.7813 1 .6 9 2 8 2 16
Psttx_20cm_24N 3 .0 6 2 5 1 .6 5 2 0 2 16
Psttx_20cm_48N 3.8750 2 .5 2 6 5 3 16
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Time Mean Std. Error
95% Confidence Interval
Lower Bound Upper Bound
1 1.547 .360 .779 2.315
2 3.078 .425 2.172 3.984
3 3.781 .568 2.570 4.992
Pairwise Comparisons
MeasureiMEASURE 1
(1) Time (J) Time
Mean Difference
(I-J) Std. Error S ig .'
95% Confidence Interval for 
Difference®
Lower Bound Upper Bound
1 2 -1.531* .509 .026 -2.902 -.161
3 -2.234* .5 6 3 .004 -3.751 -.718
2 1 1.531* .509 .0 2 6 .161 2 .9 0 2
3 -.703 .449 .413 -1.911 .5 0 5
3 1 2 .2 3 4 * .563 .004 .718 3.751
2 ■ .703 .449 .413 -.505 1.911
Based on estimated marginal means
*. The mean difference is significant at the .05 level.
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LMG Biofeedback.” Rub ley MD, Peluaga MN, Liceralde P, Randolph S, Tritsch 
AJ, Holcomb WR, Tandy RD. Athletic Training Research Laboratory. University 
of Nevada, Las Vegas.
“The Effects of Cryotherapy on Deep Tissue Cooling.” Rubley MD, Liceralde P, 
Peluaga MN, Touton TM, Tritsch AJ, Milligan M, Knight KL. Athletic Training 
Research Laboratory. University of Nevada, Las Vegas.
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Presentation of Original Research:
Peluaga M N, Rubley MD, Klaasen JM, Tandy RD. “The Efficacy of 
Common Sterilization Procedures used for Im plantable Therm ocouples.” 
Them atic Poster Session The Far West Athletic Trainers Association, 
Regional Chapter, San Francisco, CA. Them atic Poster Session University 
o f  Nevada, Las Vegas, Health Sciences Interdisciplinary Research  
Scholarship Day, Las Vegas, NV. Them atic Poster Session The National 
Athletic Tra iners’ Association, National Chapter, St. Louis, MO.
Rubley MD, Peluaga MN, M endoza J, Threat J, Holcom b WR, Tritsch AJ, 
Tandy RD. “U ltrasound Heating o f the A chilles Tendon: A Com parison o f 
D irect and Indirect Application Techniques.” Them atic Poster Session The 
Far West Athletic Tra iners’ Association, R e p o n a l  Chapter, San 
Francisco, CA. Them atic Poster Session University o f  Nevada, Las Vegas, 
Health Sciences Interdisciplinary Research Scholarship Day, Las Vegas, 
NV. Oral Presentation The National Athletic T ra iners’ Association, 
National Chapter, St. Louis, MO.
Thesis Title: The Effects of Cryotherapy on Eccentric Peak Torque Recovery after an
Intense Eccentric Exercise.
Thesis Examination Committee:
Chairperson, Mack D. Rubley Ph.D, LAT, ATC, CSCS 
Committee Member, William R. Holcomb Ph.D, LAT, ATC, FNSCA 
Committee Member, John A. Mercer Ph.D, FACSM 
Graduate Faculty Representative, J. Wesley McWhorter Ph.D, MPT
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